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Abstract
4,15-Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring
predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on
Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health
related to its presence in food and feed. Very limited information was available on toxicity and on
toxicokinetics in experimental and farm animals. Due to the limitations in the available data set, human
acute and chronic health-based guidance values (HBGV) were established based on data obtained in
clinical trials of DAS as an anticancer agent (anguidine) after intravenous administration to cancer
patients. The CONTAM Panel considered these data as informative for the hazard characterisation
of DAS after oral exposure. The main adverse effects after acute and repeated exposure were
emesis, with a no-observed-adverse-effect level (NOAEL) of 32 lg DAS/kg body weight (bw), and
haematotoxicity, with a NOAEL of 65 lg DAS/kg bw, respectively. An acute reference dose (ARfD) of
3.2 lg DAS/kg bw and a tolerable daily intake (TDI) of 0.65 lg DAS/kg bw were established. Based on
over 15,000 occurrence data, the highest acute and chronic dietary exposures were estimated to be
0.8 and 0.49 lg DAS/kg bw per day, respectively, and were not of health concern for humans. The
limited information for poultry, pigs and dogs indicated a low risk for these animals at the estimated
DAS exposure levels under current feeding practices, with the possible exception of fattening chicken.
Assuming similar or lower sensitivity than for poultry, the risk was considered overall low for other
farm and companion animal species for which no toxicity data were available. In consideration of the
similarities of several trichothecenes and the likelihood of co-exposure via food and feed, it could be
appropriate to perform a cumulative risk assessment for this group of substances.
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Summary
In a request from the European Commission, the EFSA Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to assess whether 4,15-diacetoxyscirpenol (DAS) in food and feed is a
potential risk for public and animal health, taking into account the toxicity of DAS and the occurrence
in food and feed. Possible interactions with other Fusarium toxins, in particular group A trichothecenes,
as regards toxicity and occurrence should be included in the evaluation. For the assessment of the
risks, the impact on different farm animal species and the speciﬁc (vulnerable) groups of the human
population should be considered.
DAS is a type A trichothecene mycotoxin with low molecular weight, produced by several Fusarium
species (mainly F. langsethiae, F. poae, F. sporotrichioides and F. sambucinum). It has mainly been
detected in cereal grains, cereal-based products and coffee but its presence in other foods and feeds
cannot be excluded. A naturally occurring modiﬁed form of DAS has been identiﬁed as DAS-glucoside.
Liquid chromatography with tandem mass spectrometry (LC–MS/MS) is currently the most widely
used and preferred technique for analysis of DAS in foods, feed and biological samples, while
high-performance liquid chromatography-ﬂame ionisation detection (HPLC-FLD), gas chromatography-
ﬂame ionisation detection (GC-FID) or gas chromatography-electron capture detector (GC-ECD) and
gas chromatography–mass spectrometry (/tandem mass spectrometry (GC–MS(/MS)) have also been
applied. None of the applied methods for DAS have been formally validated in interlaboratory studies
and certiﬁed reference materials are not available. Calibrants are commercially available.
In the published literature, DAS has mainly been reported in various cereal grains (principally
wheat, sorghum, maize, barley and oats) and cereal products, but also in potato products, soybeans
and coffee. The highest levels have been reported for wheat, sorghum and coffee. DAS has been
found to co-occur with many other mycotoxins in grains and grain-based products, in particular
Fusarium toxins including type A and B trichothecenes, and zearalenone.
Based on the analytical results of food and feed in the EFSA database up to the end of 2017 and
the literature, a total of 15,786 and 2,098 analytical results, respectively, fulﬁlled the quality criteria
applied and have been used in the assessment. These concern the data reported to EFSA by Member
States (97%) and literature data reported for Europe (3%). The proportion of left-censored data
(results below the limit of quantiﬁcation (LOQ)) was 98.6% in food and 93.9% in feed. For food, the
highest mean concentrations of DAS were recorded in the category of ‘cereal-based dishes’, and for
feed in the categories ‘maize grains and maize silage’ and ‘rice, broken’.
No studies on the effect of cleaning, sorting and milling of grains could be identiﬁed, but these
practices are expected to result in a redistribution and/or reduction of DAS in the ﬁnal products, as is
the case with other trichothecenes.
In humans, the highest mean acute exposure estimates ranged from 17 ng/kg body weight (bw) to
186 ng/kg bw across different surveys and population groups when applying the probabilistic
approach. When considering the 95th percentile, the values ranged from 54 to 799 ng/kg bw. The
highest values were recorded for ‘infants’ and ‘toddlers’
The estimates of mean chronic exposure to DAS across different dietary surveys and all age groups
ranged from 0.2 ng/kg bw per day (lowest minimum lower bound (LB), observed in ‘infants’ and at
ages ≥ 18 years) to 185 ng/kg bw per day (highest maximum upper bound (UB) observed in
‘toddlers’) when applying the deterministic approach. Highest values are generally recorded for young
people because of high food consumption when expressed per kg bw. The estimates of 95th percentile
chronic exposure ranged from 0.4 ng/kg bw per day (lowest minimum LB, observed in ‘elderly’ and
‘very elderly’) to 491 ng/kg bw per day (highest maximum UB observed in ‘other children’). The most
important contributors to the chronic dietary exposure to DAS were ‘grains and grain-based products’,
especially ‘cereal-based dishes’.
Exposure of farm and companion animals to DAS is primarily from consuming cereal grains and
cereal by-products. Due to the lack of data on compound feeds, exposures for all livestock other than
poultry were estimated using data for individual feed materials and their assumed inclusion rates in the
diets. The highest estimated exposures were for ruminants (dairy cows and beef cattle) fed with maize
silage-based diets. For dairy cows on a maize silage-based diet, the estimated mean diet concentration
ranged from 1.3 (LB) to 43 (UB) lg/kg dry matter (DM), the latter corresponding to a maximum of 1.8
lg/kg bw per day. Estimated exposures for beef cattle on maize silage-based diets were marginally
lower. For horses, the maximum estimated exposure was 0.58 lg/kg bw per day.
Exposures for starter pigs, growing/fattening pigs, ﬁnisher pigs and lactating sows were broadly
similar, however, not all mean and P95 LB values could be determined. The mean and P95 UB
4,15-Diacetoxyscirpenol in food and feed
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2018;16(8):5367
estimates ranged from 11 to 18 and 20 to 32 lg/kg DM, respectively (corresponding to 0.35–0.92 and
0.61–1.6 lg/kg bw per day). For poultry, the highest diet levels were estimated for laying hens. Mean
and P95 exposures ranged from non-determined (LB) to 27 (UB–mean) or 48 (UB–P95) lg/kg DM
(corresponding to 1.61 and 2.9 lg/kg bw per day, respectively). For farmed rabbits and mink, the
mean and P95 LB estimates were < 1.0 lg/kg DM. The UB values were highest for mink (2.4 and 4.2
lg/kg DM, respectively, for mean and P95 exposures, corresponding to 0.09 and 0.15 lg/kg bw per
day). Similarly, the estimated LB mean and P95 for ﬁsh (salmonids and carp) were < 1.0 lg/kg DM.
Due to the higher levels of cereals in carp diets, UB estimates were highest for carp (25 and 45 lg/kg
DM, for mean and P95 estimates, respectively, corresponding to 0.55 and 1 lg/kg bw per day). Finally,
for companion animals (cats and dogs), mean and P95 LB estimates were < 1 lg/kg DM, while the UB
mean and P95 exposure estimates were higher for cats (7.3 and 13 lg/kg DM, respectively;
corresponding to a maximum of 0.20 lg/kg bw per day) than for dogs (5.1 and 9.1 lg/kg DM,
respectively; corresponding to a maximum of 0.13 lg/kg bw per day).
No pharmacokinetic data in humans were available from clinical studies after intravenous (i.v.)
administration of DAS and no data after oral administration were identiﬁed. After oral administration in
rats and mice, the absorption of DAS has not been quantiﬁed but the excretion ratio between urine
and faeces indicated high absorption. DAS was rapidly distributed to most organs. Tissue
concentrations decreased rapidly with no apparent accumulation in any tissue and more than 90% of
radiolabelled DAS was excreted within 24 h.
In vitro, DAS is metabolised to a large number of metabolites. The main metabolic processes are
deacetylation, hydrolysis, deepoxidations and glucuronide conjugation. Deepoxidation reactions were
primarily found after incubation with gastrointestinal and ruminal contents, rumen ﬂuids or faeces.
Also, in vivo DAS was rapidly metabolised to a large number of metabolites. Although in vivo studies
on the toxicokinetics of DAS in farm animals were rare and not all relevant parameters were
determined, a rapid absorption, distribution, metabolism and excretion was generally shown. The main
systemic metabolites were determined as 15-monoacetoxyscirpenol (15-MAS) and scirpentriol (SCT). In
pigs, a large portion of orally administered DAS could be found in faeces, mainly as deepoxidised SCT.
In chickens, DAS was rapidly absorbed from the gastrointestinal tract, extensively metabolised and
excreted as 15-MAS and 7-OH-DAS in faeces and in urine. No data were available for ruminants,
horses, dogs and cats, and farmed rabbits, mink and ﬁsh.
There was insufﬁcient evidence to conclude on the transfer of DAS from feed to food of animal
origin.
When administered orally to rodents, the LD50 values ranged from 2 to 16 mg/kg bw.
Haematological effects such as anaemia, leucopenia and thrombocytopenia were observed. When
administered i.v., the LD50 ranged from 1 to 12 mg/kg bw, while the LD50 ranged from 0.8 to 23 mg
DAS/kg bw after intraperitoneal (i.p.) administration. Repeated dose studies in rodents were scarce
and not of sufﬁcient quality for hazard identiﬁcation and characterisation.
After a single i.v. administration to dogs, DAS induced emesis, diarrhoea, haematological changes
and effects in the bone marrow. Repeated dosing by i.v. in dogs and monkeys induced emesis,
diarrhoea, body weight loss, erythema, increased haematocrit, anaemia, leucocytosis and/or
leucopenia, neutrophilia, lymphopenia, elevated aspartate aminotransferase, alanine transaminase and
blood urea nitrogen, and nucleated erythrocytes. The no-observed-adverse-effect level (NOAEL) for
emesis and haematological effects after i.v. administration was 31 and 16 lg/kg bw per day for dogs,
respectively, and 125 lg/kg bw per day for monkeys.
Developmental and reproductive toxicity was reported after i.p. administration of DAS in
experimental animals, and adverse effects were seen in tissues with high proliferation rate. No NOAEL
could be identiﬁed; however, the CONTAM identiﬁed a lowest observed adverse effect level (LOAEL) of
1 mg/kg bw in mice after a single injection based on increase in resorption, reduction in fetal body
weight and gross and skeletal malformations. Furthermore, a LOAEL of 1.7 mg/kg bw in rats was
identiﬁed based on reduced testicular weight and sperm production and an increased frequency of
hypocellular seminiferous tubules.
There was no evidence that DAS induces bacterial reverse mutation in vitro. The only in vivo i.p.
genotoxicity study in mice reported chromosomal abnormalities in somatic cells (bone marrow) and in
germ cells (spermatocytes). Protein synthesis inhibition is likely to be a mechanism underlying the
observed in vivo chromosomal abnormalities. The Panel considered that there are currently insufﬁcient
data on the genotoxicity of DAS.
No chronic toxicity or carcinogenicity studies were identiﬁed.
4,15-Diacetoxyscirpenol in food and feed
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2018;16(8):5367
The limited available toxicological data for the main metabolites of DAS (4- or 15-MAS, SCT)
indicate that their toxicity is equal to or less than the toxicity of DAS in vitro and in vivo after oral
exposure.
The CONTAM Panel identiﬁed adverse health effects in humans exposed to DAS when it was tested
as a cytostatic anticancer drug (named anguidine) in phase I and phase II clinical trials on cancer
patients by i.v. administration. Based on the data of the phase I studies, the CONTAM Panel identiﬁed
nausea and vomiting as the most relevant acute adverse health effects of DAS with a NOAEL at 1.2
mg DAS/m2 (equivalent to 32 lg DAS/kg bw). Haematotoxicity and myelosuppression were the most
frequently observed and persistent adverse effects observed in the phase I studies when DAS was
given repeatedly (5-day regimen) in treatment cycles of 3–4 weeks. A NOAEL of 2.4 mg DAS/m2
(equivalent to 65 lg DAS/kg bw per day) was identiﬁed. The reported adverse health effects at doses
from 3 to 5 mg DAS/m2 (equivalent to 81–135 lg DAS/kg bw per day) of the phase II clinical trials,
performed at the proximity of the maximum tolerable doses, supported these ﬁndings.
DAS is binding to ribosomes, inducing a ‘ribotoxic stress response’ with activation of
ribosome-associated MAPKs and inhibition of protein synthesis. DAS also possesses cytotoxic properties,
while no clear indications for reactive oxygen species (ROS) production are available. An increase in gut
satiety hormones (e.g. cholecystokinin (CCK)) levels is considered the mechanism of DAS (and
trichothecenes) induced anorexia. In vitro assays indicated cytotoxic properties on haematopoietic
progenitors which could be due to stimulation of apoptosis or inhibition of protein synthesis.
Data on combined effects of DAS and other mycotoxins in vivo were available mainly in poultry, and
only one experiment was performed in pigs. Although limited, the effects observed for DAS in
combination with T-2 toxin, aﬂatoxin B1, ochratoxin A and fusaric acid were generally more marked
than when DAS was administered alone. The CONTAM Panel noted that because of the lack of
dose–response data, it was difﬁcult to draw deﬁnitive conclusions concerning the nature of the
combined effects and interaction with other Fusarium toxins, including type A trichothecenes.
Based on the conclusions on the genotoxicity and the mode of action (MoA) of DAS, the CONTAM
Panel decided to establish health-based guidance values (HBGV) for both the acute and chronic
exposure of DAS to humans. The Panel concluded that the database from the oral studies on rats and
guinea pigs and the i.v. studies in dogs and monkey was insufﬁcient for the identiﬁcation of a
reference point (RP) for the human hazard characterisation. For both acute and chronic hazard
characterisation, data from clinical studies in patients treated by i.v. administration of DAS (anguidine)
for cancer were used. Since the data from experimental and farm animals suggest almost complete
absorption following oral administration, the Panel under a conservative approach considered an
equivalent bioavailability after oral exposure and i.v. dosing. In addition, the Panel noted that following
oral exposure DAS is subject to extensive presystemic degradation in the gastrointestinal tract and
hepatic metabolisation. Based on limited information showing that DAS metabolites would have similar
or lower toxicity than DAS, oral exposure would not lead to higher systemic toxicity than i.v.
administration.
The CONTAM Panel identiﬁed 32 lg DAS/kg bw as a RP for acute health effects, based on nausea
and emesis observed in clinical studies in cancer patients. The Panel then applied the default
uncertainty factor of 10 accounting for interindividual toxicokinetic and toxicodynamic variability and
derived an acute reference dose (ARfD) of 3,200 ng DAS/kg bw.
The haematotoxic and myelotoxic effects observed in clinical studies were identiﬁed as the critical
endpoint for human chronic hazard characterisation. The CONTAM Panel concluded that these effects
would not be expected in humans at a dose equal or below 65 lg/kg bw per day which was therefore
selected as a RP for chronic effects. The CONTAM Panel considered the default uncertainty factor of 10
as adequate to cover for interindividual toxicokinetic and toxicodynamic variability. In addition, the
Panel applied an uncertainty factor of 10 to account for the limited duration and the intermittent
dosing regimen of the human clinical studies used for the chronic RP selection. Taking the overall
uncertainty factor into account, the CONTAM Panel established a tolerable daily intake (TDI) of 650 ng
DAS/kg bw per day.
The CONTAM Panel concluded that data were too scarce to identify a RP for adverse health effects
of DAS in ruminants. A few studies on adverse effects of DAS in pigs were available. Oral lesions in the
gastrointestinal tract were observed following exposure to ≥ 2.0 mg DAS/kg feed, corresponding to
0.08 mg/kg bw per day. Reduced body weight gain was seen at feed concentrations resulting in doses
≥ 0.12 mg/kg bw per day. No NOAEL could be identiﬁed from the available data. For poultry, oral
lesions were observed at the lowest level of exposure in the following species: chickens, laying hens,
turkeys and ducks with LOAELs of 0.010, 0.054, 0.012 and 0.022 mg DAS/kg bw per day, respectively.
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At equal or higher doses, reduction of body weight gain, decreased eggs production and decreased
fertility were other adverse effects observed in various studies in different poultry species.
No data were available on the oral exposure of dogs. Emesis and haematotoxicity were observed
following i.v. administration. Assuming equivalent bioavailability and systemic toxicity of DAS following
i.v. and oral administration, the CONTAM Panel identiﬁed NOAELs of 0.031 and 0.016 mg/kg bw per
day for acute and chronic toxicity, respectively.
In addition to ruminants, no toxicity data suitable for hazard characterisation of DAS were identiﬁed
for farmed rabbits, farmed ﬁsh, farmed mink, horses and cats. In order to obtain an indication on the
risk of DAS in these species, the CONTAM Panel considered the lowest LOAEL of 0.01 mg DAS/kg bw
per day identiﬁed for fattening chicken as indicative for potential adverse health effects.
In humans, all mean and 95th percentile exposure estimates were below the established HBGV
values (ARfD and TDI), and therefore not of health concern. The impact of the uncertainties in the
human risk assessment of DAS is large and the risk is more likely to be over than underestimated.
Because of the limited data for farm and companion animals, health risk characterisation was
carried out only for pigs, poultry and dogs. For pigs, the CONTAM Panel noted that the exposure levels
in starter and growing/fattening pigs were 1.2% and 2.0%, respectively, of the identiﬁed critical LOAEL
of 80 lg/kg bw per day. Although the hazard characterisation was based on very limited data on
adverse effects, the Panel concluded that the risk for adverse health effects from feed containing DAS
is low for pigs at the estimated exposure levels under current feeding practices. For poultry, the
CONTAM Panel noted that the higher exposure estimates for fattening chicken was about up to 25%
of the lowest LOAEL identiﬁed for oral lesions (10 lg/kg bw per day), indicating a possible risk for
adverse effects. The risk was considered low for laying hens, fattening turkeys and ducks at the
estimated exposure levels under current feeding practices. In the dog, the estimated exposure levels
were less than 1% of the identiﬁed NOAELs of 31 and 16 lg/kg bw per day for both acute and chronic
effects, indicating a low risk for adverse health effects.
The CONTAM Panel noted that the largest available exposure estimate for species where a RP could
not be identiﬁed (ruminants, horses, cats, farmed rabbit, ﬁsh and mink) was in the majority of cases a
small fraction of the LOAEL of 10 lg/kg bw per day for oral lesions in poultry (maximum 18% in dairy
cows). Therefore, the adverse health effects from feed containing DAS would be unlikely to occur for
these farm and companion animals at the levels of exposure estimated for current feeding practices,
with the exception of dairy cows fed on maize silage-based diets where a possible risk may exist.
Conclusions for these animal species are affected by a high degree of uncertainty.
In order to decrease the level of uncertainty in the risk assessments, the CONTAM
Panel recommends that a well-designed 90-day oral toxicity study be undertaken with rats using
puriﬁed DAS, in accordance with the relevant OECD guidelines and with special focus on the
assessment of haematotoxicity, myelotoxicity and reproductive performance. In addition, studies of the
toxicokinetics of DAS after oral and i.v. exposure in experimental animals are required, in addition to
in vivo studies on the genotoxicity of DAS. More data would also be needed on the cellular and
molecular MoA, in particular for a better understanding of cytotoxicity, DNA and protein synthesis
inhibition, stimulation of apoptosis and effects on haematopoietic progenitors and bone marrow.
Well-designed dietary studies on adverse effects (including the investigations for oral and
gastrointestinal lesions) of DAS in farm animals other than poultry are also recommended.
More occurrence data on DAS in food and feed obtained with state-of-the-art validated analytical
methods with adequate sensitivity, such as LC–MS/MS, are needed to also reduce the uncertainty in
the exposure assessment for humans and farm and companion animals.
Finally, in consideration of the similar toxicity proﬁles and structural similarities of several
trichothecenes, together with their likely co-exposure via food and feed, it would be appropriate to
perform a cumulative risk assessment for this group of substances.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
4,15-Diacetoxyscirpenol (DAS) is one of the trichothecene mycotoxins produced by certain species
of Fusarium. DAS is considered to be one of the most toxic trichothecenes and it belongs to the group
A trichothecenes. DAS is mainly produced by Fusarium langsethiae, F. poae, F. sporotrichioides. and
Fusarium sambucinum. DAS has been found to occur in cereals and cereal-based products and in
coffee beans.
1.1.1.1. Available information (not exhaustive)
In accordance with Article 36 of Regulation (EC) No 178/2002, a report “Scientiﬁc information on
mycotoxins and natural plant toxicants” has been produced following a grant agreement between the
European Food Safety Authority (EFSA) and the author(s) of the report (CFP/EFSA/CONTAM/2008/01).
The report presents information, inter alia, regarding diacetoxyscirpenol in feed and food and is
available on the EFSA website (http://www.efsa.europa.eu/en/scdocs/doc/24e.pdf).
1.1.1.2. Issue
There might be possible risk for animal and public health, related to the presence of
4,5-diacetoxyscirpenol in feed and food. The European Commission asks EFSA to assess on the basis
of the available information the risk for farm animals and public health in order to enable the European
Commission and the competent authorities in the Member States to consider the need for a possible
follow up including to ﬁll the knowledge gaps.
1.1.2. Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority to provide a scientiﬁc opinion on the risks for public health related to
the presence of diacetoxyscirpenol in feed and food.
The assessment should, based upon the available information, assess if the presence of 4,
15-diacetoxyscirpenol in food and feed is a potential risk for public and animal health taking into
account the toxicity of diacetoxyscirpenol and the occurrence in feed and food and to assess possible
interactions with other Fusarium toxins, in particular group A trichothecenes, as regards toxicity and
occurrence. For the assessment of the risks, the situation for the different farm animal species and the
speciﬁc (vulnerable) groups of the human population (e.g. high consumers, children, people following
speciﬁc diets, etc.) should be considered.
1.2. Interpretation of the Terms of Reference
The CONTAM Panel concluded that the terms of reference provided by the Commission were clear.
1.3. Supporting information for the assessment
1.3.1. Chemistry
4,15-Diacetoxyscirpenol (3a,4b)-3-hydroxy-12,13-epoxy-trichothec-9-ene-4,15-diyl diacetate; Chem-
ical Abstracts Service (CAS) No. 2270-40-8; C19H2607; molecular weight 336.405 Da) or anguidine is a
type A trichothecene mycotoxin produced by several Fusarium species (Thrane et al., 2004; Lysoe
et al., 2016), see Figure 1 and Table 1.
4,15-Diacetoxyscirpenol (from now onwards indicated as DAS) is naturally present in various crops,
in particular cereals. It is a white crystalline compound with a melting point ranging between 162°C
and 164°C (Lewis, 1999). The chemical structure of trichothecenes is characterised by a tetracyclic
sesquiterpenoid 12,13-epoxytrichothec-9-ene ring with different patterns of substitution around this
core. Type A trichothecenes (Table 1) do not have a carbonyl function at C-8 in contrast to type B
trichothecenes with deoxynivalenol as the best-known example. DAS differs from the type A
trichothecene T-2 toxin only by missing the isovaleryl group at C-8 (Dellaﬁora et al., 2017).
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Due to the lack of a keto group at C-8 and less free hydroxyl functions, DAS is less polar compared
to the type B trichothecenes (Rodrıguez-Carrasco et al., 2017). DAS is highly soluble in ethyl acetate,
acetone, chloroform, methylene chloride and diethyl ether (Battilani et al., 2009) and stable at neutral
and acidic pH (Rodriguez et al., 2014). When treated with alkali or dilute solutions of potassium
carbonate, sodium hydroxide or ammonium hydroxide DAS is hydrolysed to scirpentriol (SCT)1 (Battilani
et al., 2009).
Within the Type A trichothecene group, it is possible to distinguish the scirpentriol subgroup; this
comprises SCT, three monoacetoxyscirpenols (MAS), three diacetoxyscirpenols and the completely
acetylated triacetoxyscirpenol (Table 2) (Schollenberger et al., 2007, 2011). DAS has been the most
studied member of the scirpentriol subgroup.
Biosynthesis of trichothecenes in the fungi starts with a series of reactions that involve the
cyclisation of the isoprenoid-pathway-intermediate farnesyl pyrophosphate to trichodiene. This is
followed by modiﬁcation of trichodiene through a series of oxygenation steps to form calonectrin (CAL)
among others (Hohn et al., 1993).
Figure 1: Chemical structure of 4, 15-DAS
Table 1: Type A trichothecenes of known relevance for human and animal health
Compound Element formula Molecular weight logPoct/water
(a)
4,15-Diacetoxyscirpenol (DAS) C19H26O7 366 0.2
T-2 Toxin C24H34O9 466 0.9
HT-2 Toxin C22H32O8 424 0.4
Neosolaniol C19H26O8 382 0.9
(a): Data obtained from PubChem repository.
Table 2: DAS-related type A trichothecenes of the scirpentriol subgroup
Compound Element formula Molecular weight logPoct/water
(a)
Scirpentriol (SCT) C15H22O5 282 1
3-Monoacetoxyscirpenol (3-MAS) C17H24O6 324 0.4
4-Monoacetoxyscirpenol (4-MAS) C17H24O6 324 0.4
15-Monoacetoxyscirpenol (15-MAS) C17H24O6 324 0.4
3,4-Diacetoxyscirpenol (DAS) C19H26O7 366 0.2
3,15-Diacetoxyscirpenol (DAS) C19H26O7 366 0.2
4,15-Diacetoxyscirpenol (DAS) C19H26O7 366 0.2
3,4,15-Triacetoxyscirpenol (TAS) C21H28O8 408 0.8
(a): Data obtained from PubChem repository.
1 It is noted that scirpentriol can be abbreviated in different ways (e.g. SCP), the CONTAM Panel decided to use SCT.
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The biosynthesis of DAS then proceeds from CAL (Figure 2) to 3,15-diacetoxyscirpenol (3,15-DAS)
which is acetylated to form 3,4,15-triacetoxyscirpenol (3,4,15-TAS). In a subsequent step, 3,4,15-TAS
is deacetylated to DAS (Desjardins et al., 1993; Kimura et al., 2007).
By deacetylation at C-4, DAS is transformed into 15-MAS, which is later deacetylated at C-15 to
form SCT (Perkowski et al., 2003; Schollenberger et al., 2011).
According to Richardson et al. (1989), all eight members of the SCT subgroup are synthesised by F.
sambucinum. However, Schollenberger et al. (2011) reported more recently a sequential accumulation
pattern of DAS, 15-MAS and SCT in F. poae and F. sporotrichioides. These observations indicate that at
least in in vitro Fusarium culture, the spectrum of DAS related type A trichothecenes of the scirpentriol
subgroup may change over time.
Nakagawa et al. (2013a,b) identiﬁed DAS-glucoside and two 15-MAS-glucosides as modiﬁed forms
of DAS and 15-MAS, respectively, in a contaminated maize powder and using high-resolution mass
spectrometric analysis (Table 3). Although the absolute structure of DAS-glucoside was not clariﬁed,
glucosylation at the 3-OH position appeared to be the most probable. The two 15-MAS-glucosides are
isomers.
It was reported that DAS can also be modiﬁed through thermal degradation with partly conversion
to DAS-M1, however under conditions that are not representative of household or commercial
processing circumstances (Shams et al., 2011). The structure of DAS-M1 was elucidated with nuclear
magnetic resonance (NMR) (Table 3) Shams et al., (2011). While the elucidated structure of DAS-M1 is
new, analogue reaction products were previously reported by Grove and Mortimer (1969).
Both, in vivo and in vitro studies have shown that DAS can be biotransformed in humans and in
animals (see Sections 3.1.1 and 3.1.2 on toxicokinetics) to a variety of metabolites (see Yang et al.,
2015 and also Table 4). The major metabolic pathways of DAS are hydrolysis, hydroxylation,
conjugation and deepoxidation, where deepoxidation takes place in the intestinal tract by
microorganisms (Swanson et al., 1987; Fuchs et al., 2002; Yang et al., 2015).
Figure 2: Proposed biosynthetic pathway for DAS and related trichothecenes in Fusarium according
to Kimura et al. (2007)2
Table 3: Modiﬁed forms of DAS
Compound Element formula Molecular weight
Plant modiﬁed
DAS-glucoside C25H36O12 528
15-MAS-3-glucoside C23H34O11 486
15-MAS-4-glucoside C23H34O11 486
Modiﬁed through thermal degradation
DAS-M1 C19H28O8 384
MAS: monoacetoxyscirpenol; DAS: diacetoxyscirpenol.
2 Reprinted by permission from Taylor & Francis Ltd, http://www.tandfonline.com; Kimura M et al.; Molecular and genetic studies
of Fusarium trichothecene biosynthesis; Bioscence, Biotechnology, and Biochemistry; 71(9), (2007) 2105–2123, (https://doi.
org/10.1271/bbb.70183)
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1.3.2. Methods of analysis
1.3.2.1. Sampling and storage
In Commission Regulation (EC) No 519/20143, methods of sampling for the ofﬁcial control of the
levels of mycotoxins are laid down. This Regulation No 519/2014 amends the earlier Commission
Regulation (EC) No 401/20064. There are no speciﬁc requirements or recommendations which should
be followed concerning the sampling and the storage of the samples intended for the determination of
DAS. However, the same criteria prescribed for other Fusarium toxins should be applied to ensure the
reliability of the generated analytical data. Prior to the determination of DAS, a representative sample
must be provided. Due to the possible non-homogeneous distribution of DAS in lots (of grains),
sampling may contribute to a signiﬁcant extent to the variability in analytical results. After sampling,
the samples should be stored under appropriate conditions (dry, preferably frozen) until analysis to
prevent further Fusarium fungal growth and toxin production.
1.3.2.2. Methods of analysis of DAS
Analytical methods for type A trichothecenes in food, feed and biological samples, including DAS,
have been reviewed by Sforza et al. (2006), Z€ollner and Mayer-Helm (2006), Schollenberger et al.
(2007), Battilani et al. (2009), Lattanzio et al. (2009) and Berthiller et al. (2017). A limited number of
the studies reported in the review papers described analysis of DAS. Other compounds of the
scirpentriol subgroup, such as 15-MAS and SCT were rarely addressed.
The analysis of DAS is mainly part of multicomponent analytical methods (Berger et al., 1999; Asam
and Rychlik, 2007; Cavaliere et al., 2007; Malachova et al., 2014; Berthiller et al., 2017). DAS
reference standard as well as 13C isotope-labelled internal standard are commercially available.
Extraction of DAS from different matrices is mostly done with acetonitrile and water (Berthiller
et al., 2005; Asam and Rychlik, 2007), or with methanol and water (Cohen and Lapointe, 1984), or
with ethylacetate and formic acid (Diana Di Mavungu et al., 2009; Garcıa-Moraleja et al., 2015a,b). In
addition, QuEChERS-based extraction has been described, which is easy to handle (Desmarchelier
et al., 2010; Sospedra et al., 2010; Rodrıguez-Carrasco et al., 2013a,b; Tamura et al., 2015). Clean-up
is mainly based on solid-phase extraction, including MycoSep® and MultiSep® columns (Berger et al.,
1999; Kl€otzel et al., 2005; Asam and Rychlik, 2007; Schollenberger et al., 2007).
Different chromatographic methods have been described in the literature.
Thin-layer chromatography (TLC) was mainly used in the past but lacks sufﬁcient sensitivity and
speciﬁcity (Gimeno, 1979; Nowotny et al., 1983; Anaya et al., 2004).
Table 4: Animal and human phase I and phase II metabolites of 4,15-diacetoxyscirpenol (DAS)
Compound Element formula Molecular weight
Phase I metabolites
15-Monoacetoxyscirpenol (15-MAS), 4-deacetyl-DAS C17H24O6 324
4-Monoacetoxyscirpenol (4-MAS), 15-deacetyl-DAS C17H24O6 324
Scirpentriol (SCT), bis-deacetyl-DAS C15H22O5 282
8b-Hydroxy-DAS (8b-OH-DAS) C19H26O8 382
Neosolaniol C19H26O8 382
7-Hydroxy-DAS (7-OH-DAS) + isomer C19H26O8 382
Deepoxy-15-MAS C17H24O5 308
Deepoxy-SCT C15H22O4 266
Phase II metabolites
DAS-3-glucuronide C25H34013 542
15-MAS-3-glucuronide C23H32O12 500
15-MAS-4 glucuronide C23H32O12 500
3 Commission Regulation (EU) No 519/2014 of 16 May 2014 amending Regulation (EC) No 401/2006 as regards methods of
sampling of large lots, spices and food supplements, performance criteria for T-2, HT-2 toxin and citrinin and screening
methods of analysis. OJ L 147, 17.5.2014, p. 29–43.
4 Regulation (EC) No 401/2006 of the European Parliament and the Council of 23 February 2006 laying down the methods of
sampling and analysis for the ofﬁcial control of the levels of mycotoxins in foodstuffs. OJ L 70, 9.3.2006, p. 12–34.
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Gas chromatography (GC) followed by ﬂame ionisation detection (FID) (Bata et al., 1983; Furlong
and Valente Soares, 1995) and by electron capture detection (ECD) (Cohen and Lapointe, 1984) have
been reported. GC coupled to mass spectrometric (MS and MS/MS) detection is still popular (Thrane
et al., 2004; Schollenberger et al., 2011; Rodrıguez-Carrasco et al., 2013a,b; Escriva et al., 2015).
However, when using GC, a derivatisation step of the hydroxyl groups is needed to increase volatility
and sensitivity. Nielsen and Thrane (2001) described a GC–MS/MS method to detect several
trichothecenes simultaneously in Fusarium cultures, including neosolaniol, SCT, DAS, 15-MAS and
4-MAS. A two-dimensional GC–time-of-ﬂight-MS method has also been described for the simultaneous
analysis of trichothecenes including SCT, 15-MAS DAS, and TAS in wheat grain without sample
clean-up (Jelen and Wasowicz, 2008).
High-performance liquid chromatography coupled to UV detection (HPLC-UV) is not suitable for DAS
because of its low intensity of UV absorption and the need to use a very low wavelength (below 205
nm), unless derivatisation of the hydroxyl groups with a strongly UV absorbing compound is performed
(Maycock and Utley, 1985). Also HPLC methods with ﬂuorescence detection of ﬂuorescent derivatives
have been developed (Jimenez et al., 2000; Dall’Asta et al., 2004). However, HPLC–MS/MS and
ultra-performance liquid chromatography (UPLC)-MS/MS have the greatest potential because they can
be used for simultaneous detection of several mycotoxins and their metabolites/derivatives and are
commonly reported in recent literature for application in all kinds of food, feed and biological matrices
(Berger et al., 1999; Schollenberger et al., 2007; Gentili et al., 2007; Njumbe Ediage et al., 2011;
Vanheule et al., 2014, 2017). Moreover, high-resolution mass spectrometry has been used for
structural elucidation and quantiﬁcation of DAS metabolites and modiﬁed forms (Rubert et al., 2011;
Nakagawa et al., 2013a; Tamura et al., 2015; Yang et al., 2015; Lysoe et al., 2016).
The development of sensitive enzyme-linked immunoassays (ELISA) for DAS has been reported.
Klaffer et al. (1988) obtained a detection limit (LOD) for DAS of about 10 pg/mL using a polyclonal
antibody. Monoclonal antibodies (mAb) against DAS were developed by Chu et al. (1984), Pauly et al.
(1988) and Hack et al. (1989) with different cross-reactivities against neosolaniol, 4-MAS, 15-MAS, SCT
and TAS. Clare Mills et al. (1988) developed an ELISA method for DAS determination in wheat. Mayer
et al. (2000) developed a multi-mycotoxin rapid ﬂow-through immunoassay for simultaneous detection
of seven mycotoxins, including DAS, in wheat and maize.
A comparison of analytical methods and their limits of quantiﬁcation (LOQ) is shown in Table 5.
Table 5: Typical examples of the method characteristics and limits of quantiﬁcation (LOQ) of
analytical methods used for the determination of DAS in food and feed
Analytical
technique
Method characteristics
LOQ
(lg/kg)
References
TLC Screening (qualitative –
semi-quantitative)
2,400–4,000 Gimeno (1979), Nowotny et al. (1983)
ELISA Screening (qualitative –
semi-quantitative -
quantitative)
5–300 Clare Mills et al. (1988), Mayer et al.
(2000)
HPLC-UV/DAD
HPLC-FLD
Conﬁrmation (semi-
quantitative – quantitative)
Possible multi-analyte
detection
0.2–800 (= LOD) Jimenez et al. (2000), Dall’Asta et al. (2004)
Omurtag et al. (2007)
GC-FID GC-ECD Conﬁrmation (semi-
quantitative – quantitative)
Possible multi-analyte
detection
25–200 Cohen and Lapointe (1984), Furlong and
Valente Soares (1995), Jimenez and Mateo
(1997), Radova et al. (1998), Kotal et al.
(1999), Schothorst and Jekel (2001)
Schothorst and Jekel, (2003)
GC–MS(/MS) Conﬁrmation (semi-
quantitative – quantitative)
Possible multi-analyte
detection
4–550 Schollenberger et al. (1998), Milanez and
Valente-Soares (2006), Rodrıguez-Carrasco
et al. (2013a,b), Escriva et al. (2016)
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1.3.2.3. Analytical quality assurance: performance criteria, reference materials and
proﬁciency testing for analysis of food
In Annex II of the Regulation (EU) No 401/2006 of 23 February 2006, as amended by the
Regulation (EU) No 519/2014 of 16 May 2014, criteria for methods of analysis for the ofﬁcial control of
the levels of various mycotoxins are laid down. Performance criteria for methods of analysis of DAS
have not (yet) been established. The quality of analytical results regarding accuracy, precision and
comparability is essentially linked to the use of reference materials (RMs) and certiﬁed reference
materials (CRMs). Currently, CRMs are not available for DAS, but non-certiﬁed calibrant solutions of
DAS are commercially available. Proﬁciency tests for the determination of DAS are not organised.
1.3.3. Previous risk and exposure assessments on DAS
Only one scientiﬁc risk assessment on DAS in food and/or feed performed by national agencies or
national and international independent expert advisory committees was identiﬁed by the CONTAM
Panel; the recent assessment of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in
November 2016 (FAO/WHO technical report 1002, 2017).
For exposure assessment, a total of 11,842 available records in the GEMS/Food contaminants
database were analysed by the JECFA. In Europe, the prevalence of DAS in cereals and cereal based
food was found to be 1.5%. Low prevalence and low concentration of DAS in European countries were
also identiﬁed in published literature.
JECFA estimated dietary exposure of DAS using the concentration data from the GEMS/Food
contaminants database and the consumption data from the GEMS/Food cluster diets. Using the
substitution approach (because of the high proportion of left-censored data), lower and upper bounds
(LB–UB values) were calculated. The highest exposure level in the ﬁve worldwide regions for which
exposure estimates were available were found in Europe with LB–UB mean and high exposure
estimates for adults of 2.8–41 and 5.6–82 ng/kg body weight (bw) per day, respectively. However, the
JECFA recognised the huge uncertainty in the exposure estimates due to the high degree of left
censorship of these data.
JECFA evaluated previously published toxicological data on DAS and concluded that neither a
dose-effect relationship nor a point of departure could be derived from the limited available
toxicological data. The Committee noted (1) the existence of structural similarity between DAS and T-
2/HT-2 toxin, (2) the similarity of toxic effects of DAS and T-2/HT-2 toxin at biochemical and cellular
levels, which was consistent with results from in vivo toxicity studies, and (3) the indication for an
additive effect of the combined exposure to DAS and T-2/HT-2 toxins. JECFA concluded that there was
sufﬁcient evidence to support the establishment of a group provisional maximum tolerable daily intake
(PMTDI) for T-2/HT-2 toxins and DAS. The group PMTDI of 60 ng/kg bw per day established for T-2/
HT-2 toxins at the ﬁfty-sixth meeting of JECFA (2001), was considered to be sufﬁciently conservative
Analytical
technique
Method characteristics
LOQ
(lg/kg)
References
LC–MS(/MS) Conﬁrmation (semi-
quantitative – quantitative)
Possible multi-analyte
detection
0.05–125 Berger et al. (1999), Berthiller et al. (2005),
Biselli and Hummert (2005) Sørensen and
Elbæk (2005), Diana Di Mavungu et al.
(2009), Santini et al. (2009), Desmarchelier
et al. (2010), Njumbe Ediage et al. (2011),
Yang et al. (2013), Bryła et al. (2014),
Capriotti et al. (2014), Malachova et al.
(2014), Flores-Flores and Gonzalez-Penas
(2015), Dong et al. (2016)
LC–HRMS Conﬁrmation (semi-
quantitative – quantitative)
Possible multi-analyte
detection Identiﬁcation of
unknown compounds
5–80 Vaclavik et al. (2010), Rubert et al. (2011),
Tamura et al. (2015)
TLC: thin-layer chromatography; HPLC: high-performance liquid chromatography; UV: ultraviolet; DAD: diode array detection;
FLD: ﬂuorescence detection; GC: gas chromatography; FID: ﬂame ionisation detection; ECD: electron capture detection; LC:
liquid chromatography; MS: mass spectrometry; MS/MS: tandem mass spectrometry; HRMS: high-resolution mass spectrometry;
ELISA: enzyme-linked immunosorbent assay.
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to include DAS because of the observation that T-2 toxin was consistently more potent than DAS when
comparing similar in vitro and in vivo endpoints. However, it was recommended to update the JECFA
evaluation from 2001 since new toxicity data on T-2/HT-2 toxin became available.
In the 2001 JECFA evaluation, the total LB mean dietary exposure of T-2/HT-2 toxins from the
European population was estimated as 16.3 ng/kg bw per day, but no UB estimate was available at
that time. From the total LB dietary exposure estimates of 16 ng/kg bw per day for T-2/HT-2 toxin
from 2001 and the LB dietary exposure estimates of up to 2.8 ng/kg bw per day for DAS, the
Committee estimated a LB mean and high dietary exposure of 19 and 38 ng/kg bw per day (twice the
mean), respectively, for the sum of DAS and T-2/HT-2 toxin. The Committee concluded that the LB
estimates for Europe do not exceed the group PMTDI for T-2, HT-2 and DAS. The group toxins
exposure was therefore considered of low public health risk concern in the Europe.
1.3.4. Legislation
Worldwide, legal maximum levels (MLs) for DAS in food or feed products are scarce. Canada has a
maximum level for DAS in feed for swine at 2,000 lg/kg and in feed for poultry at 1,000 lg/kg. Israel
has a maximum level for DAS in all grains for feed at 200 lg/kg (FAO, 2004; Leatherhead Food
Research, 2010). In the EU, MLs in food for speciﬁc contaminants shall be established if this is
necessary to protect public health (Article 2 of Council Regulation (EEC) No 315/93 of February 1993
laying down Community procedures for contaminants in food5). Once adopted, they are laid down in
the Annex of Commission Regulation (EC) No 1881/2006. DAS is not included in this Annex. MLs for
undesirable substances in feed are laid down in EU Directive 2002/32/EC6. Annex I of this Directive
contains MLs of a number of inorganic and organic contaminants in feed. DAS is not regulated under
this Directive. While some Fusarium toxins are regulated within Recommendation 2006/576/EC7, in
which guidance levels are given for these mycotoxins in certain products intended for animal feed,
DAS is not included in the Recommendation.
1.3.5. Other supporting information
The CONTAM Panel noted that several reviews on trichothecenes and Fusarium toxins identiﬁed the
possible effects of DAS to humans and to several animal species (Ueno, 1983; D’Mello et al. 1999;
Conkova et al., 2003; Meissonier et al., 2008).
2. Data and methodologies
2.1. Methodology of data collection for supporting information for the
assessment
2.1.1. Collection and selection of evidence (search strategy, eligibility criteria)
for supporting information
A literature search was carried out for scientiﬁc evidence for the Sections 1.3 (Supporting
information for the assessment), 3.3.1 (Occurrence data on food and feed reported in the available
literature) and 3.4 (Food and feed processing). The collected scientiﬁc evidence in these sections, used
as background information for the assessment and for contributing data for the exposure assessment
(Section 3.3.1), was limited to the most relevant information identiﬁed by the experts of the CONTAM
Panel Working Group (WG) on Fusarium toxins.
A search for recent reviews was conducted to identify scientiﬁc publications dealing with methods
of analysis, chemistry, formation in food, exposure and occurrence in food and feed. The literature
5 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
6 Directive 2002/32/EC of the European Parliament and the Council of 7 May 2002 on undesirable substances in animal feed. OJ
L 140, 30.5.2002, p. 10–21.
7 Commission Recommendation 2006/576/EC of 17 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A,
T-2 and HT-2 and fumonisins in products intended for animal feeding. OJ L 229, 23.8.2006, p. 7–9.
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search was performed in February 2017 and October 2017 for updated information. Web of Science,8
PubMed9 and Embase10 were identiﬁed as databases appropriate for retrieving literature for the
present evaluation using the word ‘diacetoxyscirpenol’ as the key term word (‘DAS’ was not used as a
keyword since it is the acronym of many other unrelated words). The references resulting from the
literature search were imported and saved using a software package (EndNote11), which allows
effective management of references and citations. Additionally, reviews and relevant scientiﬁc
evaluations by national or international bodies were considered for the current risk assessment, i.e.
JECFA (2016). When relevant papers were identiﬁed during the risk assessment process (e.g. from
other studies or reviews), they were also considered. The references obtained were screened using
title and abstract to identify relevant literature.
2.1.2. Appraisal of evidence for supporting information
The inclusion of studies for the Sections 1.3 (Supporting information for the assessment), and 3.4
(Food and feed processing) was based on consideration by the expert judgement of the CONTAM WG
on Fusarium toxins on the extent to which the study was informative and relevant for the assessment
and taking account of study quality considerations. With regard to the Section 3.3.1 (Occurrence data
on food and feed reported in the available literature), the appraisal and reporting of selected data
used for the exposure assessment were in compliance with the quality requirements of EFSA for the
occurrence data (see Section 2.3).
2.2. Methodology of data collection for hazard identiﬁcation and
characterisation
2.2.1. Collection and selection of evidence (search strategy, eligibility criteria)
for hazard identiﬁcation and characterisation
A literature search was conducted in scientiﬁc databases aimed at identifying relevant studies
published in the open scientiﬁc literature and in scientiﬁc peer-reviewed journals until 6 February 2017.
The collection of scientiﬁc studies available in the public domain was done by searching scientiﬁc
literature databases (Web of Science, PubMed and Embase) using the word ‘diacetoxyscirpenol’ as the
key term word (‘DAS’ was not used as a keyword since it is the acronym of many other unrelated
words). The search aimed to retrieve as many studies as possible that might be relevant for hazard
identiﬁcation and hazard characterisation of DAS. The search was not limited to the evidence published
in English language. No ﬁlters were applied regarding language and date of publication. The references
resulting from the literature search were imported and managed using a software package (EndNote).
An update of this literature search was conducted on 12 October 2017, in order to retrieve any
additional papers published from January 2017.
In addition, on 12 October 2017, a literature search was performed using the diacetoxyscirpenol
synonym: ‘anguidine’. In order to avoid duplicates, ‘Diacetoxyscirpenol’ was excluded using the
Boolean operator ‘NOT’.
All the references retrieved in February and October 2017 were uploaded in Endnote.
The literature search details are given in Appendix B.
2.2.2. Appraisal of evidence for hazard identiﬁcation and characterisation
The retrieved evidence was reviewed by the CONTAM WG on Fusarium toxins and has been used
for this assessment as considered relevant by expert judgement. Any limitations noted by the WG in
the evidence used for the risk assessment of DAS in food and feed are described in this scientiﬁc
opinion. Selection of the scientiﬁc papers considered study quality and the extent to which the study
was relevant (e.g. sufﬁcient details on the methodology, performance and outcome of the study,
information on dosing and route of administration and details of reporting).
8 Web of Science (WoS), formerly ISI Web of Knowledge, Thomson Reuters. Available online: http://thomsonreuters.com/
thomson-reuters-web-of-science/18
9 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI),
NationalLibrary of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health
andHuman Services. Available online: http://www.ncbi.nlm.nih.gov/pubmed
10 Embase – Elsevier. Available online: https://www.elsevier.com/solutions/embase-biomedical-research
11 EndNote X8, Thomson Reuters. Available online: https://endnote.com/
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The amount of available data on DAS for different sections of the assessment varied greatly. In a
ﬁrst step, only those data from which it could clearly be concluded that the adverse effects in
experimental and farm and companion animals were associated with an oral exposure to DAS alone
were included in the sections on hazard characterisation of humans and farm and companion animals.
Second, papers reporting oral co-exposure to DAS and other mycotoxins were included when it was
clear from the study description and content that the co-exposure did not have a substantial impact on
toxicity of DAS: for example when the other identiﬁed mycotoxins had concentrations that were not
considered to induce or notably contribute to the observed adverse effects, or when the other
identiﬁed mycotoxins were known to have speciﬁc adverse effects which could not be attributed to
DAS, or when the other identiﬁed mycotoxins were not expected to interact with the effects of DAS.
The information retrieved has been screened and evaluated by relevant domain experts from the
CONTAM WG on fusarium toxins in food and feed and has been used for the present assessment. Any
limitations in the information used are documented in this scientiﬁc opinion. Selection of the scientiﬁc
papers for inclusion or exclusion was based on consideration of the extent to which the study was
relevant to the assessment or on general study quality considerations (e.g. sufﬁcient details on the
methodology, performance and outcome of the study, on dosing, substance studied and route of
administration and on statistical description of the results), irrespective of the results.
List of papers assessed with reason(s) for exclusion by the relevant domain expert is stored in the
EFSA document management system.
2.3. Occurrence data on DAS used for the assessment
2.3.1. Data collection and validation
Following an European Commission mandate to EFSA, a call for annual collection of chemical
contaminant occurrence data in food and feed, including DAS, was issued by the former EFSA Dietary and
Chemical Monitoring Unit (now DATA Unit) in December 2010 with a closing date of 1 October of each
year. European national authorities and similar bodies, research institutions, academia, food business
operators and other stakeholders were invited to submit analytical data on DAS in food and feed.
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures on ‘Data collection and validation’ and on ‘Data analysis of food
consumption and occurrence data’.
In the data validation phase, data identiﬁed as suspect samples were excluded from the present
analysis. Suspect samples are usually samples taken from the same site as a consequence of evidence
or suspicion of contamination, and are often taken as a follow-up of demonstrated non-compliance
with legislation. Some of the remaining samples may also have been collected in a more targeted way
(i.e. selective sampling, convenient sampling) (see also Section 2.3.2).
Data on DAS in food and feed available in the EFSA database from 2000 onwards to the end of
December 2017 were used for the present assessment. Data received after this date were not included
in the data set used for further evaluation for this opinion.
In addition to the occurrence data collected from the Member States within the call for data, the
CONTAM Panel also searched the published literature for occurrence data of DAS in food and feed for
possible inclusion as additional data in the occurrence data sets submitted to EFSA within the call for
data and to be used for the exposure assessment. The literature data were included when they
conformed to the most important EFSA requirements on data collection and validation, and the details
on country of origin, product, analytical method, LODs/LOQs and occurrence levels (e.g. mean,
median) were adequately reported.
2.3.2. Data analysis
Following the EFSA Standard Operating Procedure (SOP) on ‘Data analysis of food consumption and
occurrence data’ to guarantee an appropriate quality of the data used in the exposure assessment, the
initial data set was carefully evaluated applying several data cleaning and validation steps. Special
attention was paid to different parameters such as ‘Sampling strategy’, ‘Sampling method’, ‘Sampling
year’, ‘Sampling country’, ‘Analytical methods’, ‘Reporting unit’, ‘LOD/LOQ’, and the codiﬁcation of the
different samples under FoodEx classiﬁcation.
In the analysis of DAS occurrence data, the left-censored data (results below LOD or below LOQ)
were treated by the substitution method as recommended in the ‘Principles and Methods for the Risk
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Assessment of Chemicals in Food’ (WHO, 2009). The same method is indicated in the EFSA scientiﬁc
report ‘Management of left-censored data in dietary exposure assessment of chemical substances’
(EFSA, 2010b) as an option in the treatment of left-censored data. The guidance suggests that the LB
and UB approach should be used for chemicals likely to be present in the food (e.g. naturally occurring
contaminants, nutrients and mycotoxins). The LB is obtained by assigning a value of zero (minimum
possible value) to all samples reported as lower than the LOD (< LOD) or LOQ (< LOQ). The UB is
obtained by assigning the numerical value of LOD to values reported as < LOD and LOQ to values
reported as < LOQ (maximum possible value), depending on whether LOD or LOQ is reported by the
laboratory.
2.4. Food consumption
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest
version of the Comprehensive Database updated in 2018 contains results from a total of 60 different
dietary surveys carried out in 25 different Member States covering 119,458 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as follows:
Infants: < 12 months old
Toddlers: ≥ 12 months to < 36 months old
Other children: ≥ 36 months to < 10 years old
Adolescents: ≥ 10 years to < 18 years old
Adults: ≥ 18 years to < 65 years old
Elderly: ≥ 65 years to < 75 years old
Very elderly: ≥ 75 years old
Four additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (≥ 15
years to ≤ 45 years old, Latvia; 17 years old to 46 years old, Portugal) and ‘Lactating women’ (≥ 28
years to ≤ 39 years old, Greece; 18 years old to 45 years old, Estonia).
For chronic exposure assessment, food consumption data were available from 53 different dietary
surveys carried out in 22 different European countries. When for one particular country and age class
two different dietary surveys were available, only the most recent one was used. This resulted in a
total of 38 dietary surveys selected to estimate chronic dietary exposure.
For the acute assessment, recent food consumption data was available for 43 surveys of 25
countries.
In a separate Excel document, Annex A_Table 3, these dietary surveys and the number of subjects
available for the acute and chronic exposure assessment are described.
The food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering from 3 to 7 days per subject.
Because of the differences in the methods used for data collection, direct country-to-country
comparisons can be misleading.
2.5. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011c).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. The system consists of a large number of individual food items aggregated into food
groups and broader food categories in a hierarchical parent–child relationship. It contains 20 main food
categories (ﬁrst level), which are further divided into subgroups having 140 items at the second level,
1,261 items at the third level and reaching about 1,800 end-points (food names or generic food
names) at the fourth level.
2.6. Feed consumption
DAS is predominantly found in cereal crops, cereal grains and in by-products of cereal processing,
all of which are widely used as feed for farm animals in Europe. They may be included as ingredients
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of manufactured complete feedingstuffs, or fed directly as individual feeds to livestock. In 2015, more
than 90 million tonnes of cereals and cereal by-products were used in the manufacture of compound
feeds, accounting for 60% of all feed materials used, almost all of which (> 95%) are grown or
produced in the EU. In addition, a further 51 million tonnes of cereal grains and by-products were fed
in on-farm mixes or as single ingredients. However, there are no industry data on the partition of these
cereal grains between livestock species (cattle, pigs, poultry, etc.).
There is considerable variation in both the feeds used and the feeding systems adopted for farm
livestock, companion animals and ﬁsh throughout Europe. This variation is largely due to the
availability of feeds and market demands for speciﬁc animal products, the quality of the feeds available
and nutritional needs of the animals concerned. For many livestock, part or all of the daily ration
is provided in the form of manufactured compound feeds and, where data on levels of DAS in
species-speciﬁc compound feeds are available, these have been used to estimate exposure. However,
for most of the livestock categories information on levels in compound feeds has not been given, or
insufﬁcient data have been provided to allow reliable estimates of exposure to be made. Therefore,
data on individual feed materials (see Appendix E) and estimates of intake have been used to estimate
exposure. It should be stressed that these do not represent ‘average’ diets, nor are the feeding
systems ‘typical’ for all of Europe. Instead, they are used to estimate levels of exposure to DAS that
might be indicative. They are based on published guidelines on nutrition and feeding (AFRC, 1993;
Carabano and Piquer, 1998; NRC, 2007a,b; Leeson and Summers, 2008; OECD, 2009; McDonald et al.,
2011; EFSA FEEDAP Panel, 2012) data on EU manufacture of compound feeds (FEFAC, 2009) and
expert knowledge of production systems in Europe. For companion animals (cats and dogs),
information on typical diet formulations have been provided by The European Pet Food Industry.
Details of feed consumption of farm and companion animals and the rations used are given in
Appendix E.
2.7. Feed classiﬁcation
Feeds were classiﬁed based on the catalogue of feed materials speciﬁed in the Commission
Regulation (EU) No 68/2013 as amended by 2017/201712 creating the Catalogue of feed materials.
Where information was available, compound feedingstuffs were classiﬁed in groups based on the
species/production categories for which the feed is intended.
2.8. Methodology for exposure assessment for DAS
2.8.1. Methodology for DAS exposure assessment in humans
The CONTAM Panel estimated acute and chronic exposure to DAS for all age groups (see
Section 3.4). The food categories represented by either very low number of samples (≤ 6 samples) or
by all data left-censored on FoodEx Level 2 were considered not being suitable and were not used in
exposure calculation.
For matching the occurrence and the consumption data, standard dilution factors commonly used in
EFSA opinions were applied in case of coffee and cereal-based foods which are to be reconstituted.
The proportion of left-censored data after excluding the categories containing 100% left-censored
data was generally very high (97%). The chronic dietary exposure cannot be performed accurately if a
large proportion of left-censored data is included (WHO, 2009; EFSA, 2011b). Therefore, the large
proportion of left-censored data and the limited available data add uncertainty to the chronic dietary
exposure assessment. Since this was the case for most of the food categories, the results of the
present assessment should be interpreted with caution. It should be noted that with a high proportion
of left-censored data, the exposure is likely to be underestimated with the LB approach, whereas it
may be highly overestimated with the UB approach (see also Section 4).
2.8.1.1. Acute dietary exposure
Acute dietary exposure to DAS was estimated using a probabilistic approach. For calculating acute
dietary exposure to DAS, food consumption and body weight data at the individual level were
accessed in the Comprehensive Database. The acute dietary exposure to DAS was calculated for each
reporting day, since individual meals are recorded for only a few countries in the consumption
12 Commission Regulation (EU) No 2017/2017 of 15 June 2017 amending Regulation (EU) No 68/2013 on the Catalogue of feed
materials. OJ L 159, p. 48–119.
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database. The preferred option is, therefore, to use individual days of consumption. Days of
consumption offer a conservative estimate of the exposure, since it will sum the contribution of all
meals during the same day.
Acute exposure was assessed for each reporting day by multiplying the total consumption amount
for each food category by an occurrence level randomly drawn among individual results available for
that food category. Respective intakes of the foods consumed that day were summed and ﬁnally
divided by the individual’s body weight. This process was iterated 500 times for each day of
consumption reported by each participant. For the calculations, occurrence data estimated using the
UB approach was used. The UB approach is a conservative approach, which better reﬂects the purpose
of an acute exposure compared to the LB approach. For each of these endpoints, the 95% conﬁdence
interval was deﬁned as the 2.5th and 97.5th percentiles obtained from the 1,000 iterations. All
analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1), including the
modelling of the probabilistic acute exposure.
2.8.1.2. Chronic dietary exposure
As suggested by the EFSA Working Group on Food Consumption and Exposure (EFSA, 2011a),
dietary surveys with only 1 day per subject were not considered for chronic exposure as they are not
adequate to assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary
studies, when the protocol prescribed more reporting days per individual, were also excluded for the
chronic exposure assessment. Not all countries provided consumption information for all age groups,
and in some cases the same country provided more than one consumption survey.
For calculating chronic dietary exposure to DAS, food consumption and body weight data at the
individual level were accessed in the Comprehensive Database. Occurrence data and consumption data
were linked at the relevant FoodEx level.
The mean and the high (95th percentile) chronic dietary exposures were calculated by combining
DAS mean occurrence values for food samples collected in different countries (pooled European
occurrence data) with the average daily consumption for each food at individual level in each dietary
survey and age class. Consequently, individual average exposures per day and body weight were
obtained for all individuals. On the basis of distributions of individual exposures, the mean and 95th
percentile exposure were calculated per survey and per age class. Dietary exposure was assessed using
overall European LB and UB mean occurrence of DAS. The contribution (%) of each food category to
overall mean chronic exposure of DAS was calculated for each age group and dietary survey.
Estimations of chronic exposure using the LB approach, which is considered to be less inﬂuenced by
results below LOD/LOQ, were used to explain the contribution of the different food categories.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1).
2.8.2. Methodology for DAS exposure assessment in farm and companion
animals
Commercially manufactured compound feeds (as complete or complementary feedingstuffs) are
important – and frequently the sole – feeds for livestock and companion animals. Ideally, levels of DAS
in these feeds should be used, together with estimates of intake (given in Appendix E) to estimate
exposure. However, in this Opinion data were only available for poultry starter feeds.
For all other species, the mean and 95th percentile (high) exposures have been made using the
levels of DAS in individual feed materials, estimates of their inclusion in the diets of the animals feed
consumed and levels of intake. Details on the diet compositions and feed intakes for each livestock
category are given in Appendix E. It should be stressed that these do not represent either ‘average’ or
‘extreme’ diets, nor are the feeding systems ‘typical’ for all of Europe. Instead, the diets are used to
estimate levels of exposure to DAS that might be indicative. They are based on published guidelines
on nutrition and feeding (AFRC, 1993; Carabano and Piquer, 1998; NRC, 2007a,b; Leeson and
Summers, 2008; McDonald et al., 2011; EFSA FEEDAP Panel, 2012; OECD, 2013), and expert
knowledge of production systems in Europe. Details of the rations used feed intakes and live weights
assumed are given in Appendix E.
DAS generally occurs in cereals crops, cereal grains and by-products of cereal processing, both for
human food and biofuel production, and these may account for 60% or more of the diet of farm and
companion animals. However, diets also include a wide range of other feed materials, particularly
vegetable proteins and by-products of food manufacture, but since no data are available on levels of
DAS in these feeds it has not been possible to estimate the contribution they make to exposure to DAS.
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For ruminant livestock and horses, forages represent essential ingredients in their diets. With the
exception of maize silage, no data on the presence of DAS in forages were available and therefore it is
assumed that, with the exception of maize silage-based diets forages make no contribution to the
exposure to DAS.
According to EFSA (2011a,b,c), caution is needed when calculating acute exposure (95th percentile)
where data on less than 60 samples are available, since the results may not be statistically robust.
Therefore, in this Opinion estimates of 95th percentile have not been made where data on < 60 samples
are available.
2.9. Methodology for risk characterisation
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), i.e. hazard identiﬁcation and characterisation, exposure assessment
and risk characterisation. Several EFSA guidance documents were applied in the assessment of DAS in
food and feed listed in Appendix A.
3. Assessment
3.1. Hazard identiﬁcation
3.1.1. Toxicokinetics in experimental animals and humans
3.1.1.1. Absorption
Absorption of DAS after oral administration has not been quantiﬁed in experimental animals or
humans. However, the excretion ratio in urine vs faeces was 4.5:1 in mice and in rats indicating that a
high proportion of DAS is absorbed, see the subsection on excretion below.
3.1.1.2. Distribution
Wang et al. (1989) administered a single oral dose of 0.55 mg 3H-labelled DAS/kg bw
intragastrically to rats and a slightly higher dose of 0.66 mg DAS/kg bw to mice. Four animals of each
species were euthanised after 90 min, 24 h and 7 days. No visible signs of toxicity were observed. The
distribution patterns, expressed as percentage of the dose, were very similar in mice and rats, with
rapid excretion (from 75% to 95%) in the ﬁrst 24 h. After 7 days, only 1–3% was found in carcass
and organs. At 24 h, distribution mainly in intestine, spleen, thymus, femur and testis (mouse) was
recorded. The Panel noted that the radioactivity levels were higher and the decrease slower in known
target organs compared to other organs.
The radioactivity in the brain was low, but decreased relatively slowly compared to other tissues.
Differences in tissue concentrations in rats and mice were small. The mice generally tended to have
higher concentrations in kidneys and liver as well as in heart and lymphoid tissues and rats tended to
have higher concentrations in the small intestine.
3.1.1.3. Metabolism
In vitro
DAS was incubated with faecal microbiota from rats in a study which also considered cattle, pigs,
chickens, horses and dogs (see Section 3.1.2) (Swanson et al., 1988). In rats, DAS was completely
transformed to deepoxy MAS (66.5%) and deepoxy SCT (33.5%). In incubations with rat caecal
content, DAS was completely transformed to deepoxy MAS (81.9%), deepoxy SCT (17.8%) and SCT
(0.3%).
DAS was deacetylated in the position 4 to form 15-MAS in microsomal incubations with rat or rabbit
liver microsomes (Ohta et al., 1978). The in vitro velocity was about six times lower after incubation
with liver microsomes from rats than from rabbits. No peaks other than of DAS and MAS were seen in
the chromatograms and the sum of DAS and MAS was almost equal to the initial amount of DAS.
Carboxylesterases isolated from CD-1 mouse liver microsomes deacetylated DAS in the position 4 to
form 15-MAS (Wu and Marletta, 1988).
Isolated rat liver was perfused with 2 mg of DAS and the bile was collected and analysed for
metabolites with and without enzymatic treatment with glucuronidase (Gareis et al., 1986). In the bile,
340 lg MAS-glucuronide and 10 lg SCT were found. This approach did, however, not allow a
determination of the positions for hydroxylation and glucuronidation reactions to occur.
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Yang et al. (2015) performed a comparative study of the in vitro phase I and phase II metabolism
of DAS using liver microsomes from rats, chickens, pigs, goats, cows and humans. DAS was incubated
with liver microsomes and incubates were later analysed by UHPLC-QTOF. DAS was extensively
metabolised in microsomal incubates from all these species. The main phase I metabolic
transformations were hydrolysis (deacetylation) in C-4 and/or C-15 positions and hydroxylation in C-8
or C-7 positions (Figure 3). The main phase II metabolites found were DAS-3 glucuronide, 15-MAS 3
glucuronide and 15-MAS-4 glucuronide. The metabolite patterns varied between species. Human liver
microsomes had the highest ability to metabolise DAS. 15-MAS was the main metabolite in the six
species studied. It was particularly high in human microsomes. Incubations with rat liver microsomes
produced seven phase I metabolites while incubations with human liver microsomes produced ﬁve.
4-MAS was only detected in incubations with rat liver microsomes and only in trace amounts. Three
phase II metabolites were described in this in vitro study, namely, DAS-3 glucuronide, 15-MAS-3-
glucuronide and 15-MAS-4-glucuronide All three were detected in incubations with both rat and human
liver microsomes. DAS-3-glucuronide was the main conjugate in incubations with human liver
microsomes (also in the case of pigs, goats and cows), while 15-MAS-3-glucuronide was the main
metabolite in incubations with rat liver microsomes.
In vivo
Male Wistar rats were given three oral doses of 2.8 mg DAS/kg bw on days 0, 7 and 14 (Sakamoto
et al., 1986). Urine and faeces were collected daily for 21 days. MAS, SCT, -deepoxy MAS and deepoxy
SCT were detected in the urine, while only the deepoxide metabolites were detected in the faeces.
Yang et al. (2015) gave a single oral dose of 3 mg DAS (purity > 98%)/kg bw to fasting rats
(n = 3/sex) with the aim to verify that the metabolites found in vitro also are formed in vivo. Urine and
faeces were collected 0–12 h and 12–24 h post-dosing. DAS was found together with four metabolites,
4-MAS, 15-MAS, neosolaniol and 7-OH-DAS in the urine samples collected in the time period 0–12 h
Figure 3: Proposed phase I and II metabolic pathways of 4, 15 – DAS: (A) hydrolysis, (B)
hydroxylation, (C) glucuronidation - from Yang et al. (2015)13
13 Reprinted by permission from Nature/Springer/Palgrave; Yang S et al.; Unraveling the in vitro and in vivo metabolism of
diacetoxyscirpenol in various animal species and human using ultrahigh-performance liquid chromatography-quadrupole/time-
of-ﬂight hybrid mass spectrometry, Analytical and Bioanalytical Chemistry; (2015) 407: 8571-8583, (https://doi.org/10.1007/
s00216-015-9016-4)
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post-dosing, while only 15-MAS and 7-OH-DAS were detected in the faeces. Consistent with the
in vitro results, 15-MAS and 7-OH-DAS were the main metabolites found. No metabolites could be
detected in the samples collected 12–24 h post-dosing. In contrast to in vitro studies, no glucuronide
conjugates were detected neither in faeces nor in urine. No deepoxide metabolites were detected in
this study.
3.1.1.4. Excretion
Urine and faeces samples were collected in rats and mice up to 7 days after a single oral dose of
respectively 0.55 or 0.66 mg 3H-labelled DAS/kg bw (Wang et al., 1989, see also the subsection on
distribution above). DAS was rapidly excreted and 93.7% and 90.3% of the dose was excreted in rats
and mice, respectively, during the ﬁrst 24 h. The urinary to faecal excretion ratio was 4.5 in both
species. The excretion was accompanied by a corresponding decrease in radiolabelled DAS in
gastrointestinal (GI) content, organs and carcass. The radioactivity in the animals levelled out during
the following 6 days, indicating that a small fraction of DAS remained in the tissue for a prolonged
time period.
3.1.1.5. Summary
In vitro, DAS is metabolised to a large number of metabolites. The main metabolic processes are
deacylations, hydroxylations, deepoxidations and glucuronide conjugations. Deepoxidation reactions
have primarily been found after incubation with GI content or faeces.
After oral administration in rats and mice, the absorption of DAS has not been quantiﬁed but the
excretion ratio in urine and faeces indicated high absorption. After absorption, DAS was rapidly
distributed to most organs. Tissue concentrations decreased rapidly with no apparent accumulation in
any tissue and more than 90% of radiolabelled DAS was excreted within 24 h, with an approximate
80% via urinary excretion. Only 2–3% of orally administered DAS was estimated to remain in the body
after a few days. DAS was rapidly metabolised to a large number of metabolites in vivo.
3.1.2. Toxicokinetics in farm and companion animals
A few studies conducted in farm animals either in vitro or in vivo have been identiﬁed, and as a
result only limited data in a few farm animal species were available. For companion animals, few
in vitro data were available for horses and dogs.
3.1.2.1. In vitro studies
Few studies on the in vitro biotransformation of DAS in farm animals have been identiﬁed. DAS was
incubated for 12, 24 and 48 h under anaerobic conditions in rumen ﬂuids (Swanson et al., 1987). MAS,
SCT and their deepoxide metabolites were detected in the incubates. Deepoxy-DAS was not detected.
In another experiment (see also Section 3.1.1.3), these authors incubated DAS with faecal
microbiota from cattle, pigs, chickens, horses and dogs (Swanson et al., 1988). One mg DAS was
incubated with 2 mg of faeces or intestinal suspensions for 4 days at 37°C. DAS was completely
transformed in the incubations from pigs and cattle, primarily to deepoxy MAS (62% and 32%) and
deepoxy SCT (24% and 40%), while smaller amounts of MAS (13% and 2%) and SCT (2% and 4%)
were also detected. In addition, 8% of unmetabolised DAS was found in the incubations from cattle.
In contrast to this, no deepoxide metabolites of DAS could be detected in faecal incubations from
horses, dogs or chickens. However, de-acetylated metabolites MAS and SCT were found in the faecal
incubations from these species, together with unmetabolised DAS.
The rapid conversion of DAS by anaerobic rumen microorganisms to metabolites has been shown in
several studies.
The in vitro biotransformation by bovine rumen ﬂuid resulted in the recovery of 24.1% of DAS (as
administered), 21.4% of deepoxy-15-MAS, 25.7% of SCT and 15.1% of deepoxy-SCT. DAS was not
detected after 48 h of incubation (Swanson et al., 1987). Isolated bacteria cultured from ovine rumen
ﬂuid (Matsushima et al., 1996) as well as isolated protozoa from ovine rumen ﬂuid (Kiessling et al.,
1984) were capable to deacetylate DAS to 15-MAS. The protozoa were more active than the bacteria
(Kiessling et al., 1984).
Gut microbiota from catﬁsh (Ameriurus nebulosus) which are known to transform DON to its
deepoxy metabolite, was also incubated with 50 lg DAS/mL for 96 h (Guan et al., 2009). After the
incubation, 54% of the added toxin was present as MAS deepoxide (form not speciﬁed), 42% as DAS
and 4% as MA (form not speciﬁed).
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3.1.2.2. In vivo studies
Ruminants
The only available in vivo toxicokinetic study on DAS in ruminants showed a rapid distribution and
metabolism after i.v. administration of 0.5 mg DAS/kg bw to four heifers (body weight 74.5–139.1 kg)
(Coppock et al., 1987). The volume of distribution was calculated as 1.9–3.5 L/kg, the total body
clearance (TBC) as 162.6–502.8 mL/min per kg and the t1/2 (half-life) in blood as 3.8–10.5 min. DAS
was rapidly metabolised to 15-MAS and SCT, 15 min after i.v. administration only 0.14 ng/mL of DAS
being detected in urine, while 15-MAS amounted to 2.10 ng/mL and SCT to 1.17 ng/mL.
Pigs
Three studies on toxicokinetics of DAS in pigs were available. Bauer et al. (1985) observed a rapid
absorption of DAS after a single oral dose of 2 mg/kg bw in female pigs (n = 4, mean bw 20 kg) The
highest amounts of DAS (9.6–21.9 ng/mL) were detected within 0.5–1 h in blood serum. The peak
concentrations of the metabolite 15-MAS (5.9–13.2 ng/mL) were measured after 0.5–4 h, while the
highest values of SCT (1.6–14.8 ng/mL) appeared after 0.5–6 h. In a follow-up report, these authors
noted that following oral administration of 2 mg DAS per kg bw, the amount of DAS and its
metabolites excreted in the urine was low, in contrast to faeces, where much higher values were found
(Bauer et al., 1989; Bauer, 1995). Within 72 h, deepoxidised MAS and SCT amounted to 30 and 1,975
lg, respectively, while 42 lg of MAS and 583 lg of SCT were found. The highest proportion was
detected in the ﬁrst 6 h after administration. Regarding the resulting toxicokinetic parameters it should
be taken into account, that up to 26% of the administered dose was eliminated, partly presystemic
hydrolysed to 15-MAS (2.3% on average), by vomiting (Bauer et al., 1989). Furthermore, the
quantiﬁcation of the deepoxide metabolites in the faeces was performed by re-measuring the samples
of only one pig (personal communication).
Coppock et al. (1987) surveyed the pharmacokinetics of DAS following i.v. administration. Two
groups of pigs (25–49.2 kg) received 0.5 (n = 4) or 1 (n = 3) mg DAS/kg bw over 48 h, respectively,
after halothane anaesthesia. The t1/2 (half-life) in blood varied in the group dosed 0.5 mg/kg between
7.5 and 150.7 min and the TBC between 27.25 and 191.67 mL/min per kg. DAS was extensively
metabolised to MAS and SCT, the highest urinary concentrations 15 min after i.v. administration being
0.51 (DAS), 0.80 (MAS) and 10.4 ng/mL (SCT). In plasma, no DAS or MAS could be found 8 h after
i.v. administration, while 240 lg/kg of SCT was detected.
Chickens
Only one study was found on the in vivo metabolism in chickens. Yang et al. (2015) administered
a single dose of DAS (> 98% pure) of 3 mg/kg bw to three male and three female Avian chickens
(1.0–1.2 kg) by gavage. During the 0- to 12-h period after administration, 15-MAS and 7-OH-DAS were
detected in the faeces and urine using a LC–MS method. In the following period of 12–24 h
post-administration, no metabolites were detected.
Regarding phase II metabolites, no glucuronide conjugates were detected. The authors concluded
that DAS is rapidly absorbed from the GI tract and extensively metabolised and excreted in chickens
(Yang et al., 2015).
3.1.2.3. Summary
Although in vivo studies on the toxicokinetics of DAS in farm animals are rare and not all relevant
parameters have been determined, a rapid absorption, distribution, metabolism and excretion (ADME)
of this mycotoxin was generally shown. In pigs, the majority of DAS and its metabolites were excreted
in faeces within one day and plasma peaks of DAS and its metabolites were quickly reached. Following
i.v. administration, the half-life in blood was very short (less than 30 min) and total body clearance
was fast. Highest urinary concentrations were seen 15 min after i.v. administration. Neither DAS nor
MAS were found in plasma 8 h after i.v. administration. The main systemic metabolites were
determined as 15-MAS and SCT. In pigs, a large portion of orally administered DAS could be found in
faeces, mainly as deepoxidised SCT.
The data of only one study in chickens receiving a single oral dose at 3 mg DAS/kg bw, indicated
that DAS is rapidly absorbed from the GI tract, extensively metabolised and excreted as 15-MAS and
7-OH-DAS in faeces and 7-OH-DAS in urine. No glucuronide conjugates were detected.
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3.1.3. Transfer
Only one study was found on the transfer of DAS. Yang et al. (2013) developed a LC–MS method
for the detection and determination of DAS and T-2 and HT-2 toxins in chicken tissues (heart, liver,
spleen, lung, kidney, glandular stomach, muscular stomach, small intestine, muscle, bone and brain).
The method was applied following a 6-week period feeding of two 42-day-old chickens with a diet
prepared from corn samples inoculated by F. poae producing T-2 toxin, HT-2 toxin and DAS. The toxin
contents in feed were mentioned as low but the levels were not reported by the authors. The
concentrations of DAS in the various tissues were not detected except in the heart and the brain.
However, because of the unknown DAS levels in feed and daily consumption by the two birds, no
percentages of transfer could be calculated.
No data were available for possible transfer to milk.
The CONTAM Panel considered that there is insufﬁcient evidence to conclude on the transfer of DAS
from feed.
3.1.4. Toxicity in experimental animals
3.1.4.1. Acute toxicity
The CONTAM Panel identiﬁed several studies which characterise the oral acute toxicity of DAS in
rodents as well as acute toxicity after i.v. exposure in other experimental animal species which were
tested in preclinical studies for the development of DAS (named anguidine) as a cytostatic anticancer
drug. The oral, intraperitoneal (i.p.) and the i.v. routes were considered relevant to describe the acute
toxicity (LD50 values summarised in Table 6).
The CONTAM Panel noted that the data from Ueno (1983) are not precisely described in the
publication and references were incomplete, it was noted that some LD50 values were extracted from
St€ahelin et al. (1968) who reported LD50 values after i.v. exposure in mouse, rat, rabbit and dogs in
which death occurred after 48 h (except in rabbits, after 4 days). Apathy, reduced breathing, cyanosis,
diarrhoea, bloody stool, vomiting, tremor and tachycardia were observed.
Table 6: Acute toxicity with DAS LD50 values associated with oral, intravenous and intraperitoneal
exposure in rodents and experimental animals
Species (gender)
Origin and
purity of DAS
Doses tested
(mg/kg bw)
LD50
(mg/kg bw)
Reference
Oral treatment
Male CD-I mouse ND 2–22 15.5
12
Conner et al.
(1986), Ueno (1983)
Rat ND ND 7.3 Ueno (1983)(a)
Guinea pig Crystalline (no more
information)
0, 1, 2, 4, 8 2.14 Kriegleder (1981)
Intravenous treatment
Mouse ND ND 12 Ueno (1983)(a)
Rat ND ND 1.3 Ueno (1983)(a)
Rabbit ND ND 1.0 Ueno (1983)(a)
Dog ND ND 1.1
(approximate)
Ueno (1983)(a)
Intraperitoneal treatment
Male CD-I mouse ND 2–22 20 Conner et al. (1986)
Mouse ND ND 23 Ueno (1983)
Rat ND ND 0.75 Ueno (1983)
bw: body weight; DAS: diacetoxyscirpenol; ND: not documented.
(a): LD values reported by St€ahelin et al. (1968 - in German) and in a review from Ueno (1983).
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Oral administration
Mice
Conner et al. (1986) performed an acute toxicity study in male CD-I mice. DAS was administered to
groups of four to six mice by gastric gavage with doses from 2 to 22 mg/kg bw, doubling the starting
dose and later increasing it by a factor of 1.5. The LD50 at 96 h was calculated as 15.5 mg/kg bw.
Lethal doses induced intestinal necrosis and extensive necrosis of lympho-haematopoietic organs.
Sublethal doses of DAS induced cell depletion and necrosis in lympho-haematopoietic organs,
multifocal necrosis of intestinal epithelium, and diffuse necrosis of germinal epithelium followed by
progressive tubule degeneration in the testes. Leucocytosis, due to both lymphocytosis and
neutrophilia in the ﬁrst few hours after exposure to DAS, followed by lymphopenia, neutropenia and
anaemia by 3 days were noted. There was rapid recovery of all sensitive organs after exposure to
sublethal doses of DAS except for testis where decreased weights and abnormal spermatogenesis
persisted for the 2-week observation period.
Rats
In order to investigate adverse effects in oesophagus and stomach, female Porton Wistar rats were
fed DAS via oral route (gastric gavage) with single doses of 0.0125, 0.06, 0.125, 0.5 and 2.0 mg
DAS/kg bw and the vehicle dimethyl sulfoxide (DMSO) alone as control (Craddock et al., 1988) with n
= 8 animals per group and sacriﬁcing twp rats per day on days 1–4, respectively, starving overnight
before. An increase in cell replication 1 day after treatment in the oesophagus and in the squamous
and glandular stomach was observed at the highest dose when compared with the control group. This
effect increased further by day 2, and returned to normality by day 4. At the lowest dose, no increase
in replication was observed in the oesophagus, but still in the squamous and glandular stomach at the
doses from 0.06 to 0.5 mg/kg bw, with maximum increase after 1 day of treatment. At 0.06 mg/kg
bw, the response was doubtful and at 0.0125 mg/kg bw staining of cells gave results similar to those
of control animals.
Guinea pigs
Kriegleder studied ﬁve groups of 5–6 guinea pigs that received vehicle (control group) or DAS at 1,
2, 4 and 8 mg/kg bw by gastric gavage (Kriegleder, 1980, 1981). Lethality was observed at 24 h
following the treatment at all doses with exception of the lowest dose where all six animals survived
until day 4. Mortality and time to death were clearly dose dependent: at maximum 16 and 22 h at the
highest doses of 8 and 4 mg/kg bw and between 24 and 96 h at 2 mg/kg bw. At the lowest dose, all
six animals survived by 96 h and no necrosis was observed. The LD50 was identiﬁed at 2.14 mg/kg bw.
Signs of GI toxicity were noted. On day 4, all surviving animals underwent haematological
investigations followed by euthanasia with collection and histological examination of selected organs.
The erythrocyte and leucocyte counts and the haemoglobin levels of a total of 12 animals were
analysed in the four dose groups (n = 4, 5, 2 and 1 at 1, 2, 4 and 8 mg/kg bw). The authors’
summarised the ﬁndings as follows: in animals from each of the different dosage groups, an increased
leukocyte count was observed compared to the starting value. An increase in the number of
neutrophils and a decrease in the small and large lymphocytes was recorded. Erythrocyte count and
haemoglobin concentration appeared to be affected following a single dose of DAS. There were no
other signiﬁcant changes in blood values in the remaining animals.
Intravenous administration
Dogs
A preclinical study in support of anticancer drug development was performed in a total of 18 beagle
dogs. One male and one female dog per group were exposed to a single injection of 0, 0.031, 0.063,
0.125, 0.25, 0.5, 1, 2 mg DAS/kg bw by i.v. (IRDC, 1973) with the exception of the group exposed to
1 mg DAS/kg bw where two males and two females were used. Complete haematological and
biochemical investigations were performed every second day after treatment in the ﬁrst week and
weekly thereafter. One dog from each dosage level was sacriﬁced on day 8 (except at the 1 mg/kg
dosage level, where two dogs were sacriﬁced) and the remaining dog(s) at each dosage level were
sacriﬁced on day 45. At the highest dose, emesis, diarrhoea, slight tremors, licking of chops, injection
of sclera and ataxia were noted for both dogs. At the lowest dose, no adverse effects compared to
control were observed. Emesis, diarrhoea and haematological changes (e.g. neutropenia and
lymphopenia) appeared from the dose of 0.063 mg/kg bw onwards and the frequency and severity of
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the toxicity was dose dependent. At the highest dose, the female dog was found dead 21 h after
treatment. Moderate to marked increases in liver enzymes (e.g. alanine transaminase (ALT) and
aspartate aminotransferase (AST)), haematocrit and nucleated erythrocyte count, leucocytosis,
neutrophilia with increase in non-segmented neutrophils, blood urea nitrogen (BUN) were recorded.
Lymphopenia and thrombocytopenia were noted in the male dog. All values had essentially returned to
normal by day 8 of study for this dog. According to the authors, the dose without adverse effect
(no-observed-adverse-effect level (NOAEL)) was 0.031 mg/kg bw.
Coppock et al. (1989) performed a study on dogs. A total of eight dogs (four animals per dose
group) were exposed to the vehicle or 0.5 mg/kg bw of DAS (purity > 98%) i.v. The animals were
euthanatised at 8 h after treatment. Blood samples were taken at half-hour intervals. Sequential
clinical signs of intoxication observed in the treatment dogs included ptyalism (hypersalivation),
emesis, diarrhoea, ataxia, muscular weakness and depression. Histopathological investigation revealed
lesions in the bone marrow of treatment animals consisting of cellular necrosis in the haematopoietic
districts. A marked increase in the number of immature neutrophils and replacement of lymphocytes
with immature cells was observed.
Mice, rats and rabbits
St€ahelin et al. (1968) reported LD50 values after i.v. exposure of mice, rats, rabbits and dogs
(Table 4) with death after 10–48 h except rabbits where some died after 4 days (also reported in
Ueno, 1983). Apathy, reduced breathing, cyanosis, diarrhoea, bloody stool, vomiting, tremor and
tachycardia was observed.
Intraperitoneal administration
Ueno (1983) reported about LD50 identiﬁed after i.p. administration in the mouse and the rat and
Conner et al. (1986) in the mouse only (Table 4). Values were ranging from 20 to 23 in mice or 0.75
mg DAS/kg bw in rats.
In summary, DAS showed a high acute toxicity in rodents with oral LD50 levels ranging from 2.14
to 15.5 mg/kg bw, while i.v. and i.p. LD50 levels ranged between 1.3 and 12 or 0.75 and 23 mg/kg
bw, respectively. In dogs, a NOAEL of 0.031 mg DAS/kg bw was identiﬁed from a single i.v. dose
study.
3.1.4.2. Repeated dose toxicity studies
Oral administration
Rats
More et al. (1990), exposed male Sprague–Dawley rats orally by oesophageal intubation to 0.1 mg/
kg bw per day for 2 days. Treatment with DAS induced changes in the reactivity of gastric
glycoproteins compared to controls. Histochemical analysis of the glycoproteins produced by
mucus-secreting cells in the rat stomach showed that they were slightly modiﬁed by short-term
treatment. No microscopic lesions were noted in any treated animal.
Van Rensburg et al. (1987) studied male Wistar rat (30 animals/group) exposed to 1 mg/kg bw by
gastric intubation three times weekly over a period of 5 weeks. The erythrocyte counts and related
parameters (i.e. haematocrit and haemoglobin) appeared to be the most sensitive ones to the toxic
action of DAS. A statistically signiﬁcant increase in the proportion of larger platelets was observed in
the treated animals. The leucocyte counts and related parameters were unaffected by the treatment.
Lymphocyte karyorrhexis and increasing numbers of granulocytes in the thymic cortex and moderate
or mild atrophy in the spleen were observed. Atrophy was also observed in the bone marrow and
lymph nodes while the bone marrow showed a predominance of myeloid cells and depletion of
megakaryocytes. Signs of lymphoid-tissue atrophy in the small intestine were also recorded.
In studies from Craddock et al. (1986, 1987, 1988), the effect of DAS on oesophagus and stomach
mucosa at different concentrations and with different durations was assessed. However, the studies
present several limitations such as low number of animals per group, single dose levels per
experiment, high doses tested, high mortality, and the absence of control and combinations of these
across the studies. Consequently, the Panel considered that these studies could not be taken into
account for hazard identiﬁcation.
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Guinea pigs
Guinea pigs (4 animals per group) received DAS by drinking water, over 30 days in daily doses of 0,
0.6, 1, 1.3 and 1.6 mg/kg bw (Kriegleder, 1980, 1981). With exception of the highest dose, feed
intake and body weight gain were not signiﬁcantly different from controls, although reduction in body
weight gain was observed (up to 20%). All animals died in the highest dose group within 10 days and
one animal per group died at the other dose levels (accidental death). Weekly haematological
investigations were performed and bone marrow smears taken at the end of observation period. The
authors reported emesis, loss of appetite and reduced movement after the second day of treatment at
the highest dose. An episode of lips necrosis was noted. In the animals that died from day 5 onwards
histological signs of necrosis in GI tract, lymph nodes and bone marrow were noted. No signiﬁcant
changes in haematological parameters (n = 8 animals evaluable in the three dose groups) were noted.
Intravenous administration
DAS has been considered as a possible anticancer drug and it has been tested in preclinical studies
by i.v. administration in dog and monkeys according to the supposed clinical schedule (5 consecutive
days or weekly administrations – IRDC report, 1973) to support the clinical development. In addition,
DAS has been also tested by i.v. earlier on in rats, dogs and monkeys (St€ahelin et al., 1968).
Rats
Rats (10 males and 10 females per group) were exposed via i.v. for 4 weeks to 0.06, 0.18 and 0.54
mg DAS/kg bw per day (St€ahelin et al., 1968). Mortality was observed at low dose (single death) and
up to 75% of rats in the high-dose groups. Adverse effects observed with dose-relationship included
weight reduction, diarrhoea, haematuria, reduced testis and liver weight. Histopathological
examination showed ﬁndings in the liver (necrotic foci, bile duct and reticuloendothelial cells
proliferation), in spleen (follicle hypoplasia) and testis (tubule atrophy and blocked spermatogenesis).
Decrease in leucocytes count and minor reduction in erythrocytes count have been observed after 4
weeks starting from animals exposed to the middle dose and with dose dependency. Effects in bone
marrow have been noted only at high dose level (e.g. decrease of granulopoiesis).
Six rats were additionally treated by i.v. for 6 weeks with doses increasing during the study from
0.15 up to 0.5 mg DAS/kg bw with treatment-free periods – no further details available (St€ahelin et al.,
1968). No mortality was recorded and only haematological effects (e.g. variable degrees of leucopenia
and lymphopenia) were observed.
Dogs
In a study performed by St€ahelin et al. (1968), four dogs per group were treated via i.v. daily for 4
weeks with 0, 0.02, 0.06 and 0.18 mg DAS/kg bw per day. At the highest dose, three dogs died during
the treatment period and vomiting after each administration, bloody stool and weight loss was
recorded. No adverse effects were observed at the lowest dose. A decrease in body weight was noted
from 0.06 mg/kg bw day. According to the authors, no haematological changes were observed at the
lowest dose, while lymphopenia and erythroblastosis in bone marrow appeared from the middle dose.
In the survived dog at the highest dose, leucopenia, follicular hyperplasia in spleen, reduction of
number of haematopoietic cells in bone marrow were noted. At low doses, it was histologically
observed reduction of lymphatic tissue in spleen, proliferation of reticuloendothelial cells and
degenerated in follicle germ cells, atrophy and reduced maturation in testis and pyknotic cells in
intestinal epithelium. Overall, the CONTAM Panel concluded that in this study the lowest dose of 0.02
mg DAS/kg bw can be considered as a NOAEL.
Daily treatment by i.v was carried out in two beagles (1 male and 1 female/group) during 5 days at
dose equal to 0, 0.016, 0.031, 0.063, 0.125 and 0.25 mg/kg bw per day in a preclinical study (IRDC
report, 1973) in support to anticancer drug development. Haematological investigations and liver
function tests were periodically performed. One dog from each dosage level was sacriﬁced on day 12 and
the remaining dog at each dosage level was sacriﬁced around day 50 of the observation period of the
study. At the lowest dose, no adverse effects compared to control were observed. From 0.031 mg/kg bw
per day, the presence of nucleated erythrocytes at haematology together with neutrophilia, lymphopenia
(11% and 37% lymphocyte in male and female respectively compared to normal values 20–52%) and
signs of slight anaemia, were noted for both dogs. Erythema and emesis after dosing were sporadically
noted in dogs exposed to 0.063 mg/kg bw per day. Haematological troubles increased with the increase
in the doses. According to the authors, the dose without toxic effect was the lowest dose tested, 0.016
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mg/kg bw per day. Overall, the CONTAM Panel concluded that in this study the lowest dose of 0.016 and
0.031 mg DAS/kg bw can be considered as a NOAEL for haematotoxicity and emesis, respectively.
Daily treatment by i.v. was performed in beagle dogs (1 male and 1 female/group) during 5 days
followed by 9 days of rest, the treatment was repeated three times (IRDC report, 1973). The doses
tested were 0.031 and 0.125 mg/kg bw per day. Complete haematological and biochemical
investigations were periodically performed. One dog from each dose level was sacriﬁced on day 40 of
the study and the remaining dog was sacriﬁced on day 78 at the end of observation period. Emesis
was noted at the high dose. At laboratory examinations slight increases in leucocytes, neutrophils,
eosinophils and hepatic enzymes (ALT, AST) together with decreased haematocrit were recorded. At
the highest dose instead, haematological effects (namely leucopenia, neutropenia, relative
lymphocytosis, thrombocytopenia, polychromasia of erythrocytes and slight anaemia) were noted with
different severity in both dogs. Slight elevation in hepatic enzymes was also recorded during treatment
periods. Overall, the CONTAM Panel concluded that in this study the lowest dose of 0.031 mg DAS/kg
bw can be considered as a NOAEL for emesis.
Weekly treatment by i.v. was also performed in beagle dogs (2 animals per group) during 6 weeks
at doses of 0.031, 0.063, 0.125 and 0.25 mg/kg bw (IRDC report, 1973). Haematological and
biochemical investigations were regularly performed during the treatment period. One dog from each
dosage level was sacriﬁced on day 43 of study and the remaining dog was sacriﬁced on day 81 of
study, at the end of the observation period. At the lowest dose, the only effects noted were slight and
sporadic and consisted in anaemia, leuco- and thrombocytopenia, reticulocytosis and elevation of liver
enzymes. From 0.063 mg/kg bw per week, emesis and slight erythema post-dosing were frequently
noted for the male dog and occasionally for the female dog. More marked anaemia, neutropenia and
lymphopenia were noted at laboratory investigations with some dose. Overall, the CONTAM
Panel concluded that also in this study the lowest dose of 0.031 mg DAS/kg bw can be considered as
a NOAEL for emesis.
Monkeys
Two rhesus monkeys were treated with DAS by i.v. daily administration for 4 weeks with DAS in a
preliminary study. The dose administrated increased after each week by the factor of 3, starting with
0.01 mg DAS/kg bw per day up to 0.27 mg DAS/kg bw per day in week 4 (St€ahelin et al., 1968). A
third monkey served as a control animal. No deaths were observed. Histological changes were
comparable with those observed in rats and dogs. It is reported by the author that no unexpected
toxic effects were noted. Taking into account the peculiarity of the experimental design (with dose
escalation), it is not possible to identify a NOAEL in this study.
DAS has been injected daily intravenously to rhesus monkeys (1 male and 1 female/group) during
ﬁve consecutive days at doses equal to 0, 0.125, 0.25, 0.50 and 1.0 mg/kg bw per day in a preclinical
study (IRDC report, 1973) for anticancer drug development. Complete haematological and biochemical
investigations were carried out at regular intervals. One monkey from each dosage level was sacriﬁced
on day 12 and the remaining monkey at each dosage level was sacriﬁced on day 50 of study. At the
lowest dose (0.125 mg/kg bw per day), no adverse effects compared to control were identiﬁed. At the
dose of 0.25 mg/kg bw per day, during the treatment period, emesis, anorexia, soft stool or diarrhoea
and hypoactivity were noted. During and immediately after the 5-day of treatment, a decrease in the
absolute number of leucocytes (up to 70% vs basal values) with lymphopenia and neutropenia was
recorded. A change in leucocyte formula was also noted with neutrophils reaching the highest value of
85% (standard values ranging from 7% to 47%) and lymphocytes the lowest value of 14% (with a
standard value ranging from 52% to 92%) with similar trend in both animals. At the dose of 0.5 mg/kg
bw per day, both monkeys died on day 4. Death was preceded by hypothermia, anorexia, emesis and
hypoactivity. At laboratory examinations leucocytosis (twice the basal values) with marked neutrophilia
(> 90% of the total leucocytes) was observed in both monkeys. At the highest dose (1 mg/kg bw per
day), both monkeys died on day 3. At laboratory, examinations similar but more marked changes in
comparison with the dose of 0.5 mg/kg bw per day were recorded for both monkeys (with leucocytes
showing values three times the basal values and marked neutrophilia, > 90% of the total leucocytes).
Slight increases in some biochemical parameters (namely ALT, AST and BUN) before the death of
animals were recorded.
The CONTAM Panel noted that under the experimental conditions applied in this study the lowest
dose tested, 0.125 mg/kg bw per day, can be considered as a NOAEL.
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3.1.4.3. Chronic toxicity
No chronic toxicity studies have been identiﬁed in the literature.
Summary
DAS showed acute toxicity in rodents with oral LD50 ranging from 2.1 to 15.5 mg/kg bw.
Haematological effects such as anaemia, leucopenia and thrombocytopenia have been observed. When
administered i.v., the LD50 resulted to be slightly lower, ranging from 1 to 12 mg/kg bw.
The oral repeated dose toxicity studies performed in rodents are very few and not sufﬁciently
described to be used for identifying a reference point (RP) for the hazard characterisation. However, in
guinea pigs, organs with a high rate of cell proliferation such as oesophagus mucosa, small intestine,
Table 7: Repeated dose intravenous toxicological studies in dogs and monkeys
Species
(number of
animals
per group)
Dosage
(mg/kg
bw per day)
Observation
(days)
Adverse effects
NOAEL
emesis
(mg/kg bw
per day)
NOAEL
haemato-
toxicity
(mg/kg bw
per day)
Reference
Dog (1 male,
1 female)
4 weeks 0.02,
0.06 and 0.18
28 Emesis, bloody
stool and weight
loss, blood
disorders
lymphopenia and
erythroblastosis
0.02 0.02 St€ahelin
(1968)
Beagle Dog
(1 male,
1 female)
5 daily
injections 0,
0.016, 0.031,
0.063, 0.125,
0.25
52 Leucopenia,
neutrophilia and
lymphopenia were
described as
emesis, erythema
and polydipsia
0.031 0.016 IRDC report
(1973)
Beagle Dog
(1 male,
1 female)
5 daily
injections
three times
with 9 days
of rest0.031,
0.125
75 Leucopenia,
neutropenia,
relative
lymphocytosis,
thrombocytopenia,
polychromasia of
erythrocytes
0.031 [LOAEL 0.031]
Beagle Dog
(1 male,
1 female)
Weekly
injection
during 6
weeks 0.031,
0.063, 0.125,
0.25
43, 81 Emesis and slight
erythema post-
dosing,
neutropenia,
anaemia,
lymphopenia
0.031 [LOAEL 0.031]
Rhesus
Monkey 1
male and 1
female/group
5 daily
injections
0,0.125,0.25,
0.50, 1.0
12, 50 Emesis, polydipsia,
diarrhoea,
erythema,
increased
haematocrit,
anaemia,
leucocytosis and/or
leucopenia,
neutrophilia,
lymphopenia,
elevated ALT and
AST activity,
elevated BUN and
nucleated
erythrocytes
0.125 0.125 IRDC report
(1973)
ALT: alanine transaminase; AST: aspartate aminotransferase; NOAEL: no-observed-adverse-effect level; BUN: blood urea
nitrogen; LOAEL: lowest observed adverse effect level.
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haematopoietic bone marrow have been identiﬁed as a target of adverse effects of DAS; emesis was
also noted.
In the well-conducted and documented repeated dose preclinical toxicity studies performed by i.v.
route in dogs and monkeys, the signs of toxicity of DAS (named anguidine) were fairly consistent for
both species on the various dosing schedules and included emesis, diarrhoea, erythema, increased
haematocrit, anaemia, leucocytosis and/or leucopenia, neutrophilia, lymphopenia, elevated AST and
ALT, elevated BUN and nucleated erythrocytes.
The lowest dose without toxic effect (NOAEL) regarding emesis and haematological adverse effects
was equal to 0.016 mg/kg bw per day for dogs and to 0.125 mg/kg bw per day for monkeys.
The CONTAM Panel noted that adverse effects observed in preclinical studies performed by i.v. with
DAS were similar to those described in acute toxicity studies after oral administration. DAS as other
trichothecenes are known to induce leucopenia, agranulocytosis, anaemia, aplastic anaemia due to
cytotoxicity on circulating blood cells and on haematopoietic progenitors cells, the source of blood cells
renewing in bone marrow (Parent-Massin, 2004; EFSA CONTAM Panel, 2011, 2017; JECFA, 2016).
3.1.4.4. Developmental and reproductive toxicity
The studies that have been reported on the developmental and reproductive toxicology of DAS all
used i.p. administration of the compound.
DAS was injected i.p. to male mice at doses of 1, 5, 10 or 15 mg/kg bw and animals were killed 1
h to 14 days later. Testicular weights were decreased 3 days after DAS exposure (15 mg/kg bw) and
this effect persisted throughout the observation period of 14 days. There was progressive depletion of
germinal epithelium which was followed by tubule degeneration (Conner et al., 1986).
Conner et al. (1990) investigated the testicular function in male Lewis rats that had been exposed
to DAS at 1.7 mg/kg bw by i.p. injection. This dose is 75% of the i.p. LD50 as measured in the
authors’ laboratory. The animals were studied up to 90 days after exposure. DAS induced a decrease
of the testicular weight and sperm production and an increased frequency of hypocellular seminiferous
tubules. These effects became more marked with increasing time after administration of DAS.
Pregnant mice were administered a single i.p. dose of DAS at 1.0, 1.5, 2.0, 3.0 and 6.0 mg/kg bw
on one of gestation days 7–11 (Mayura et al., 1987). The two highest doses resulted in maternal
toxicity. There was no signiﬁcant effect on total number of implants at all dose levels tested during the
various gestation periods. The incidence of resorption was dependent on dose, reaching 100% at the
higher doses, and increases were seen at the lower doses. The exposure caused a reduction in fetal
body weight even at the dose of 1.0 mg/kg bw, on all the days tested. Signiﬁcant incidences of gross
and skeletal malformations in mouse foetuses were observed at all doses of DAS tested (1–3 mg/kg
bw). The authors commented that DAS is a potent inhibitor of protein synthesis and that this may be
responsible for the effects induced by it.
Summary
Developmental and reproductive toxicity has been reported for studies where DAS was
administered by the i.p. route to experimental animals. The lowest dose where effects were seen in
mice was 1 mg/kg bw (females, incidence of resorption, reduction in fetal body weight and gross and
skeletal malformations), and in rats it was 1.7 mg/kg bw (males, decrease of the testicular weight and
sperm production and an increased frequency of hypocellular seminiferous tubules). No lower doses
were used and thus no NOAELs were observed. The CONTAM Panel noted that tissues with high
proliferation rate such as testicular are targets of adverse effect of DAS.
3.1.4.5. Genotoxicity
In vitro assays
Wehner et al. (1978) showed that DAS did not induce mutation in the Salmonella Typhimurium
bacterial mutation assay (Ames test) using strains TA98, TA100, TA1535 and TA1537 (0.25–250 lg
DAS/plate) with and without metabolic activation with an induced rat liver S9 fraction.
Kuczuk et al. (1978) obtained negative data in the S. Typhimurium bacterial mutation assay (Ames
test) using strains TA1535 and TA1537 and TA1538 (0.1–100 lg DAS/plate) with and without
metabolic activation with induced rat liver S9 fraction. DAS was also screened for mutagenic activity in
Saccharomyces cerevisiae D-3 and none was detected: DAS was tested in this study at the
concentration 100 lg/mL without metabolic activation, and at 50 lg/mL with metabolic activation.
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Sinsheimer et al. (1989) found that DAS lacked alkylating activity as measured by its reaction with
4-(4-nitrobenzyl)pyridine, and also lacked mutagenicity using S. Typhimurium strain TA 100 (0.01–15
lmol DAS/plate).
The genotoxicity of DAS in Escherichia coli was investigated by Krivobok et al. (1987) using the
SOS chromotest, which is an assay to detect the SOS response. No SOS inducing activity was
detected, either with or without metabolic activation. The maximal concentration of DAS that was
tested was 60 lg/ml.
Cooray (1984) studied the effect of DAS on DNA synthesis, by measurement of [3H]-thymidine
incorporation, and sister chromatid exchange (SCE) frequency in phytohaemagglutinin-stimulated
human peripheral lymphocytes. Addition of DAS to the cell cultures resulted in a dose-related inhibition
of [3H]-thymidine incorporation, with complete inhibition at a concentration of 8 ng DAS/mL. Toxicity
was slightly reduced by addition of rat liver cells to the incubation. No increase in SCE frequency was
observed either with or without the presence of rat liver cells (1.5–12.0 ng DAS/mL).
In vivo studies
The genotoxicity of DAS following i.p. injection was investigated in male Swiss albino mice by
Hassanane et al. (2000). For both single and repeat dose studies, groups of mice (n = 5) received 0,
0.5, 0.75 and 1 mg DAS/kg bw. In the repeat dose study, the dose was administered on days 1, 10
and 20. The study was carried out on both somatic and germ cells. After single doses, DAS
signiﬁcantly reduced the mitotic activity of the bone marrow cells at all doses tested. Increased
structural chromosome abnormalities (chromatid gaps, breaks, centromeric attenuation, endomitosis)
were observed after single doses. The increases of centromeric attenuation, endomitosis and total
abnormalities were highly signiﬁcant (p < 0.01) for the two highest doses of DAS. After repeat doses,
increased chromatid gaps, breaks and endomitosis were also observed. Finally, there was evidence of
chromosome damage in spermatocytes, and sperm abnormality after DAS treatment.
DAS gave negative results in the wing somatic mutation and recombination test (SMART) in
Drosophila melanogaster, at concentrations ranging from 5 to 40 lM (G€urb€uzel et al., 2015).
Summary
In summary, there was no evidence that DAS induces bacterial reverse mutation in vitro. One
in vivo genotoxicity study in mice has been reported where DAS was administered by the i.p. route.
Chromosomal abnormalities were observed in somatic cells (bone marrow) and in germ cells
(spermatocytes). It is probable that the impairment of DNA synthesis is caused as a secondary event
of inhibition of protein synthesis. Protein synthesis inhibition is likely to be the mechanism underlying
the observed in vivo chromosomal abnormalities (see Section 3.1.8).
The Panel considered that there are currently insufﬁcient data on the genotoxicity of DAS.
3.1.4.6. Carcinogenicity
Lindenfelser et al. (1974) carried out a study on the initiating and promoting activity of mycotoxins
in a 22-week skin tumour test according to Boutwell (1964) with a focus on the interactions of
aﬂatoxin B1 with T-2 toxin and DAS. Groups of Charles River female mice (n = 8) were treated, by skin
application, with the initiating compound and then after 4 days promoter compounds were
administered twice weekly for 22 weeks. The compounds that were tested for either initiation or
promotions were aﬂatoxin B1, T-2 toxin and DAS, and positive controls were 7,12-dimethylbenz[a]
anthracene (DMBA) (initiation) and croton oil (promotion). A variety of compound combinations were
studied, and three of these involved DAS. These were: DMBA initiation (50 lg) with DAS promotion
(10 and 25 lg), aﬂatoxin B1 initiation (25, 50 or 100 lg) with DAS promotion (10 and 25 lg) and DAS
initiation (25 lg) with DAS promotion (10 lg). In addition T-2 ability to act as initiator (25 lg) or
promoter (10 and 25 lg) was also investigated. After DMBA initiation and DAS promotion there was a
minimal tumour response (1 papilloma in a single mouse). Similarly, after DMBA initiation, one of the
eight mice treated with T-2 developed one papilloma. No papillomas were seen in mice after aﬂatoxin
B1 initiation and DAS or T-2 promotion. The group administered DAS (or T-2) over both the initiation
and promotion stages developed no papillomas. After DMBA initiation and promotion with the positive
control croton oil (1,000 lg) all eight mice had papillomas. After aﬂatoxin B1 initiation (25, 50 and
100 lg) and croton oil promotion, papillomas were observed in 5, 5 and 6 out of 8 mice, respectively.
The authors concluded that there is an indication of weak promoting activity of DAS.
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Summary
In summary, no long-term studies on carcinogenicity have been identiﬁed to assess carcinogenicity
of DAS. No initiating activity was identiﬁed for DAS.
3.1.4.7. Toxicity of metabolites
The toxicity of metabolites of DAS was reviewed by JECFA (2016). The only few data available
indicate that the toxicity of the main metabolites of DAS (4 or 15 MAS, SCT) is equal to or less than
the toxicity of DAS in vitro (JECFA, 2016; Thompson and Wannemacher, 1986) and in vivo after oral
exposure (JECFA, 2016; Thompson and Wannemacher, 1986; Richardson and Hamilton, 1990;
Ademoyero and Hamilton, 1991a,b). The observed clinical symptoms after exposure to the metabolites
are also similar to the symptoms observed after exposure to DAS.
3.1.5. Adverse effects in farm and companion animals
3.1.5.1. Ruminants
Following single i.v. administration of DAS at 0.5 mg/kg bw (according to the authors equivalent to
25 mg/m2 body surface) to four heifers (body weight 74.5–139.1 kg) animals showed a variety of
clinical signs of acute intoxication like ptyalism, fragmentary defecation, abdominal pain, ruminal stasis,
diarrhoea, muscular weakness, congestion of mucous membranes, and coma (Coppock et al., 1989).
Anuria was not observed and death did not occur. In the same study, haematological changes were
monitored. The numbers of metarubricyte, myelocytes, metamyelocytes, and band-neutrophiles VII
were signiﬁcantly elevated at that dose compare with controls (n = 4). Changes in other parameters
like the number of segmented neutrophils and morphologically abnormal blood cells in blood from
principal heifers, vacuolated and prominent chromatin strands in the nuclei of myelocytes and
metamyelocytes were occasionally observed. Moreover, lesions were found in bone marrow sections
from principal calves.
A diet of 5.0 mg DAS/kg feed (corresponding to 0.16 mg DAS/kg bw per day considering the
reported intake and initial body weight) for 35 days resulted in a statistically signiﬁcant reduced feed
intake and weight loss in ewe lambs compared with controls (n = 6 per group, 3 lambs in 3 pens,
initial mean bw 38–39 kg) (Harvey et al., 1995). Furthermore, the treatment with DAS decreased of
about 23% or 32% urea nitrogen and serum cholinesterase, respectively.
Summary
Among ruminants only two small studies on heifers and lambs were identiﬁed. Both indicated
adverse health effects: in the heifers at the only single tested dose of 0.5 mg DAS/kg bw per day i.v.,
while in the lambs at the oral repeated dose corresponding to 0.16 mg DAS/kg bw per day. The
CONTAM Panel concluded that the data were too scarce to determine a RP for adverse health effects
of DAS in ruminants.
3.1.5.2. Pigs
The acute toxicity of DAS in pigs was studied by Weaver et al. (1978). Twelve crossbred fattening
pigs weighing from 8 to 48 kg and a 30-months-old sow (115 kg) were administered DAS (95% pure
in ethanol) i.v. in doses varying from 0.30 to 0.50 mg/kg bw. Seven animals from the test group died
within 24 h, the other ones were killed after 2–14 days and underwent haematological and biochemical
analysis and bone marrow examination. In this study, the mycotoxin occasionally induced
haemorrhagic bowel lesions (two feeder pigs) and mucosal congestion of the jejunum and ileum in a
sow. Furthermore, a variety of clinical signs consisting of emesis, lethargy, signs of extreme hunger,
frequent defecation of normal stools and posterior paresis have been observed. The i.v. LD50 of DAS in
swine was calculated as 0.376  0.043 mg DAS/kg bw.
To investigate the subchronic toxicity in pigs, Weaver et al. (1981) fed puriﬁed DAS (94–96% pure)
in two separate experiments to male, weanling crossbred pigs (7.1–9.1 kg bw). In the ﬁrst experiment,
the animals were given rations containing 0 (n = 1), 2, 4, or 8 (n = 2 each), or 10 mg/kg (n = 1) of DAS.
After 4 weeks, three pigs (one each at 2, 4 and 8 mg DAS/kg feed) were euthanised, the other pigs
were euthanised after 9 weeks. In the second experiment, ﬁve pigs were fed for four weeks with 4 mg
DAS/kg feed, one pig was used as control. Exposure to DAS caused multifocal, proliferative, gingival,
buccal and lingual lesions at all dose levels. The small intestine showed glandular and mucosal cell
hyperplasia. Furthermore, feed intake and weight gain were decreased at all DAS concentrations used.
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At 10 mg/kg feed, a total feed refusal was observed. For the observed lesions, the feed intake and the
reduced weight gain, a lowest observed adverse effect level (LOAEL) of 2 mg/kg feed could be
identiﬁed. Assuming a feed efﬁciency of 2 kg/kg resulting in 37.6 and 14.8 kg ﬁnal weights of the two
pigs, respectively, an intake of about 0.08 mg DAS/kg bw was considered plausible for this experiment.
The toxicity of DAS in pigs was also surveyed by Harvey et al., 1991. The mycotoxin (> 98% pure)
was incorporated in the feed of 9-week-old crossbred barrows (mean weight 25.0 kg, n = 9) for 28
days at a concentration of 2.0 mg DAS/kg feed. The diets of the control group (n = 9) did not contain
detectable (< 10 lg/kg) concentrations of aﬂatoxin (AF), DAS, T-2 toxin, zearalenone, deoxynivalenol,
patulin, penicillic acid, ochratoxin, or cyclopiazonic acid. Body weight gain and serum iron binding
capacity were signiﬁcantly decreased in the DAS group and such 2.0 mg/kg feed (corresponding to
0.12 mg/kg bw) was identiﬁed as LOAEL for these effects.
Coppock et al. (1985) administered DAS (96% purity, solved in ethanol) i.v to 12 pigs (9 female
and 3 male, n = 4 per group) at single doses of 0.0 (ethanol only), 0.5, and 1.0 mg/kg bw (according
to the authors equivalent to 0, 16.5 and 32.9 mg/m2 body surface, respectively), with mean bw per
group of 32.6, 36.6 and 35.5 kg respectively. The authors used i.v. administration to what they called
‘ensure uniform dosing’. One male died after 4 h at the low dose and another at 7 h at the high dose.
All surviving animals were euthanatised after 8 h. Clinical signs of intoxication observed in the DAS
administered pigs included ptyalism, emesis, diarrhoea, ataxia, mahogany ﬂushing of the skin,
muscular weakness, and depression. The haematologic changes included necrosis of bone marrow
haematopoietic elements, a sequential increase in the type and number of abnormal cells, a marked
left shift in the neutrophil population. Furthermore, metarubricytes and large platelets were found and
lymphocytes were replaced with immature cells.
Summary
Only few studies on adverse effects of DAS in pigs were available. An i.v. LD50 was identiﬁed at
0.38 mg DAS/kg bw. An oral LOAEL of 2.0 mg DAS/kg feed could be identiﬁed for oral lesions
(corresponding to about 0.08 mg/kg bw) and reduced body weight gain (corresponding to 0.12 mg
DAS/kg bw) as most sensitive effects.
3.1.5.3. Poultry
All studies from the literature in which DAS toxicity was investigated in poultry were performed via
oral administration. Description of acute adverse effects including the determination of an LD50, were
based on results from either a single dose or multiple daily doses of DAS. Other studies including
chronic toxicological experiments were based on the use of doses below the identiﬁed LD50 values
administered over several consecutive days.
Chickens
Acute Toxicity
The ﬁrst study on LD50 determination identiﬁed in the literature was performed by Chi et al. (1978).
Pure DAS (authenticity determined by combined GC–MS) in solution was administered by gastric
intubation to one day old chickens as single dose. The oral 7-day LD50 was 3.82 mg DAS/kg bw.
Clinical signs started with asthenia, feed refusal and diarrhoea 4–10 h after dosing followed by coma
before death.
Hoerr et al. (1981a) performed two trials on acute toxicity. In the ﬁrst trial, pure commercially
purchased DAS was dissolved at appropriate concentrations, added to the feed (presence of other
mycotoxins not reported) and administered by gavage to 7-day-old male broiler chickens (Hubbard x
Hubbard) at doses of 1, 2, 3, 4, 5 and 6 mg DAS/kg bw in single dose. The 72-h single oral LD50 was
5.0 mg/kg bw. In the second trial, doses of 2.5, 3.0 and 3.5 mg DAS/kg bw were given daily over 14
consecutive days by gavage to 7-day old male broiler chickens (Hubbard x Hubbard) and a LD50 of 4.15
mg/kg bw was estimated by extrapolation. Hoerr et al. (1981b), observed as ﬁrst clinical symptom,
after a 2.7 mg/kg single dose given by gavage reduced spontaneous activity and slightly ﬂuid faecal
droppings within the ﬁrst 24 h. The small intestine, skeletal muscles, liver (with disseminated foci) and
gall bladder were affected. Necrosis and hyperplasia occurred in various intestinal tissues, lymphoid
tissue and bone marrow. Most lesions recovered within 168 h after treatment.
Hoerr et al. (1982a) observed some mortality in comparison with a control group of 10 birds
receiving a diet with solvent only: two birds died in each of the two groups fed at 2.5 and 3.5 mg
DAS/kg bw and one bird in the group fed at 3.0 mg DAS/kg bw. Reduced body weight gain was
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observed in surviving birds; the feathers were malformed, and the beak and legs were pale yellow. At
necropsy, the lymphoid organs were atrophic, bone marrow was pale red or yellow, the liver was
discoloured yellow, and the crop mucosa was ulcerated. Microscopic lesions included necrosis and cell
depletion in lymphocytic and haematopoietic tissues and necrosis of hepatocytes, bile duct epithelium,
enteric mucosa, and germinal regions of feather barbs. Other hepatic lesions were fatty change of
hepatocytes and hyperplasia of bile ductile. Thyroid follicles were small, contained pale colloid and had
tall epithelial cells.
In an experiment performed by Richardson and Hamilton (1990) puriﬁed DAS (purity tested by
NMR and MS) was administered by gavage (to the crop) to one day old chickens. The 24-h-LD50 was
2.0 mg/kg bw accompanied with reduced activity, loose faecal droppings and decreased feed
consumption. At necropsy, the authors found haemorrhages in the vascular beds of the beak and toe
nails, in the hock joint, in the internal and external surfaces of the proventriculus and the ventriculus.
In the intestine, they found pinpoint haemorrhages on the liver and the heart.
Subchronic and chronic toxicity
Other studies of different duration including subchronic and chronic toxicological experiments were
based on the daily use of doses below the identiﬁed LD50 values administered over several consecutive
days. All adverse effects including zootechnical parameters such as body weight gain which were
observed by the authors are described below. Because of the relevance of these parameters, when
possible NOAELs and LOAELs were identiﬁed for each of these adverse effects.
In an experiment performed by Hoerr et al. (1982b), 7-day-old male broiler (Hubbard x Hubbard)
chickens (5–20 birds per group) were fed for 21 days. Commercial broiler starter mash was used as
control and added with commercially purchased DAS (purity at least 95% determined by mass
spectrometry) to provide diets at levels of 4.0 and 16.0 mg DAS/kg feed, corresponding to 0.7 and 2.6
mg DAS/kg bw per day. No mortality was noticed but reductions of feed consumption and body weight
gain were observed in treated birds compared with controls. Oral lesions (focal yellow plaques on the
palate, tongue and buccal ﬂoor) were observed at day 2, progressing to raised yellowish-crust which
covered ulcers. From this study, the CONTAM Panel identiﬁed for 7-day-old chickens a LOAEL for body
weight gain reduction and oral lesions of 4 mg DAS/kg feed, corresponding to 0.7 mg DAS/kg bw per day.
Burditt et al. (1983a,b)reported a reduction of 77% feed consumption compared to controls in 6 h
in 7-day-old Selkab chickens (n = 30) when the diet given boilers as starter mash contained 87 mg
DAS/kg feed from a culture ﬁltrate of Fusarium roseum. From this study, the CONTAM Panel noticed
the high level of the contamination, which was not useful for identiﬁcation of either a LOAEL or a
NOAEL.
Ademoyero and Hamilton (1991a) fed graded dietary levels at 0 (as control), 1.0, 2.0 and 4.0 mg
DAS/kg feed to groups of 10 one-day-old male broiler chickens (Arbor Acres x Arbor Acres) for 21
days. Crystalline DAS was added to the starter mash containing mainly yellow corn and protein
soybean meal shown to be free of T-2 toxin and SCT, TAS, MAS and DAS (chromatographic
determination). Oral lesions were observed already at 1.0 mg DAS/kg feed. Lesions were obvious after
one week toxin and the total number of lesions tripled by the end of the second week. The rank
orders from greatest to least affected oral sites were upper beak, lower beak, tongue, and angles.
Reduction of body weight gain was observed in chickens fed 2.0 and 4.0 mg DAS/kg feed levels. In a
follow up study, Ademoyero and Hamilton (1991b) fed groups of 10 one-day-old male broiler chickens
with several diets at 0, 1.0, 2.0, 4.0 and 8.0 mg DAS/kg feed for 21 days and at the two dietary fat
proportions of 6% and 12%. Crystalline DAS was produced from broth cultures of F. sambucinum and
its purity was ascertained by TLC in comparison with DAS (standard authenticated by mass
spectrometry and nuclear magnetic resonance). There was a highly signiﬁcant interaction between
dietary fat and DAS, whereby increased dietary fat increased the reduction of body weight gain by
DAS. The authors concluded that their data were consistent with the high-fat diet promoting lipid
micellar absorption of DAS. DAS, once absorbed, would inhibit protein synthesis at the ribosomal level,
a well-established mechanism of action for trichothecenes. From these two studies on 1-day-old
chickens, the CONTAM Panel identiﬁed the level of 1.0 DAS/kg feed as LOAEL generating mouth
lesions and the levels of 2.0 and 1.0 mg DAS/kg feed as LOAEL and NOAEL for body weight gain
reduction, respectively.
One-day-old male broiler chickens (Peterson x Hubbard; six replicates of 10 broilers per dietary
treatment until 3 weeks of age) were fed two dietary treatments (Kubena et al., 1993). A basal diet
with 0 mg DAS/kg feed (occurrence of other mycotoxins not reported) as control and a basal diet of 5
mg of pure DAS/kg feed (purity of DAS at least 99%) were examined. Beginning at the eighth day of
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feeding the diet, body weight gain was reduced without alteration of relative weights of all organs
examined (liver, kidney, heart, proventriculus, gizzard, spleen, and pancreas). Oral lesions were
observed in all treated birds at the end of the experiment. Among the haematological and biochemical
values, only the triglycerides (signiﬁcant reduction) and the corpuscular volume (decrease) were
affected. In a similar experiment, Kubena et al. (1994) treated one day-old male broiler chicks
(Peterson x Hubbard, 8 replicates of 7 broilers per dietary treatment during 19 days) with 6 mg
DAS/kg feed. At the end of the experiment, reduction of body weight gain was observed in all treated
birds and oral lesions in at least 90% of treated birds. Only the relative weights of proventriculus and
gizzard were increased. The mean corpuscular volume and corpuscular haemoglobin were signiﬁcantly
decreased but only creatine kinase activities were signiﬁcantly reduced among the blood serum
parameters. From these two studies despite of discrepancies noticed for biochemical values and
enzyme activities, the CONTAM Panel considered the level of 5–6 mg DAS/kg feed as LOAEL for
generating oral lesions, reduction of body weight gain.
Two trials were conducted by Brake et al. (1999) on fertility and hatchability of broiler breeders. In
a ﬁrst one, daily allocation of feed containing 0.0 (basal diet as control), 1.25, 2.5, or 5.0 mg DAS/kg
diet was provided to 4 groups of 10 broiler breeder males and 4 groups of 25 broiler breeder females
from 67 to 69 week of age. Crystalline DAS was produced from broth cultures of F. sambucinum and
its purity was ascertained by TLC and GC in comparison with pure DAS authenticated by mass
spectrometry and nuclear magnetic resonance and was added to the control diet which was free of
aﬂatoxin and DAS (data on possible contents of other mycotoxins were not reported). A restricted
feeding regimen of 154 g feed/bird per day was applied. Fertility was consistently improved at 5.0 mg
DAS/kg diet and intermittently at 1.25 and 2.50 mg DAS/kg diet. The effect disappeared upon removal
of DAS. Percentage hatchability of fertile eggs was increased at 1.25 and 2.50 mg DAS/kg diet with
the 5.0 mg DAS/kg intermediate. The authors concluded that there was an apparent beneﬁcial
spermatozoal storage effect caused by DAS in females. In a second trial, broiler breeder males
(4 groups of 10) and females (4 groups of 25) were fed a basal diet containing 0 (as control), 5.0,
10.0, or 20.0 mg DAS/kg diet from 25 to 27 week of age. Pure DAS was added to the basal diet as
described for the ﬁrst trial. A restricted feeding regimen of 119–125 g feed/bird per day was applied.
Semen was pooled from males within each treatment and used to inseminate females from each
treatment. Female-related fertility was increased at 5.0 and 10.0 mg DAS/kg feed and male-related
fertility was decreased by the 10.0 and 20.0 mg DAS/kg feed. Upon necropsy, mall, ﬂuid-ﬁlled cysts
were observed on the testes of many DAS-treated males. Conversely, dietary levels of DAS at 10 mg
DAS/kg and above decreased male related fertility, presumably by direct toxic effects on the testes.
Although results appeared inconsistent, the authors concluded that diet levels of DAS at 10 mg/kg
feed or less improved female-related fertility, presumably because of enhanced spermatozoal storage
within the oviduct, but only in the presence of sufﬁcient spermatozoa. Dietary levels below 5 mg
DAS/kg feed were not detrimental to fertility and hatchability (Brake et al., 1999).
Under a similar study design, Brake et al. (2000) conducted experiments where DAS was prepared
and added as described in Brake et al. (1999). In the ﬁrst experiment, groups of 20 female broiler
breeders of 24 weeks of age were fed diets containing DAS levels at 0 (as control), 5.0, 10.0 and 20.0
mg DAS/kg feed during 2 weeks. The feeding of DAS coincided with the initiation of lay. After the
week 25, the control diet was fed for the following 7 weeks through 32 weeks of age. Feed
consumption and body weight were decreased and mouth lesions were observed in all treated birds
compared to control. After cessation of the DAS feeding, feed consumption increased rapidly and
returned to levels similar to those of the controls. However, at the end of the experiment, 7 weeks
after DAS exposure, the body weight of females fed 20 mg DAS/kg feed remained insigniﬁcantly lower
compared to controls. In a second trial, 4 groups of 10 broiler breeder males and 4 groups of 20
broiler breeders females were fed diets from 24 weeks to 27 weeks of age containing DAS levels at 0
(as control), 5.0, 10.0 and 20.0 mg DAS/kg feed restricted to 150 g feed per bird and per day using
individual feeders. Feed consumption was decreased in males and females but body weight gain was
not affected in males whereas a reduction of body weight was observed in females. Mouth lesions in
palatine and sublingual area were observed in all DAS levels in all treated birds. In a third experiment
reported by Brake et al. (2000), 2 groups of 10 broiler breeder males from 23 weeks to 26 weeks of
age were fed diets containing DAS levels at 0 (as control) and 10.0 mg DAS/kg feed restricted to 119
g feed per bird and per day by individual feeders. Feed consumption decreased after 1 week of
treatment but not further on and body weight gain was not affected. No information on mouth effects
were reported.
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From these two papers, the CONTAM Panel considered 5 mg DAS/kg feed as NOAEL for detrimental
fertility and hatchability, and 10 mg DAS/kg feed as LOAEL for decrease of fertility in 25-week-old male
broiler breeders. The CONTAM Panel considered 5 mg DAS/kg feed as LOAEL for the generation of
mouth lesions in 24-week-old broiler breeder males and females. Furthermore, the CONTAM
Panel considered 5 and 10 mg DAS/kg feed as NOAEL and LOAEL, respectively, for decrease of body
weight in 24-week-old female broiler breeder. Finally, the CONTAM Panel considered 20 mg DAS/kg
feed as NOAEL for reduced of body weight gain in 24-week-old male broiler breeders.
Curtui (2000) conducted a trial on 1-day-old chickens using F. poae extract mixed into a basal diet
to prepare a diet containing nivalenol, T-2 toxin and DAS at levels 6.4, 1.3 and 2.6 mg/kg feed,
respectively. No mortality was recorded and the feed refusal was the major syndrome observed in the
treated group compared to the control group receiving the basal diet only. The CONTAM Panel noted
the occurrence of several mycotoxins and moreover that DAS was not the dominant toxin present in
the contaminated diet. Because of the possibility of these toxins to interfere, the CONTAM Panel did
not consider this study further for risk assessment.
Sklan et al. (2001) studied 4 groups of 10 one-day-old male Ross chickens fed mash diets in which
commercial pure DAS added to a basal feed (analysed as free of aﬂatoxins, T-2 toxin, ochratoxin and
DON) at 0.0 (as control), 0.2, 0.5, 1.0 mg DAS/kg feed for 35 days. After 10 days, oral lesions were
observed at the low doses of 0.2 and 0.5 mg DAS/kg feed in 58% and 92% of the chicks, respectively.
The severity of oral lesions was maximal between 15 and 20 days and then decreased slightly with
time. No difference in body weight gain was observed at day 35 between control and treated birds. At
doses of 0.5 and 1.0 mg DAS/kg feed some slight diarrhoea was observed and birds at the highest
dose exhibited mild lymphoid depletion in the spleen and occasional small hepatic lymphocytic
perivascular aggregates. From this study, the CONTAM Panel identiﬁed the LOAEL at 0.2 mg DAS/kg
feed for generating mouth lesions in one day old chickens and the level of 1.0 mg DAS/kg feed as
NOAEL for reduced body weight gain.
Diaz (2002) conducted an experiment on 1-day-old chickens (Ross) for 3 weeks. Groups of seven
birds were amended with diets that consisted of a commercial starter ration mixed with the following
inclusion rates of DAS: 0.0 (as control), 1.0, 2.0 mg DAS/kg feed. Puriﬁed DAS was prepared from
broth cultures of Fusarium sambucinum. Toxin purity greater than 95% was conﬁrmed by TLC. The
basal commercial diet was free of aﬂatoxin, ochratoxin A, and four type-A trichothecene mycotoxins
(T-2 toxin, DAS, HT-2 toxin, and neosolaniol). Both levels of dietary DAS signiﬁcantly decreased body
weight and feed intake and caused oral lesions, with the effect of 2 mg DAS/kg feed being more
severe. Based on these data, the CONTAM Panel considered the level of 1.0 mg DAS/kg feed as LOAEL
for oral lesions.
In a case report Konjevic et al. (2004) described the death of two out of 10 Brahma chickens
approximately 2 months old preceded by signs of depression and loss of appetite. Histopathological
analysis revealed vacuolar dystrophy of the liver, necrosis and depletion of lymphocyte in the bursa of
Fabricius as well as multiple necrosis in the glandular stomach and gut. A subsequent
mycotoxicological analysis revealed the presence of Fusarium spp. in the feed with a T-2 toxin level of
0.7 mg/kg, DAS at the level of 0.5 mg/kg and DON levels not reported. Because of the presence of
several toxins which could interfere for effect interpretation, the CONTAM Panel did not consider this
study for further risk assessment.
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Table 8: Summarised data on adverse effects in broiler chickens exposed to DAS in feed from studies considered for further risk assessment
Species (age)
No. per
treatment
Concentration
(mg/kg feed)
Toxin source
in feed
Exposure
time
Adverse effects
LOAEL
(mg/kg
feed)
NOAEL
(mg/kg
feed)
Reference
Hubbard 9
Hubbard (day 1)
10 15, 18, 21 Spiked with
puriﬁed DAS
10 days Mortalities, reduction bw gain,
hepatic lesions
15 Hoerr et al. (1982a)
Hubbard 9
Hubbard (day 1)
10 4, 16 Spiked with
puriﬁed DAS
21 days Reduction bw gain oral lesions 4
4
Hoerr et al. (1982b)
Arbor Acres 9
Arbor Acres
(day 1)
30 0.5, 1, 2, 4 Spiked with
pure DAS
21 days Reduction bw gain oral lesions 2
1
1
0.5
Ademoyero and
Hamilton (1991a)
Peterson 9
Hubbard (day 1)
10 5 Spiked with
puriﬁed DAS
8 days Reduction bw gain 5 Kubena et al. (1993)
Petersons 9
Hubbard (day 1)
10 6 Spiked with
puriﬁed DAS
19 days Reduction bw gain oral lesions 6
6
Kubena et al. (1994)
Broiler breeders
Male female
(day 25)
10
25
5, 10, 20 Puriﬁed 2 weeks Decreased male fertility
Decreased female bw
Decreased male bw oral lesions
in males and females
10
10
5
5
5
10
Brake et al. (1999,
2000)
Male Ross (day 1) 10 0.2, 0.5, 1 Pure 35 days Oral lesions for half of the birds
Reduction of bw gain
0.2 1 Sklan et al. (2001)
Male Ross (day 1) 7 1, 2 Puriﬁed 3 weeks Oral lesions and reduction of
bw gain
1 Diaz (2002)
DAS: diacetoxyscirpenol; LOAEL: lowest-observed-adverse-effect level; NOAEL: no-observed-adverse-effect level; bw: body weight.
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Laying hens
Allen et al. (1982) reported two trials on DAS in White Leghorn hens. In the ﬁrst, 3 groups (n = 15
each) of 36-week-old hens were fed 8 weeks a culture of Fusarium roseum containing 15 lg DAS/g
and 30 lg of other unidentiﬁed mycotoxins per g at diet levels of 0% (as control), 1% (with an
equivalent to 0.15 mg DAS/kg feed), and 2% (0.30 mg DAS/kg feed). Afterwards, all hens were
placed on 0% diet for the following 6 weeks. Birds were inseminated weekly with 0.05 mL of pooled
semen from males given control diets. During the initial 8 weeks, the 1% and 2% level groups showed
no signiﬁcant effect on body weight change or egg weights but egg production was signiﬁcantly
depressed. Feed consumption, fertility and hatchability of fertile eggs were reduced at the 2% level,
the majority of embryo mortality occurring the ﬁrst week of incubation. Egg production levels returned
to normal during the ﬁnal 6 weeks without exposure. In the second trial, three groups (n = 15 each)
of 15 White Leghorn hens (50 weeks old) were fed control (0%), 0.5 mg/kg puriﬁed DAS, and 3% F.
roseum culture (i.e. 0.45 mg DAS/kg feed) for 4 weeks and followed by 2 weeks with the control diet.
In the ﬁrst 4 weeks, egg weight, body weight, feed consumption, egg production and fertility were not
affected, whereas the hatchability of fertile eggs was 58% under DAS treatment and 3% under culture
of F. roseum treatment. Percentages of fertility and hatchability of fertile eggs returned to 60–65%
after the toxins were removed for both treatments. Oral lesions were not observed. Following authors’
interpretation, the CONTAM Panel could not consider this study for hazard characterisation of laying
hens because of the co-exposure of DAS with other unidentiﬁed mycotoxins.
Engster et al. (1982) conducted a study on White Leghorn hens 63-week-old. The birds were fed
diets at levels of 0.0 (as control), 0.5, 1.0, 2.0, 4.0 and 8.0 mg DAS/kg feed based on F. roseum
extract. The basal diet contained no toxins. There were no signiﬁcant effects of DAS in any dietary
levels on egg production or egg weight. The authors indicated that body weight decreased with
increased levels of DAS in the ration and mouth lesions were observed not only in the treated birds
but also in the control group of birds. The CONTAM Panel noted that only limited experimental details
were available to allow a toxicological interpretation. For this reason, the CONTAM Panel did not
consider this study suitable for risk assessment.
In an experiment conducted by Diaz et al. (1994), one group of ten 33-week-old commercial Single
Comb White Leghorn hens were fed a basal diet which was free of aﬂatoxin, ochratoxin,
sterigmatocystin, citrinin, ergot alkaloids, penicillic acid, T-2 toxin, DAS and zearalenone, and in which
only traces of DON (0.3 mg/kg) were detected. A second group of 10 hens was given the basal diet
containing 2 mg DAS/kg feed. Hens were kept on these treatments for 24 days. After 48 h of
exposure, 4 of the 10 treated hens had oral lesions, and half of them were affected at the end of the
experiment. The treated hens consumed signiﬁcantly less feed compared to the controls. Egg
production in the treated hens decreased. However, no statistically signiﬁcant change in body weight
was observed over the experimental period. Plasma activities of aspartate aminotransferase, alanine,
aminotransferase, glutamate dehydrogenase, lactate dehydrogenase (LDH) and creatine kinase were
not affected. The CONTAM Panel considered the level of 2 mg DAS/kg feed generating oral lesions and
reduction of egg production as LOAEL and as NOAEL for reduction of body weight for hens.
In a study conducted by Brake et al. (2000) on broiler breeder females, DAS was prepared as
described in Brake et al. (1999). Groups of 20 hens at 24 weeks of age were fed diets containing DAS
levels at 0 (as control), 5.0, 10.0 and 20.0 mg DAS/kg feed. Feed consumption and body weight gain
decreased at 10 and 20 mg DAS/kg feed. Oral lesions in palatine, tongue and sublingual area were
observed from second week on in all three treatment groups with dose-related severity. A follow up
study was conducted by Brake et al. (2002) involving three trials and was focused on egg production.
In a ﬁrst trial, four groups of hens were fed basal breeder diet as control and diets containing 1.25,
2.5, or 5.0 mg DAS/kg feed from 67 to 69 weeks of age followed by a 3 weeks recovery period. In a
second trial, four groups of hens were fed diets containing 0.0 (as control), 5, 10, or 20 mg DAS/kg
feed from 25 to 27 weeks of age followed by a 4 weeks recovery period. In a third trial, four groups of
hens were fed diets containing 0.0 (as control), 5, 10, or 20 mg DAS/kg feed for 2 weeks beginning at
week 24, followed by the control diet for 7 weeks. Egg production was not affected by levels of up to
5 mg DAS/kg in 67- to 69-week-old hens of the ﬁrst trial. When fed from 25 to 27 weeks of age in the
second trial, DAS treatment caused a decrease of egg production but at the 20 mg/kg level only.
When fed from 24 to 25 weeks of age in the third trial, DAS treatment had no signiﬁcant effect on egg
production or egg quality. From these studies on laying hens, the CONTAM Panel identiﬁed the level of
5 mg DAS/kg feed as LOAEL for oral lesions. The CONTAM Panel considered the levels of 5 and 10 mg
DAS/kg feed as NOAEL and LOAEL for reduction of body weight gain, respectively. The CONTAM
4,15-Diacetoxyscirpenol in food and feed
www.efsa.europa.eu/efsajournal 40 EFSA Journal 2018;16(8):5367
Panel considered the levels of 10 and 20 mg DAS/kg as NOAEL and LOAEL for decreased egg
production, respectively.
Turkeys
Kubena et al. (1997) fed 1-day-old female Nicholas Large White turkey poults (n = 24, 4 replicates
of 6 poults per dietary treatment during 3 weeks) a basal diet spiked with pure DAS (purity of DAS at
least 99%) at 4 mg DAS/kg feed and compared those with a control group fed the basal diet only.
Both diets were shown to be free of aﬂatoxins DON, Cyclopiazonic acid and Zearalenone. By end of
week 1, body weight gains, feed consumption and feed efﬁciency were signiﬁcantly reduced at 4 mg
DAS/kg feed and after 3 weeks oral lesions were observed in most of the exposed birds. The relative
weight of the spleen was decreased in the treated group but the relative weights of the kidney, bursa
of Fabricius, and proventriculus were not signiﬁcantly altered. Triglycerides and cholesterol were
signiﬁcantly reduced and increased, respectively. From these study results, the CONTAM
Panel considered the level of 4 mg DAS/kg feed as LOAEL generating oral lesions, body weight gain
reduction and changes in some biochemical values in turkey poults.
Sklan et al. (2003) studied four groups of 12 one-day-old male poults fed mash diets at 0.0 (as
control), 0.22, 0.43, 0.86 mg DAS/kg feed for 33 days. Feed intake and feed efﬁciency were not
affected by DAS but oral lesions were apparent at day 7. The severity of the lesions plateaued after
7–15 days. Slight diarrhoea was observed at 0.43, 0.86 mg DAS/kg feed and villus width, length and
area in the jejunum was decreased at the highest dose. The proportion of proliferating cells along the
villi was not changed in the duodenum but was increased in the jejunum. There were no other gross
pathological lesions and no histological abnormalities. The authors concluded that except changes in
small intestinal morphology, feeding turkeys of up to 0.86 mg DAS/kg feed for 33 days did not depress
but enhanced growth, and did not inﬂuence antibody production. From these study results, the
CONTAM Panel considered the level of 0.22 mg DAS/kg feed as LOAEL for causing oral lesions and the
level of 0.86 mg DAS/kg feed as NOAEL since no adverse effects on body weight gain in turkey poults
were noted.
In Fairchild et al. (2005) study, day-of-hatch Large White Hybrid turkey poults were fed basal
starter diet which was found to be below detection limits for aﬂatoxin, fumonisin, deoxynivalenol,
zearalenone, and T-2 toxin as control and a diet composed with the control feed plus 5.0 mg DAS/kg
feed. DAS was prepared from cultures of Fusarium sambucinum and the identity was conﬁrmed by
mass spectroscopy. There were 10 poults per pen with 6 replicate pens per treatment. Poults fed DAS
had mouth lesions, lower body weight, signiﬁcantly lower relative intestine weight, higher relative
bursa Fabricius weight and an alteration of the intestinal architecture compared to the control poults.
The CONTAM Panel identiﬁed that the level at 5 mg DAS/kg feed generated oral lesions and decreased
body weight gain in turkey poults.
Ducks
Schlosberg et al. (1986) studied four groups of 10 day-old domesticated Muscovy ducklings (Cairina
moschata) at 0.0 (as control), 0.25, 0.5, or 1 mg DAS/kg of feed (commercially purchased DAS added
to commercial chicken starter concentrate) for 7 days. Oral lesions were recorded in all treated groups:
incidence, ﬁrst appearance and severity of the lesions were dose related. In addition, reduced feed
intake was observed but no differences in body weight gain were reported. From these data a LOAEL
at 0.25 mg DAS/kg feed was identiﬁed for the occurrence of oral lesions in ducks.
Summary for poultry
For acute toxicity, available studies were performed only on chickens. Oral LD50 were reported
ranging from 3.82 to 5.0 mg DAS/kg bw for 7 day old chickens. An oral 24-h LD50 was reported at 2.0
mg DAS/kg bw for one day old chickens.
Main acute toxicities were reduced spontaneous activity and slightly ﬂuid faecal droppings within
the ﬁrst 24 h. The small intestine, skeletal muscles, the liver (with disseminated foci) and the gall
bladder were affected. Haemorrhages in the vascular beds of the beak and toe nails, in the hock joint
were observed. At necropsy, the lymphoid organs were atrophic, bone marrow was pale red or yellow,
the liver was discoloured yellow, and the crop mucosa was ulcerated. Microscopic lesions included
necrosis and cell depletion in lymphocytic and haematopoietic tissues and necrosis of hepatocytes, bile
ductile epithelium, enteric mucosa, and germinal regions of feather barbs. Other hepatic lesions were
fatty change of hepatocytes and hyperplasia of bile ductile. Thyroid follicles were small, contained pale
colloid and had tall epithelial cells.
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For subchronic and chronic toxicity, NOAELs and/or LOAELS were identiﬁed speciﬁcally to
some types of adverse effects for the following poultry species: chickens, broiler breeders, laying hens,
turkeys and ducks. For 1- to 10-day-old chickens, in several studies oral lesions were observed
after 7–10 days of DAS exposure. The LOAEL was identiﬁed at 0.2 mg DAS/kg feed, corresponding to
the dose of 0.010 mg DAS/kg bw per day for 1-day-old chickens. Regarding body weight reduction,
several studies allowed to identify the levels of 1 and 2 mg DAS/kg feed as NOAEL and LOAEL
(corresponding to 0.050–0.065 mg DAS/kg bw per day and 0.100–0.130 mg DAS/kg bw per day,
respectively). For 25-day-old male broiler breeders, investigated in two studies at the levels of 5
and 10 mg DAS/kg feed, a NOAEL and a LOAEL for decreased fertility (corresponding to the dose of
0.200 and 0.400 mg DAS/kg bw per day, respectively) were identiﬁed. Based on three experiments on
laying hens, the CONTAM Panel identiﬁed 2 mg DAS/kg feed as LOAEL for generating oral lesions
(corresponding to 0.054 mg DAS/kg bw per day) and 5 and 10 mg DAS/kg feed as NOAEL and LOAEL
causing reduction of body weight gain, corresponding to the dose of 0.333 and 0.598 mg DAS/kg bw
per day, respectively. The CONTAM Panel considered the levels at 10 and 20 mg DAS/kg as NOAEL and
LOAEL corresponding to 0.598 and 1.012 mg DAS/kg bw per day for decreased egg production,
respectively. For turkeys, based on the three studies available, the CONTAM Panel considered 0.22
mg DAS/kg feed (corresponding to 0.012 mg DAS/kg bw per day) as LOAEL for oral lesions, and 0.86
and 4.0 as NOAEL and LOAEL for bw reduction corresponding to 0.047 and 0.286 mg DAS/kg bw per
day, respectively.
Based on the data from only one study (Schlosberg et al., 1986) on ducks, the CONTAM
Panel considered the level at 0.25 mg DAS/kg feed corresponding to 0.022 mg DAS/kg bw per day as
LOAEL for oral lesions.
Oral lesions were the ﬁrst observed adverse effect at the lowest level of DAS exposure in the
poultry species of chickens, turkeys, ducks and laying hens at the doses of 0.010, 0.012, 0.022 and
0.054 mg DAS/kg bw per day, respectively. The Panel noted that oral lesions had been also observed
for the type A trichothecenes T-2 and HT-2 (EFSA CONTAM Panel, 2011).
3.1.5.4. Horses
No studies have been identiﬁed.
3.1.5.5. Farmed rabbits
No data on chronic intoxication by oral ingestion were available from the literature.
The CONTAM Panel could only identify a review of Mezes and Balogh (2009) who reported a LD50
after intravenous injection of 1.0 mg DAS/kg bw (also included in Table 4).
Since no other data were identiﬁed, a hazard characterisation of DAS was not possible for farmed
rabbits.
3.1.5.6. Farmed ﬁsh
No studies have been identiﬁed.
3.1.5.7. Farmed mink
No studies have been identiﬁed.
3.1.5.8. Cats and dogs
Data on adverse health effects were only available for dogs but not for cats. Data from the
preclinical i.v. studies on the acute and repeated dose toxicity of DAS (anguidine) in beagle dogs
identiﬁed a NOAEL of 0.031 mg DAS/kg bw for acute adverse health effects (emesis, Section 3.1.4.1)
and a NOAEL of 0.016 mg DAS/kg bw for chronic adverse health effects (haematotoxicity,
Section 3.1.4.2).
3.1.6. Combined effects of DAS with other mycotoxins
Data were identiﬁed for combined effects and interactions of DAS with T-2 and HT-2, AF, OTA and
fumonisins.
In the study on LD50 determination of DAS performed by Hoerr et al. (1981a) (see Section 3.1.5.3),
the determination of LD50 of combined DAS and T-2 toxin was included. In a ﬁrst trial, commercially
purchased DAS and puriﬁed T-2 toxin (purity percentage non mentioned) were dissolved at
appropriate concentrations and then added to the feed and administered alone and in combination to
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7 day-old male broiler chickens (see details in Section 3.1.5.3). The 72-h single oral dose LD50 for DAS
alone and T-2 toxin alone was 5.0 and 4.0 mg/kg bw, respectively. LD50 of combined DAS and T-2
toxin (DAS: T-2 toxin) were determined as 3.05:1.03, 2.26:2.26 and 1.14:3.25 mg/kg bw. In a second
trial, multiple oral dose test of DAS alone and T-2 toxin alone administered as 14 consecutive daily oral
doses determined a LD50 of 4.15 and 2.9 mg/kg bw, respectively. Multiple oral dose tests of combined
DAS and T-2 toxin (DAS:T-2 toxin) at several doses lead to a LD50 of combined DAS and T-2 toxin as
of 2.38:0.88, 1.55:1.55 and 0.88:2.38 mg/kg bw. The authors concluded that combinations of these
toxins caused additive lethal effects in the both single and multiple dose tests (Hoerr et al., 1981a).
Diaz et al. (1994) fed four groups of ten 33-week-old commercial Single Comb White Leghorn hens
during a 24 day experiment. One group was fed a basal diet which was free of aﬂatoxin, ochratoxin,
sterigmatocystin, citrinin, ergot alkaloids, penicillic acid, T-2 toxin, DAS and zearalenone, and in which
only traces of DON (0–3 mg/kg) were detected. Three other groups of 10 hens were given the basal
diet containing 2 mg T-2 toxin, 2 mg DAS and a combination of 2 mg T-2 toxin and 2 mg DAS per kg
feed, respectively. After 48 h of exposure, half of the hens fed diet containing both T-2 toxin and DAS
had oral lesions, while 3 and 4 out of 10 hens were affected in the T-2 toxin and DAS groups,
respectively. The number of affected hens increased gradually during the trial and almost all hens in
group fed the combined toxin diet developed oral lesions, while half of the birds in the T-2 and DAS
groups were affected at the end of the experiment. Signiﬁcantly, less feed was consumed by the
treated hens compared to the control. However, hens receiving the combination of T-2 toxin and DAS
showed the lower feed intake than the groups given a single dietary toxin or the control birds. Egg
production was affected by the treated diets and the lowest production was observed in the group fed
DAS alone or in combination with T-2 toxin. Plasma activities, of aspartate aminotransferase, alanine,
aminotransferase, glutamate dehydrogenase, LDH and creatine kinase were not affected in groups fed
DAS alone. But a signiﬁcant reduction of glutamate dehydrogenase activity was observed in hens
receiving T-2 toxin and the LDH values of hens receiving T-2 toxin singly or with DAS were signiﬁcantly
higher than those of control hens.
Sklan et al. (2001) evaluates the effects of the combination of DAS and T-2 toxin and the
combination of DAS, T-2 toxin and aﬂatoxin B1 (AFB1) (commercially purchased pure DAS, T-2 toxin
and AFB1). Four groups of 10 one day old male Ross chickens were fed basal diet into which pure DAS
was added at the levels of 0.0 (as control), 0.2, 0.5, 1.0 mg/kg feed (see details in Section 3.1.5.3).
Two additional groups of 10 birds were fed the basal diet into which pure DAS and pure T-2 toxin was
added at levels of 0.5 mg DAS plus 0.5 mg T-2 toxin/kg feed and DAS, pure T-2 toxin and pure AFB1
at levels of 0.5 mg DAS plus 0.1 mg T-2 toxin and plus 0.2 AFB1 mg/kg feed for 35 days. Chicks fed
0.2 mg DAS/kg feed or more developed oral lesions. Similar severities of oral lesions were found in the
two groups fed mixtures of toxins. Neither DAS nor the mixture of DAS plus T-2 toxin diets affected
body weight gain and feed efﬁciency whereas the mixture of DAS plus T-2 toxin plus AFB1 diet
reduced growth and feed efﬁciency. In chickens fed 0.5 and 1.0 mg DAS/kg feed and the mixture of
DAS plus T-2 toxin some slight diarrhoea was observed. Concentrations of antibodies against
Newcastle disease virus were not inﬂuenced by the intake of the toxins. The authors concluded that at
the tested levels despite of oral lesions, DAS and the mixture of DAS plus T-2 toxin did not affect body
weight gain whereas the mixture of DAS plus T-2 toxin and plus AFB1 depressed growth and feed
efﬁciency, and neither DAS nor DAS plus T-2 toxin nor DAS plus T-2 toxin and plus AFB1 impaired
antibody production (Sklan et al., 2001).
Harvey et al. (1991) conducted a study on combined effects of aﬂatoxins (AFs) and DAS in pigs.
Four groups of nine 10- to 14-week-old growing barrows (Hampshire x Yorkshire x Landrace) were fed
basal diets for 28 days as follows: 0 mg AFs and 0 mg DAS/kg feed (as control), 2.5 mg AFs/kg feed,
2.0 mg DAS/kg feed, and 2.5 mg AFs + 2.0 mg DAS/kg feed. The basal diet did not have detectable
(below 10 lg/kg of diet) concentrations of AFs, DAS, T-2 toxin, zearalenone, deoxynivalenol, patulin,
penicillic acid, ochratoxin or cyclopiazonic acid. Aﬂatoxins was produced by fermentation of rice by
Aspergillus parasiticus and the AFs content was measured by spectrophotometric analysis and
consisted of 79.0% AFB1, 16.0% AFG1, 4.0% AFB2 and 1.0% AFG2. The DAS was at least 98% pure,
as determined by nuclear magnetic resonance and mass spectrometry. Body weight gain was
signiﬁcantly decreased by each toxin but more by the combination treatment. The AFs or AFs + DAS
treatments induced diffuse hepatocellular vacuolisation, early portal ﬁbrosis, and early bile duct
hyperplasia. Aﬂatoxins increased serum values of creatinine and gamma-glutamyltransferase (GGT),
cholinesterase, and alkaline phosphatase (ALP) activities; increased packed cell volume, haemoglobin
and decreased urea nitrogen and total iron binding capacity. DAS alone reduced serum iron binding
capacity. The AFs + DAS treatment increased serum GGT and ALP activities, increased haemoglobin,
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and decreased serum iron binding capacity. The authors concluded that the combination treatment
could be described as additive or as less than additive, with most of the effects attributable to AFs.
In the experiment performed by Kubena et al. (1993), see Section 3.1.5.3, the effects of the
combination of AFs and DAS were also studied. In addition to control diet and a diet with 5 mg
DAS/kg feed, day-old male broiler chicks were fed 3.5 mg AFs/kg feed and 3.5 mg AFs/kg plus 5 mg
DAS/kg feed until 3 weeks of age. AFs were produced through the fermentation of rice by a toxigenic
strain Aspergillus parasiticus. The AFs contaminated rice consisted of 79% AFB1, 16% AFG1, 4%
AFB2, and 1% AFG2 (by HPLC determination) and then was autoclaved, and ground to a powder
incorporated into the feed. When compared with the controls, beginning the 8th day of diet, body
weight gain was reduced continuing throughout the experiment by both the treated diets with AFs
alone and DAS alone, whereas body weight gains were reduced during the ﬁrst time period (1–7 days)
for the AFs plus DAS combination treatment. Feeding DAS did not alter relative weights of any of the
organs (liver, kidney, heart, proventriculus, gizzard, spleen and pancreas), whereas the relative weights
of these organs were increased in the chickens consuming the AFs plus DAS diet. Moreover, alterations
in haematological values (decrease in both mean corpuscular volume and mean corpuscular
haemoglobin) and serum biochemical values (reduction of concentrations of triglycerides, cholesterol,
glucose, total protein, and albumin) were observed for the AFs and the AFs and DAS combination,
whereas feeding DAS resulted in a signiﬁcant reduction only in triglyceride concentration and in a
decrease in the mean corpuscular volume. Among the serum enzyme activities, feeding AFs alone
caused an increase in creatine kinase activity and a decrease in LDH and aspartate amino transferase
activities. Feeding the DAS diet resulted in no changes in enzyme activities. Feeding AFs plus DAS
resulted in an increase in 7 GGT activity. The authors concluded that apparently a synergistic
interaction occurred between AFs and DAS for reduced body weight gain (Kubena et al., 1993).
In the same experiment performed by Kubena et al. (1994), see also 3.1.5.3 with a design similar
as in Kubena et al. (1993), the effects of the combination of ochratoxin A (OTA) and DAS were
studied. In addition to control diet and a diet with 6 mg DAS/kg feed, day-old male broiler chicks were
fed 2 mg OTA/kg feed and 2 mg OTA/kg plus 6 mg DAS/kg feed during 19 days. OTA was at least
95% pure (HPLC determination). When compared with the controls, OTA and DAS signiﬁcantly
reduced body weight gains when fed alone and in combination. The reduction of body weight gains
due to the combination of OA and DAS was almost identical to that of DAS alone. 90% of the chicks
fed diets containing DAS with or without OTA had oral lesions. When compared with controls, relative
weights of the liver and kidney were increased by feeding OTA singly or in combination with DAS,
whereas no changes in these organs were observed when DAS was fed alone, and the relative weights
of the proventriculus and gizzard were increased by feeding DAS alone but also by feeding the OTA
and DAS combination. The relative weights of the others organs (spleen, pancreas and bursa of
Fabricius) were not signiﬁcantly different from those of the control in any of the treatments. When
compared with controls, serum total protein and albumin concentrations were reduced by OA when
present alone or in combination with DAS. There was a signiﬁcant increase in serum uric acid
concentrations in birds fed the diet containing OTA alone, whereas uric acid concentrations were not
increased in the chickens receiving DAS alone or the OTA plus DAS combination. Serum concentrations
of triglycerides were signiﬁcantly increased, whereas concentrations of cholesterol were decreased in
birds fed the diet containing OTA alone. The serum concentrations of triglycerides or cholesterol were
not altered in the chickens receiving the diets containing DAS alone or in combination with OTA. No
effects of the combination OTA plus DAS were observed for the serum enzyme activities and
haematological values. The authors concluded that there was signiﬁcant interactions between OTA and
DAS which could best be characterised as less than additive for body weight gains and for decreased
serum albumin A, a signiﬁcant antagonistic interaction occurred between OTA and DAS for cholesterol
and for the uric acid concentrations (Kubena et al., 1994).
In the another experiment performed by Kubena et al. (1997) with study design similar to the
Kubena et al. (1993, 1994), the effects of the combination of fumonisin B1 (FB1) and DAS were
studied in turkeys. In addition to control diet and a diet with 4 mg DAS/kg feed, 1 day-old female
Nicholas Large White turkey poults were fed a diet at 300 mg FB1/kg feed and a diet at 300 mg
FB1/kg plus 4 mg DAS/kg feed in combination until 3 weeks of age. To obtain FB1 contaminated diet,
ground Fusarium moniliforme culture material was substituted for ground corn to prepare the desired
level of FB1 (300 mg/kg of diet). The diet also contained approximately 89 mg/kg FB2 and 27 mg/kg
FB3. When compared with the controls, by the end of week 1, body weight gains were signiﬁcantly
reduced in poults fed the 3 contaminated diets but the birds fed the diet containing FB1 plus DAS in
combination had signiﬁcantly lower body weights than birds fed the 2 other diets (FB1 alone and DAS
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alone). Feed consumption and feed efﬁciency were reduced by all three treatments. Oral lesions were
observed in most of the birds fed the both DAS contaminated diets (alone and in combination).
Relative weights of the liver and gizzard increased and in the opposite relative weight of the heart
decreased in birds fed FB1 diet with or without DAS, whereas relative weight of the spleen decreased
in all treated groups. The relative weight of the pancreas was increased in birds fed FB1 alone. The
relative weights of the kidney, bursa of Fabricius, and proventriculus were not signiﬁcantly altered by
any of the 3 treatments. Regarding serum enzyme activities, the combined diet increased activities of
aspartate aminotransferase and LDH. However, serum concentrations of cholesterol were signiﬁcantly
higher in birds fed the DAS diet but were signiﬁcantly lower in birds fed FB1 or the combination of FB1
and DAS. The authors concluded that their results indicated an additive or less than additive toxicity
(e.g. reduction in body weight gain and relative weight of heart), whereas there was a signiﬁcant
antagonistic interaction between FB1 and DAS for cholesterol concentration when turkeys were fed the
combined FB1 plus DAS diet (Kubena et al., 1997).
In the Fairchild et al. (2005), study, day-of-hatch Large White Hybrid turkey poults were fed basal
starter diet which was found to be below detection limits for aﬂatoxin, fumonisin, deoxynivalenol,
zearalenone, and T-2 toxin as control and 3 different diets composed with the control feed plus 5.0 mg
DAS/kg feed, a second plus 119 mg fusaric acid (FA)/kg feed and a third one plus a combination of 5
mg DAS and 137 mg FA per kg feed. The DAS was prepared from cultures of Fusarium sambucinum
and FA was commercially purchased. The identity of both toxins was conﬁrmed by mass spectroscopy.
There were 10 poults per pen with 6 replicate pens per treatment. Poults fed DAS or the toxin
combination had more severe oral lesions than poults fed FA. FA had no effect on body weight or body
weight gain at any period compared to control birds. Poults fed the toxin combination had reduced
body weight gain compared to controls, while poults fed DAS diet had lower bw than all treatments at
every period. Poults fed FA had signiﬁcantly lower relative intestine weight than poults fed the other
diets. The authors concluded that dietary DAS resulted in decreased poult performance, while dietary
FA had little or no effect. Fusaric acid fed in combination with DAS resulted in some protective effect
towards DAS.
Summary
Combined effect of DAS and others mycotoxins was investigated in vivo mainly in poultry, one
experiment has also been performed in pigs. These experiments investigated the effect of DAS with
T-2 toxin, AFB1, OTA and fusaric acid. Except for fusaric acid that reduced the effect observed with
DAS, all other experiments revealed a greater effect when DAS was present in combination with T-2
toxin, AFB1 and OTA. The CONTAM Panel noted that because of the lack of dose–response data, it is
difﬁcult to perform a reﬁned statistical analysis and to draw deﬁnitive conclusion concerning the nature
of the combined effects.
A few in vitro experiments were performed to investigate the combined effect of DAS and other
mycotoxins (Alassane-Kpembi et al., 2017) but they were not sufﬁcient for establishing the nature of
combined effects.
The CONTAM Panel noted that the available database describing possible effects of combined
exposure to DAS and other mycotoxins is weak and inconclusive.
3.1.7. Human data
The Panel identiﬁed data on adverse health effects in humans exposed to DAS in clinical studies
and few epidemiological data which suggested an association with the incidence of a disease that
possibly related to DAS.
Information on human food poisoning outbreak that has been identiﬁed as being possibly
associated with DAS refers to the ‘alimentary toxic aleukia’ (AKA) disease. AKA, occurring in the early
20th Century in the Soviet Union has been associated with the consumption of food contaminated with
Fusarium toxins, T-2 and in particular, with DAS, having been suspected although not conﬁrmed (Joffe,
1974; Joffe and Yagen, 1978; Bennett and Klich, 2003). The symptoms included inﬂammation of the
GI tract in the early disease stages, followed by leucopenia, anaemia and other haematotoxicity
symptoms, and lesions and necrosis in the mouth and gut. The CONTAM Panel noted that some of
these symptoms have close similarity with symptoms observed as clinical side effects of DAS (see
below) but the Panel considered the available data unsuitable for hazard characterisation of DAS in
humans.
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In the 1970s, DAS (named as ‘anguidine’) was developed as a potential anticancer drug and tested
in a series of phase I and phase II trials on patients with different cancer types. Exclusively given by
intravenous (i.v.) administration, the established route for chemotherapy at these times, DAS doses
ranged between 0.1 and 10 mg/m2 in these studies, with different treatment schedules e.g. i.v.
injection (bolus) or infusion (up to several hours). Treatment in phase 1 studies was usually at an initial
low dose in small patient cohorts and then escalated in subsequent cohorts to high doses with weekly
or ﬁve consecutive days schedule, repeated 2 or 3 weeks apart. Some studies escalated the dose also
within patients. The dose ranges applied expressed as mg/m2 corresponded to 2.7–270 lg/kg bw,
when using a transformation factor of 37 (FDA, 2005)14 to convert mg/m2 into lg/kg bw. The clinical
development of DAS was discontinued because the treatment showed lack of efﬁcacy on different types
of cancer and severe side effects (Bukowski et al., 1982; DeSimone et al., 1986; Thigpen et al., 1981).
The adverse effects reported in these studies were examined by the CONTAM Panel in order to
identify relevant human toxicities of DAS and a possible RP for the hazard characterisation. The
CONTAM Panel noted that the aim of phase I clinical trial is to identify a dose with acceptable adverse
effects to be used in the phase II trials and not to identify a NOAEL. In addition, treatment schedule
varied with a total of more than one hundred patients and a small number (between 3 and 6) of
patients were usually treated per dose group in different studies. Although sample size of phase II
studies were larger (usually from about 20 to about 60 patients each) these studies only provided
conﬁrmatory toxicological information. Because of the relatively high and ﬁxed doses used and looking
for clinical efﬁcacy while accepting some adverse effects, their usefulness in identifying reference
doses was very limited.
Phase I studies
Goodwin et al. (1978), selected a starting dose of 0.2 mg/m2 (5.4 lg/kg bw) for DAS when given as
i.v. bolus over 5 min and repeated for 5 consecutive days, escalating the dose by 50% with three or
more patients at each dose level. Nausea and vomiting were seen in 10/24 patients at doses equal to or
lower than 2.4 mg/m2 (65 lg/kg bw). At these doses 5 out of 24 patients showed leucopenia and 3 out
of 24, thrombocytopenia. The percentage of patients with signs of myelotoxicity increased at higher
doses. Central nervous system (CNS) symptoms ranging from mild confusion to short periods of coma
and hallucinations started at 3.1 mg/m2 (84 lg/kg bw). CNS toxicity and hypotension were dose limiting
at 4.5 mg/m2 (121 lg/kg bw) and myelosuppression was unacceptably high at 6 mg/m2 (162 lg/kg bw)
when administered by i.v. bolus over 5-day period. A dosing regimen of 4–8 h infusion at 4.5 mg/m2 per
day provided a more acceptable balance between toxicities. Although the dose of 2.4 mg/m2 (65 lg/kg
bw) resulted to be well tolerated with some mild adverse effects (nausea, vomiting and
haematotoxicity), no sufﬁcient information was available on the paper to identify a NOAEL or a LOAEL.
Murphy et al. (1978) evaluated the toxicity of DAS in 33 cancer patients with various malignancies.
The i.v. treatment was scheduled as daily for 5 days every 2 weeks. The dose was escalated from
initially 0.1 mg/m2 (2.7 lg/kg bw) up to the dose of 7.5 mg/m2 (278 lg/kg bw). At doses < 2.4 mg/m2
per day (< 65 lg/kg bw), there was no drug related adverse effects reported and at 2.4 mg/m2 only
one patient reported mild nausea and vomiting. Above this dose GI symptoms were more frequently
noted. At doses of 3 mg/m2 (81 lg/kg bw) and higher signiﬁcant toxicity including nausea/vomiting was
observed in all patients, moderate myelosuppression (79%), hypotension (20%) and also CNS toxicity
including ataxia (20%) and fever (12%). Above 5 mg/m2 per day (135 lg/kg bw) severe toxicity was
observed in patients with impaired liver function. While all patients suffered nausea and vomiting at this
dose, those with abnormal liver function experienced more severe expression of these symptoms.
The NOAEL for acute toxicity (nausea and vomiting) was identiﬁed as 1.2 mg/m2 (32 lg/kg bw).
No myelosuppression was reported at doses less than 3 mg/m2 (81 lg/kg bw), therefore a NOAEL for
myelotoxicity in the subacute/chronic scenario was identiﬁed at 2.4 mg/m2 (65 lg/kg bw).
Belt et al. (1979), treated 20 patients weekly (33 courses ranging between 1 and 19 weeks
duration, median 4 weeks) by i.v. infusion mostly over 4-h and with a few high doses over 8 h. The
starting dose of 2 mg/m2 (54 lg/kg bw) was escalated in steps of 0.5 to 1 mg/m2 up to 10 mg/m2
(270 lg/kg bw). GI and CNS toxicity symptoms were dose-limiting at > 4 or > 6 mg/m2 (> 108 or 162
lg/kg bw, respectively) in patients with or without hepatic dysfunction, respectively, but
myelosuppression was infrequent. Thrombocytopenia was reported at the lowest dose (2–3.5 mg/m2,
54–94 lg/kg bw) in 50% patients but only in 1 and 2 patients at the highest dose (6.5–10 mg/m2,
14 Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy
Volunteers, FDA - Center for drug evaluation and research, July 2005.
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176–270 lg/kg bw) and it was not dose related. No information was given on the times when
symptoms developed.
From the available data the LOAEL for acute toxicity (nausea and vomiting) ranged from 2 mg/m2
(corresponding to 54 lg/kg bw) to 3.5 mg/m2 (94 lg/kg bw).
DeSimone et al. (1979) also found no myelosuppression in 23 patients with various solid
malignancies given a weekly dose of 1.5–7.5 mg/m2 (40–203 lg/kg bw) for three to six weekly
treatments over a 3-h infusion. They reported no adverse effects at 1.5 mg/m2 (40 lg/kg bw) except
for one patient with pancreatic cancer (mild nausea/vomiting). Nausea and vomiting also appeared at
3 mg/m2 (81 lg/kg bw). More severe nausea and vomiting lasting longer, together with low grade
fever and mild hypertension were reported for 5 mg/m2 (135 lg/kg bw) and CNS symptoms were
observed at 7.5 mg/m2 (203 lg/kg bw). As noted by Murphy et al. (1978), toxicity was more severe in
patients with liver dysfunction. The LOAEL for acute toxicity (nausea and vomiting) was identiﬁed as
1.5 mg DAS/m2 (40.5 lg DAS/kg bw), although considering sporadic nature (1 out of 6), severity
(mild) and the susceptibility of the patient (pancreatic cancer) it can be even considered as a NOAEL.
In summary, DAS caused no toxic effects at i.v. dose of 1.2 mg/m2 (32 lg/kg bw) in phase I
trials. Signiﬁcant toxicity was observed in cancer patients treated with daily doses above 2.4 mg/m2
(65 lg/kg bw). The adverse effects included nausea and vomiting, fever, hypotension,
myelosuppression and CNS effects that all increased in frequency and severity with dose (Goodwin
et al., 1978; Murphy et al., 1978; Belt et al., 1979) although some trials with weekly schedule did not
show myelosuppression (DeSimone et al., 1979; Belt et al., 1979). The treatment was poorly tolerated
by patients with a signiﬁcant proportion suffering severe toxicity at doses of 5 mg/m2 (135 lg/kg bw)
including some life threatening episodes of hypotension. Patients with impaired liver function
constantly showed worse toxicity.
From these studies, the CONTAM Panel overall identiﬁed nausea and vomiting as the most
frequently observed acute toxic effects with a NOAEL at 1.2 mg/m2 (32 lg/kg bw). For the subacute
toxicity, myelosuppression was the most frequently observed adverse effect; a NOAEL was identiﬁed at
2.4 mg/m2 (65 lg/kg bw).
Phase II studies
Numerous phase II trials in cancer patients using DAS were conducted typically at a ﬁxed dose for
clinical cancer treatment effect. While these studies may further conﬁrm the toxicities identiﬁed above
they did not provide speciﬁc information for determining RPs (e.g. NOAELs) for the hazard
characterisation since a large portion of patients experienced toxicity at the dose chosen for the
chemotherapy with DAS.
Yap et al. (1979), tested 30 patients with advanced refractory breast cancer with DAS given i.v. at 5
mg/m2 per day (135 lg/kg bw) for 5 days, repeated every three weeks or 3 mg/m2 per day (81 lg/kg
bw) if liver function was impaired. The treatment was poorly tolerated, with nausea/vomiting, fever,
hypotension, confusion, lethargy occurring as side effects. In addition to nausea and vomiting, the most
signiﬁcant adverse effect noted was hypotension. Myelosuppression resulted to be mild with a nadir
(the lowest number) of cells count between the second and the third week following treatment.
Thigpen et al. (1981), conducted a phase II trial on 25 patients with sarcoma, using 4.5 mg/m2 per
day (121 lg DAS/kg bw) for 5 days (only one patient received more than 3 courses i.v.). There was no
observed effect on the tumours and the most relevant adverse effect was the myelosuppression
observed in 16 out of 25 patients (leucopenia and/or thrombocytopenia). Although no deaths were
recorded two patients developed life-threatening myelosuppression. A total of 16 out of 25 patients
suffered of various degrees of nausea and vomiting and 6 out of 25 of mild hypotension.
Bukowski et al. (1982), conducted an i.v. phase II study in 134 patients with GI malignancies using
doses of 3–4.5 mg/m2 (81–121 lg/kg bw) daily for 5 consecutive days every 28 days. Non-haematological
toxicities were substantial with approximately 50% of patients suffering nausea and vomiting and 40%
hypotension. In addition, approximately 20% of patients suffered of mild myelosuppression
(thrombocytopenia and leucopenia with nadir in third and fourth week after treatment).
Adler et al. (1984) conducted a phase II study on 276 patients using 3 or 5 mg/m2 per day (81–135
lg/kg bw) for 4 or 5 days continuous i.v. infusion every 4 weeks (cycle). Substantial haematological
toxicity was seen in patients with solid tumours, including severe reduction of granulocyte and platelet
in approximately 30% of patients, which was sporadically life threatening. Haematological toxicity was
not cumulative after three courses. GI and CNS toxicities (16% and 6%, respectively) were also
observed.
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DeSimone et al. (1986), reported on the effects of 5 mg/m2 (135 lg/kg bw) 3–6 h daily i.v infusion for
5 days every 3-week in 33 patients with advanced colorectal adenocarcinoma. Hypotension and fever
was observed in approximately 25% of patients while 10% experienced CNS or haematological toxicity.
In the paper from Goodwin et al. (1983), it is reported that mild myelosuppression, CNS and GI
(nausea and vomiting) symptoms were observed in some patients when treated at 3.5 or 5 mg/m2
(94–135 lg/kg bw) weekly.
When 19 patients with metastatic carcinoma from colorectal cancer were treated with i.v. doses
(2–3 h infusion) from 3.5 to 5 mg/m2 (94–135 lg/kg bw) for 5 days every 3 weeks approximately
85% had fever, 75% experienced nausea and vomiting and 35% hypotension (sometimes severe).
Myelotoxicity was only moderate with decrease in white blood cells and platelets, no further details
were available (Diggs et al., 1978).
Using a prediction model taking into account in vitro data from clonogenic assays on rodents and
human haematopoietic progenitors and in vivo data in rodents, Parent-Massin and Parchment (1998)
calculated that the maximum tolerated dose (MTD) in human could be equal to 7.9 mg/m2 (equivalent
to 213 lg/kg bw) while clinical data gave 6 mg/m2. It is important to note that in this case, the MTD is
not a NOAEL but the dose inducing acceptable adverse effects in patient. MTD was considered to be
the dose inducing 90% of cytotoxicity and keeping 10% of haematopoietic progenitors able to renew
blood cells.
In summary, the dosing regimen (5 mg/m2 per day or 3 mg/m2 per day, if liver function was
impaired) caused in phase II studies similar toxicity as seen at these doses in the phase I trials.
Overall, it is clear that doses of 3 mg DAS/m2 day (81 lg/kg bw) and above are associated with
substantial toxicities, in particular nausea and vomiting, myelosuppression, haematological toxicity and
hypotension which can be life threatening at doses of 5 mg/m2 per day (135 lg/kg bw) and higher.
While these phase II clinical trials conﬁrmed DAS-related adverse effects, for the characteristics and
objectives of the studies they were considered of limited value to identifying RPs for hazard
characterisation.
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Table 9: Summary table for IV clinical studies with DAS (anguidine) as an anticancer agent
Ref Phase Organ cancer
Dose mg/m2
per day
Dose(a) lg/kg
bw per day
Duration/
intervals
days
Route
No. patients
treated
(no. patient
evaluated
for toxicity)
Adverse effects
Goodwin et al. (1978) I Advanced
malignancies
resistant to
conventional
therapeutic
modalities
From 0.2 up to 6
[dose escalation]
From 5.4 up to
162
Daily for 5
days (one
month
interval)
i.v.
From bolus
up to 8 h
infusion
36 (24) Dose ≤ 2.4 nausea, vomiting
Dose ≥ 2.4 neurotoxicity, GI
toxicity, cardiotoxicity
Myelotoxicity (inacceptable for
highest dose)
Murphy et al. (1978) I Advanced
malignancies
From 0.1 and
then 0.4
0.6–1
1.2–2.4
3–7.5 [dose
Escalation]
From 2.7 then
11
16–27
32–64
81–203
Daily for 5
days at 2-
week
intervals
i.v.
30–60 min
Infusion
39 (33) Dose ≥ 3, nausea, vomiting,
hypotension, central nervous
system symptoms (including
somnolence, confusion, and
ataxia), diarrhoea, chills and fever,
generalised burning erythema,
stomatitis, shortness of breath,
moderate myelosuppression
Belt et al. (1979) I Advanced
malignancies
resistant to
conventional
therapeutic
modalities
2, 3.5, 4, 6, 6.5,
10 Weekly
infusion
54, 94, 108,
162, 175, 270
Until 36
weeks (5
patients)
i.v.
4–8 h
Infusion
20 Dose ≥ 2 gastrointestinal and
neurologic toxic effects.
Thrombocytopenia at lowest doses
(2–3.5)
DeSimone et al. (1979) I From 1.5, then
3, 5, 7.5
Weekly infusion
From 40 then
81, 135, 203
Repeated for
3–6 weeks
i.v.
3 h Infusion
29 (23) Dose ≥ 3 Nausea and vomiting,
hypotension, CNS symptoms
(confusion, hallucinations, and
psychomotor seizures), chills,
fever, and diarrhoea
Diggs et al. (1978) II Metastatic
Adenocarcinoma
colon rectum
3.5 – liver
injuries – or 5
94, 135 Daily for
5 days at 3-
week
intervals
i.v.
2–3 h
infusion
19 Hypotension (acute)
Nausea and vomiting tolerable
Myelosuppression moderate
Fever and chills
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Ref Phase Organ cancer
Dose mg/m2
per day
Dose(a) lg/kg
bw per day
Duration/
intervals
days
Route
No. patients
treated
(no. patient
evaluated
for toxicity)
Adverse effects
Yap et al. (1979) II Advanced Breast
cancer
3 or 5 mg/m2 81, 135 Daily for 5
days
i.v.
No details
available
30 (25) Nausea and vomiting, hypotension,
CNS symptoms (confusion,
hallucinations, and psychomotor
seizures), chills, fever, and
diarrhoea
Bukowski et al. (1982) II Colon carcinoma,
pancreatic, gastric
cancer,
miscellaneous
3.0, 4.5 mg/m2
daily 9 5-day
(dose escalation)
81,121 Daily for 5
days every 28
days
i.v.
4-h infusion
134 (93) Thrombocytopenia (19.8%),
leucopenia (18.8%), nausea and
vomiting (49%), hypotension
(37%) confusion (12%)
Thigpen et al. (1981) II Sarcoma 4.5 mg/m2 per
day
121 Daily for 5
days every 21
days.
i.v. 4-h
infusion
27 (25) Myelotoxicity, nausea and
vomiting, mild to moderate
hypotension
Goodwin et al. (1983) II Nervous system
tumour
3.5–5 mg/m2
Weekly infusion
94, 135 with schedule i.v.
4-h infusion
17 (16) myelosuppression, gastrointestinal
symptoms, and central nervous
system symptoms
Adler et al. (1984) II 7 different types 3–5 mg/m2 94, 135 4- or 5-day
continuous
infusion every
28 days
i.v.
Continuous
infusion
276 (177) Myelotoxicity
DeSimone et al. (1986) II Colorectal
adenocarcinomas
5 mg/m2 daily x 135 Daily for 5
days every 21
days.
i.v
3–6 h
infusion
33 (29) Hypotension (7/29), fever (7/29),
CNS(3/29), myelotoxicity (3/29)
bw: body weight; i.v.: intravenous.
(a): Transformation factor of 37 (FDA, 2005) to convert the dose from m2 to kg bw.
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Summary
No human epidemiological data on exposure to DAS were identiﬁed. DAS has been evaluated as a
candidate anticancer drug, from the 1970s until mid-1980s, in both phase I and II studies.
DAS administrated by i.v. induced various adverse effects during the course of treatments. The
adverse effects included GI effects (nausea and vomiting), myelosuppression and haematotoxicity,
hypotension, fever and CNS effects. Patients with impaired liver function showed worse symptoms.
The drug ceased for development because of the lack of efﬁcacy in cancer treatment and the
exacerbation of side effects.
The CONTAM Panel considered the data on the toxicity of DAS collected in these clinical trials on
about 500 patients as informative for the hazard characterisation of DAS. From the phase I trials,
nausea and vomiting were the most frequently observed acute toxic effects and derived a NOAEL
corresponding to a dose of 32 lg DAS/kg bw (1.2 mg/m2).
Accounting for the duration of the treatment and the repeated observation of adverse effect over
several cycles (generally covering from 1 to 3–4 months), the CONTAM Panel considered the same
studies as informative for the subacute/subchronic toxicity of DAS in humans and identiﬁed
haematotoxicity and myelosuppression as relevant adverse effects resulting in the identiﬁcation of a
NOAEL as of 65 lg/kg DAS bw (2.4 mg/m2) when administered i.v..
The CONTAM Panel noted that the aim of phase I clinical trial is to identify a dose of acceptable
adverse effects to be used in the phase II trial and not to identify a NOAEL. This was considered to
limit the accuracy of the NOAEL as RP for hazard characterisation.
Data from phase II studies performed at high ﬁxed doses for the cancer treatment purpose
conﬁrmed these toxicities.
3.1.8. Mode of action
Trichothecene mycotoxins, including DAS, are known to target tissues with high proliferative or
turnover rates such as epithelium, bone marrow and lymph nodes (Escriva et al., 2015).
Inhibition of protein synthesis and ribotoxic stress
It is well known that trichotecenes are potent inhibitors of protein synthesis. This inhibitory effect
was demonstrated in whole animals, protozoan, rat liver, primary cells and tumour cell lines (Ueno,
1983). The trichothecenes target the ribosome protein synthesis machinery, binding to the 60S subunit
(Mc Cormick et al., 2011; Garreau de Loubresse et al., 2014). The mechanism of protein synthesis
inhibition can be of two types; inhibition of the initial step of protein synthesis by interference with the
activity of peptidyltransferase or inhibition of the elongation-termination step. In vitro data indicate
that DAS as well as T-2 and HT-2 especially inhibit the initial step, but at high doses DAS was also
found to block the elongation step in both yeast and mammalian cells (Cundliffe and Davies, 1977;
Hernandez and Cannon, 1982). Similar inhibition of proteins synthesis was also observed in Hela cells
at concentrations much lower than those causing inhibition of DNA synthesis (Liao et al., 1976). As
in vitro, trichotecenes exerted no inhibitory effects on DNA or RNA polymerases as well as on other
enzymes involved in DNA/RNA synthesis; it is probable that the impairment of DNA synthesis is caused
as a secondary event of inhibition of protein synthesis (Ueno, 1980). Inhibition of protein synthesis
associated with DAS exposure is therefore likely to be a mechanism underlying the observed in vivo
chromosomal abnormalities (Section 3.1.4.5).
For several trichothecenes, the binding to ribosome has been shown to activate also several
ribosome-associated mitogen-activated protein kinases (MAPKs), including p38, c-Jun N-terminal kinase
(JNK), and extracellular signal-regulated kinase 1 and 2 (ERK1/2), an effect called ‘ribotoxic stress
response’ (Pestka, 2010; Payros et al., 2016). A similar response can be anticipated for DAS.
Induction of oxidative stress
Among mycotoxins, trichothecenes are able to trigger the production of reactive oxygen species
(ROS) (Arunachalam and Doohan, 2013; Da Silva et al., 2018). However data concerning the speciﬁc
implication of DAS in the induction of oxidative stress are very limited. In yeast cells, a 18% increase
in ROS production was observed after treatment with 150 lM DAS for 6 h, however, when the
duration of the treatment was increased to 18 h, a 65% decrease in ROS generation was observed
(Bin-Umer et al., 2011).
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Effect on proliferation, cell-cycle and apoptosis
Trichothecenes possess potent cytotoxicity to eukaryotic cells and several studies have
demonstrated that DAS is cytotoxic for human cells such as cervical carcinoma cells (HeLa, IC50 =
2.7 9 108M, Ueno, 1983), embryonic kidney cells (HEK, IC50 = 2.7 9 108M, Ueno, 1983), Jurkat T
lymphocytes (IC50 = 5 9 10
9M, Nasri et al., 2006) and haematopoietic progenitors (see below). DAS
has also been shown to be cytotoxic for animal cells such as rabbit reticulocytes (IC50 = 8.2 9 10
8M,
Ueno et al., 1977); monkey kidney (Vero) cells (IC50 = 3 9 10
8M, Thompson and Wannemacher,
1986) rat spleen lymphocytes (IC50 = 1 9 10
8M, Thompson and Wannemacher, 1986), chicken
macrophages (Qureshi et al., 1998) and porcine kidney epithelial cells (Morrison et al., 2002).
As indicated in data obtained on HeLa cells, the cytotoxic effect of DAS is observed at level within
the same order of magnitude than the inhibition of protein synthesis (IC50 of 2.7 9 10
8 M for
cytotoxicity vs IC50 of 8.2 9 10
8 M for inhibition of protein synthesis, Ueno, 1983).
In Jurkat T cells, it was demonstrated that DAS-induced cytotoxicity was due in part to apoptosis
initiated by caspase-8 activation and subsequent mitochondrial-dependent or independent activation of
caspase cascades and in part to the interruption of cell cycle progression initiated by downregulation
of cyclin-dependent kinase (CDK) 4 and cyclin B1 proteins (Jun et al., 2007).
Effects on blood cells and haematopoietic progenitors
Type A trichothecenes are known to induce haematological disturbances. The mode of action (MoA)
has been explored using in vitro tests.
Murine peritoneal macrophages were pre-incubated for 4 h with DAS concentrations ranging from
of 0.1 ng/mL to 1 lg/mL. At concentrations that did not affect the cell viability, DAS reduced
phagocytosis (2 ng/mL), microbicidal activity (1 ng/mL), superoxide anion production (1 ng/mL) and
phagosome-lysosome fusion (0.1 ng/mL) and LDH 10 mg/mL). According to the authors, these data
indicated that the inhibition of microbicidal activity arise from both oxidative and non-oxidative
pathways (Ayral et al., 1992).
Aggregation of bovine platelets was inhibited by DAS tested at concentrations ranging from 0.1 to
16 mM when either collagen or adenosine diphosphate was used as the stimulatory agent for
aggregation. The degree of inhibition was dependent on mycotoxin concentration but was not
dependent on the time of exposure of the platelets to the toxin. T-2 toxin and HT-2 toxin were always
more toxic than DAS, and DAS was also less toxic than DON (Chan and Gentry, 1984).
Human and murine haematopoietic progenitors have been incubated in the presence of DAS in
order to study its effect on viability, proliferation and differentiation in white blood cells, red blood cells
and platelets respectively. The authors demonstrated that DAS is cytotoxic at very low concentration
(107 M) and without any cytotoxicity from 2.5 9 108 M for human white blood cell haematopoietic
progenitors to 5 9 1010 M for human red blood cell haematopoietic progenitors. DAS also inhibited
the haemoglobin synthesis at higher concentrations (Parent-Massin et al., 1994, Parent-Massin and
Thouvenot, 1995, Lautraite et al., 1995; Rio et al., 1997, Froquet et al., 2001). The CONTAM
Panel noted that concentrations equal to 107 M and 5 9 109 M for DAS and T-2 toxin, respectively,
are cytotoxic to white blood haematopoietic progenitor cells and that no effect concentrations were
equal to 2.5 9 108 M and less than 1010 M for DAS and T-2 toxin respectively (Lautraite et al.,
1995, Lautraite et al., 1997).
When comparing the myelotoxicity of the four major trichothecenes (DAS, DON, HT-2 and T-2
toxin) in in vitro clonogenic assays, Parent-Massin (2004) concluded that T-2 and HT-2 among these
four mycotoxins were the most myelotoxic ones to human haematopoietic progenitors. The author
concluded that DAS was at least ten times less myelotoxic than T-2 on white blood cell progenitors. In
all cases white blood cells progenitors and platelets progenitors were more sensitive to the
myelotoxicity of these trichothecenes than the erythroblastic progenitors. The authors also concluded
that haematological toxicity induced in vivo by DAS, T-2 and HT-2 toxin, was due to a strong
cytotoxicity on haematopoietic progenitors in the bone marrow. As life time of circulating white blood
cells and platelets is shorter compared to red blood cells (3–4 days vs 4 months) thrombocytopenia
and leucopenia occurred before anaemia.
Effects on gut satiety hormones
Anorexia is a hallmark of the trichothecenes adverse effects, including DAS, but the underlying
mechanisms are not yet fully understood. In a mouse model, oral gavage of 1 mg/kg bw DAS or
intraperitoneal injection of 1 mg/kg bw DAS, resulted in dramatically decreased food intake (Zhang
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et al., 2017a,b). Therefore an increased concentration of the gut satiety hormones cholecystokinin
(CCK), glucagon-like peptide-17–36 amide (GLP-1), peptide YY3-36 (PYY3-36) and glucose-dependent
insulinotropic polypeptide (GIP) were observed in the plasma. More speciﬁcally, after oral exposure,
CCK, PYY3-36 and GIP peaked at 2 h, whereas for GLP-1 plasma concentration still increased after 6
h. These ﬁndings suggest an implication of gut satiety hormones in DAS-induced anorexia but speciﬁc
receptor antagonists have never been used.
Summary
The available data suggested that the mode of action of DAS is by binding to ribosomes, inducing a
‘ribotoxic stress response’ with activation of ribosome-associated MAPKs and inhibition of protein
synthesis. DAS also possesses cytotoxic properties while no clear indications for ROS (reactive oxygen
species) production are available. Increase in gut satiety hormones (e.g. CCK) levels is considered the
mechanism of DAS (and trichothecenes) induced anorexia.
The CONTAM Panel concluded that the mode of action clearly indicated cytotoxic properties on
haematopoietic progenitors which could be due to stimulation of apoptosis or inhibition of protein
synthesis.
3.2. Consideration of critical effects and identiﬁcation of reference
points
3.2.1. Human hazard characterisation and derivation of health-based guidance
values
3.2.1.1. Consideration of critical studies
Based on the conclusions on the genotoxicity and the MoA of DAS (see Sections 3.1.4.5 and 3.1.8)
the CONTAM Panel decided to establish health-based guidance values (HBGV) for both the acute and
chronic exposure of DAS for humans.
The CONTAM Panel noted that the human risk of DAS in food had not been assessed by EFSA
previously and therefore reviewed all available data from studies conducted in experimental animals
and humans as described in Section 3.1.
No oral chronic toxicity studies were identiﬁed in experimental animals and only few subacute oral
toxicity studies were found in rats and guinea pigs, treated over a period of 5 or 4 weeks at the dose
(s) of 1 mg/kg bw per day and 0.6–1.6 mg/kg bw per day, respectively. The Panel considered the
database of these oral studies insufﬁcient for the derivation of a RP for the human hazard
characterisation.
In a next step, the CONTAM Panel noted that the selection of the starting dose in phase I clinical
trials was based on the outcome of preclinical studies in dogs and monkeys. To mimic different clinical
scenarios, DAS was administrated in these studies repeatedly via i.v. (weekly administration or for ﬁve
consecutive days every two weeks, eventually repeated a few times) at doses ranging from 0.016 to 2
mg DAS/kg bw per day in dogs and 0.125 to 1 mg DAS/kg bw per day in monkeys. Dose-dependent
emesis, haematotoxicity and myelotoxicity (see Section 3.1.4.2, Table 5) were observed. The CONTAM
Panel considered that this database in dogs and monkeys was too limited to be used for the derivation
of a RP for the human hazard characterisation.
By contrast human data from clinical studies (summarised in Section 3.1.7) were considered by the
CONTAM Panel as relevant, consistent and sufﬁciently informative to establish HBGV for both acute
and chronic exposure of humans.
No clinical studies after oral administration of DAS and no other data in humans that would inform
on the hazard of oral exposure (e.g. from a human food poisoning outbreak clearly associated with
DAS) were identiﬁed. Therefore, the CONTAM Panel decided to base the human hazard
characterisation of DAS on the available clinical studies in patients treated by i.v. administration of DAS
(anguidine) for cancer.
Data on the toxicity of DAS was available for almost 500 patients recruited in phase I and II clinical
trials conducted between 1978 and 1986. The Panel noted that about 100 patients were treated in
clinical dose-ﬁnding studies of phase I starting with i.v. doses as low as about 0.1 mg DAS/m2
(corresponding to 0.0027 mg DAS/kg bw) per day. These doses were chosen low enough to avoid
signs of toxicity, however in principle not too far from a dose possibly effective against cancer. The
dosed used in the phase I study ranged up to 10 mg DAS/m2 (corresponding to 0.27 mg DAS/kg bw)
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per day where severe toxicity was reported, considered as dose limiting in the phase I studies. DAS
treatment was administered in cycles where one cycle usually consisted of 5-day i.v. infusion every 3
weeks or once a week. Since the treatment period lasted from a few weeks to a few months the
CONTAM Panel considered these clinical trials as short-term studies of DAS. The reported data on
clinical side effects (also denoted as adverse effects or events in the context of clinical drug
development) were considered as informative for oral toxicity of DAS in humans.
It was also noted that these patients may be considered as a speciﬁc vulnerable subpopulation
since patients entering phase I studies usually are at advanced cancer stage and in general already
pre-treated with other anticancer drugs.
3.2.1.2. Relationship between oral and i.v. administration and toxicity of DAS
In order to evaluate a relationship between the i.v. and the oral exposure of DAS, the CONTAM
Panel assessed all available information pertaining to ADME characteristics in humans and in animals.
No pharmacokinetic data in humans were available from clinical studies after i.v. administration of
DAS and no data after oral administration were identiﬁed neither in humans nor in experimental
animals. Therefore metabolic or kinetic differences between oral and i.v. administration of DAS could
not be assessed for humans. In general, oral administration is expected to lead to delayed and lower
peak concentrations in the organism, with longer half-life than after i.v. administration (Timbrell, 2000;
Goodman et al., 2001).
In addition after oral ingestion, DAS might be subject to gastro-intestinal degradation and a strong
ﬁrst-pass effect with early production of metabolites may occur. There were also indications from
in vitro studies that DAS might be deepoxidated or deactylated to a large extent in the gut
(Section 3.1.1.3).
The CONTAM Panel considered that the available data from animals are suggestive for an almost
complete absorption and/or quick clearance after oral and i.v. administration (see Sections 3.1.1 and
3.1.2). Accounting for some variability in the bioavailability, the levels of DAS after oral administration
may reach a fraction of up to about 80% of the i.v. levels. Therefore, considering exposure after oral
dosing as equivalent to i.v. dosing can be regarded as a worst-case scenario.
The limited available experimental data suggested that the toxicity of DAS when given orally was
not higher than the toxicity after i.v. administration, as shown in the comparison of LD50 values over
various species in Table 4 (Section 3.1.4.1).
In humans, severity of adverse effects observed in clinical use of DAS was correlated with the
duration of the i.v. infusion. Bolus injection (e.g. 5–10 min) caused more severe acute effects (mainly
nausea, vomiting, hypotension and CNS toxicity) compared to prolonged infusion (e.g. 4–8 h) with a
tendency to an increased severity of haematotoxicity and myelotoxicity, see Section 3.1.7.
Available data on the MoA indicate for DAS cytotoxicity and binding with ribosomes, inducing a
‘ribotoxic stress response’ with activation of ribosome-associated MAPKs and inhibition of protein and
DNA synthesis, but without clear indications for ROS production (Section 3.1.8). Therefore, what is
currently known about the MoA is not against the assumption of similar toxicity of DAS when given
orally or via i.v.
Taking into account the similar or lower toxicity of DAS metabolites (MAS and SCT, see
section 3.1.4.7 and the aforementioned ADME aspects), the Panel assumed that the toxicity of DAS
after oral administration would not lead to higher systemic toxicity compared to that after i.v.
administration.
The CONTAM Panel noted, however, data gaps that prevent a proper assessment of possible GI
toxicity (i.e. mucositis) of DAS when orally ingested. Furthermore the available clinical data of patients
treated via i.v. do not permit a full assessment of local oral and GI tract toxicity. Oral administration
might lead to exposure by contact in the upper GI tract. The Panel noted that GI effects, and
particularly oral mucositis, are mainly ascribed to damage of basal mucosal layers after i.v.
administration of anticancer cytotoxic chemotherapy (Duncan and Grant, 2003; van Vliet et al., 2010).
In clinical trials with cytotoxic drugs mucositis often occurs together with other adverse effects such as
GI symptoms, nausea and vomiting, haematotoxicity and CNS toxicity. It should be noted that the
toxicity proﬁle of DAS in phase II trials conducted at 3–5 mg/m2 per day was very similar to the proﬁle
seen in phase I studies. The absence of effects in the mucosa in a total of 11 independent i.v. clinical
studies of DAS would therefore not support the hypothesis that oral toxicity of DAS would be
signiﬁcantly larger than i.v. toxicity at similar doses.
In summary, toxicity after oral exposure of DAS was considered as similar to or lower than that
after i.v. administration and equitoxic effects for the same DAS dose were assumed when DAS was
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administered orally or intravenously. That might lead to an overestimation of the hazard after oral
exposure such that the CONTAM Panel concluded that the use of data generated by i.v. administration
might represent a worst-case scenario for hazard characterisation and therefore be adequately
protective for the consumers.
3.2.1.3. Critical effects and derivation of an acute reference dose (ARfD) for DAS
Data on acute adverse health effects in humans were identiﬁed in clinical phase I studies when DAS
was administered to humans in dose-ﬁnding studies with doses ranging from 0.1 to 2.0 mg DAS/m2
(corresponding to 0.0027 to 0.054 mg DAS/kg bw, using the conversion factor of 3715 to express doses
from square meters (m2) on a kg/bw basis). The most frequent acute adverse effects observed were
nausea, vomiting, some CNS effects and hypotension followed by haematotoxicity (Murphy et al., 1978;
Goodwin et al., 1978, DeSimone et al., 1979). The CONTAM Panel identiﬁed nausea and emesis as the
most prominent acute adverse health effect of DAS in humans and selected this as critical effect to
determine a RP for the acute risk of humans exposed to DAS. The dose of 1.2 mg DAS/m2, equivalent to
0.032 mg DAS/kg bw, was indicated as dose without any emetic effect from clinical studies of phase I.
The CONTAM Panel considered these data sufﬁciently informative to determine a low level of
dietary human intake at which no substantial acute health effects occurred. Nausea and vomiting were
identiﬁed as the critical acute effects to allocate an ARfD for humans exposed to DAS.
Based on these clinical data and conservatively assuming 100% bioavailability, the CONTAM
Panel identiﬁed 0.032 mg DAS/kg bw as a RP for acute adverse health effects of DAS.
The CONTAM Panel acknowledged that the cancer patients might represent a vulnerable population
more prone to develop adverse acute effect (mainly nausea and vomiting) compared with the general
population. Nevertheless in order to ensure a more protective approach, the Panel considered the
application of an uncertainty factor (UF) for inter-human variability (EFSA Scientiﬁc Committee, 2012)
and used the UF of 10 to account for differences in toxicokinetics and toxicodynamics between
humans. This is considered as a conservative approach since human variability and toxicokinetic
differences would be limited to metabolism and excretion in the case of i.v. administration.
Therefore, applying the UF of 10 to the RP of 0.032 mg DAS/kg bw identiﬁed above, the CONTAM
Panel established 0.0032 mg DAS/kg bw (i.e. 3,200 ng DAS/kg bw) as ARfD for the acute exposure of
humans to DAS.
3.2.1.4. Critical effects and derivation of a tolerable daily intake (TDI) for DAS
The CONTAM Panel identiﬁed haematotoxicity and myelotoxicity as critical adverse health effects
after repeated exposure to DAS.
The Panel noted that haematotoxicity and myelotoxicity of DAS are expected to induce leucopenia,
agranulocytosis, and anaemia due to its cytotoxicity on circulating blood cells and on haematopoietic
progenitor cells in bone marrow (Section 3.1.8). These haematological effects were also observed in
repeated dose studies in animals after repeated oral or i.v. exposure to DAS (Section 3.1.4.2).
The observed adverse health effects in clinical phase I studies were identiﬁed as pivotal data also
for human chronic hazard characterisation and the data from three prospectively deﬁned dose-
escalation schemes were investigated for the identiﬁcation of a NOAEL for haematotoxicity and
myelotoxicity (DeSimone et al., 1979; Murphy et al., 1978; Goodwin et al., 1978 – Section 3.1.7). The
CONTAM Panel concluded from these data that haematotoxicity and myelotoxicity would not constitute
an adverse health effect in humans when exposed at a dose of 2.4 mg/m2 per day (i.e. 65 lg/kg bw
per day).
While the phase II clinical trials conﬁrmed DAS-related adverse effects, for the characteristics and
objectives of the studies they were considered of limited value to identifying a RP for hazard
characterisation. However, they might be considered as conﬁrmatory for the choice of the critical
adverse effect.
In order to account for inter-human toxicokinetic (possible accumulation in bone marrow cannot be
assessed or ruled out) and toxicodynamic variability of DAS, the CONTAM Panel applied the UF of 10
(EFSA Scientiﬁc Committee, 2012) on this RP for chronic adverse health effects.
In addition, the Panel noted that the adverse health effects in phase I clinical studies were
observed usually within less than 3–6 months (i.e. about 3–8 treatment cycles using intermittent
dosing regimens). Taking into account the limited duration of the exposure and the relatively limited
15 US FDA, Guidance for industry; Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult
healthy volunteers; July 2005.
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number of patients exposed in the phase I studies used for the determination of the RP for chronic
exposure above, the Panel decided to apply an additional UF of 10 to adjust for those limitations.
Considering the range of factors (2–10) suggested for the extrapolation from short-term to chronic
studies by different agencies (EFSA Scientiﬁc Committee, 2012) and accounting for the type of human
clinical phase I data available, the CONTAM Panel noted that the use of a factor of 10 to account for
these above-mentioned limitations should be considered as conservative approach in the hazard
characterisation of human chronic exposure.
Therefore, the CONTAM Panel applied an overall UF of 100 to the NOAEL of 65 lg DAS/kg bw per
day, and established a TDI of 650 ng/kg bw per day for the chronic dietary exposure of humans to
DAS. It is noted that the application of two UFs of 10 is a conservative approach.
3.2.2. Consideration of critical effects and identiﬁcation of reference points for
farm and companion animal risk assessment
Because of the limited available data on toxicity after oral exposure, NOAELs and/or LOAELs for
adverse effects of DAS for farm and companion animals were only identiﬁed for pigs, poultry
(Section 3.1.5) and dogs (Section 3.1.4).
3.2.2.1. Pigs
Reduced feed intake and body weight gain, oral lesions and GI hyperplasia were identiﬁed as
adverse health effects in two short-term (28–63 days) oral studies on pigs. The CONTAM
Panel identiﬁed from these data a LOAEL of 2 mg DAS/kg feed for oral lesions corresponding to 0.08
mg DAS/kg bw per day as RP see Table 10. The LOAEL for reduced bw gain was 0.12 mg DAS/kg bw
per day. The Panel noted that this hazard characterisation was based on sparse data.
3.2.2.2. Poultry
Oral lesions were the ﬁrst observed adverse effect and were also observed at the lowest level of
DAS in chickens, laying hens, ducks and turkeys.
For chickens, the CONTAM Panel identiﬁed oral lesions as the most sensitive critical effects of DAS
with a LOAEL of 0.2 mg DAS/kg feed, corresponding to 0.01 mg DAS/kg bw per day. It was not
possible to deﬁne a NOAEL for this effect. NOAELs (LOAELs) for reduced bw gain were 1.0 (2.0) mg
DAS/kg feed corresponding to 0.05 (0.1) mg DAS/kg bw per day (Table 10).
For Broiler breeders, the CONTAM Panel identiﬁed only a LOAEL but no NOAEL for the most
critical adverse effect i.e. oral lesions; this LOAEL was 5.0 mg DAS/kg feed corresponding to 0.2 mg
DAS/kg bw per day.
For laying hens, the CONTAM Panel identiﬁed a LOAEL of 2.0 mg DAS/kg feed for oral lesions as
the critical effect, corresponding to 0.054 mg DAS/kg bw per day. It was not possible to deﬁne a
NOAEL for this effect. NOAELs (LOAELs) for reduced bw gain and for reduced egg production were 5.0
(10.0) and 10.0 (20.0) mg DAS/kg feed, respectively, corresponding to 0.33 (0.60) and 0.60 (1.01) mg
DAS/kg bw per day (Table 10).
For ducks, the CONTAM Panel identiﬁed a LOAEL of 0.25 mg DAS/kg feed for oral lesion,
corresponding to 0.022 mg DAS/kg bw per day. NOAELs (LOAELs) for reduced bw gain or other
adverse effects were not identiﬁed.
For turkeys, the CONTAM Panel identiﬁed a LOAEL of 0.22 mg DAS/kg feed for oral lesions as the
most sensitive critical effect of DAS, corresponding to 0.012 mg DAS/kg bw per day whereas no
NOAEL was identiﬁed, see Table 10. The NOAEL (LOAEL) for reduced bw gain was 0.86 (4.0) mg DAS/
kg feed, corresponding to 0.047 (0.29) mg DAS/kg bw per day.
3.2.2.3. Dogs
No data were available on the toxicity after oral exposure of DAS for dogs. However, the CONTAM
Panel noted that suitable data on the toxicity of DAS were available from several preclinical studies on
DAS (anguidine) administered via i.v. in beagle dogs that inform on the toxicity of DAS
(section 3.1.4.2). The Panel considered these data as informative and useful for the hazard
characterisation of dogs, similarly as the data on i.v. administration which were used for the hazard
characterisation of humans. Therefore, when considering the bioavailability of the oral dose as same as
for the i.v. dose and assuming equitoxic effects of both administration routes, the Panel identiﬁed a
NOAEL of 0.031 and 0.016 mg/kg bw per day for acute and chronic risk for dogs, respectively (related
to emesis or haematotoxicity, see Table 10). These doses were calculated as equivalent to 0.08 and
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0.04 mg DAS/kg feed when assuming a weight of 10 kg and 0.25 kg feed per day. The Panel noted
that the use of these preclinical data generated by i.v. administration is subject to uncertainty and
might overestimate the risk.
3.2.2.4. Other farm and companion animals
Only one experiment was identiﬁed which compared lambs exposed to 5 mg DAS/kg feed
(equivalent to 0.16 mg DAS/kg bw per day) with controls (n = 6 per group) and identiﬁed reduced
feed intake and weight loss as adverse health effects for these ruminants. No RP could be derived
from this study. For the other farm animal such as farmed rabbits, ﬁshes and mink, and also for horses
and cats no toxicity data were available or suitable for the hazard characterisation of DAS to identify
NOAELs/LOAELs.
In order to obtain an indication on the risk of DAS for these species, the CONTAM Panel considered
the lowest LOAEL of 0.2 mg DAS/kg feed (corresponding to 0.01 mg DAS/kg bw per day) for oral
lesions in poultry as indicative for potential adverse health effects of DAS.
3.3. Occurrence of DAS in food and feed
3.3.1. Occurrence data on food and feed reported in the available literature
Data on the occurrence of DAS in food and feed have been published in the literature, in particular
in the last decade. DAS has been reported to co-occur with many other mycotoxins in grains and grain
products DAS co-occurred in particular with Fusarium toxins including type A and B trichothecenes and
zearalenone. In coffee, DAS co-occurred with type A and B trichothecenes, zearalenone, aﬂatoxins,
fumonisins, ochratoxin A, sterigmatocystin, enniatins and beauvericin.
3.3.1.1. Food
Twenty-three publications could be identiﬁed, which contained relevant information about the
occurrence of DAS in food grains and food products, marketed in Europe and sampled from 2000
onwards (Appendix C). Data from previous years were not considered, due to limitations in the
performance of the analytical methods used before 2000 and to ascertain a representative picture,
because changes in environmental conditions and agricultural practices might have inﬂuenced DAS
Table 10: Summary of NOAELs and LOAELs identiﬁed for hazard characterisation of DAS for those
farm and companion animal species for which data on relevant adverse health effects
could be identiﬁed. The NOAEL/LOAEL values are reported both as doses (mg DAS/kg
bw) and concentrations (mg DAS/kg feed)
Animal
species
Reference point dose Reference point concentration
Adverse effectNOAEL
(mg DAS/kg
bw per day)
LOAEL
(mg DAS/kg
bw per day)
NOAEL
(mg DAS/ kg
feed)
LOAEL
(mg DAS/kg
feed)
Pigs n.d. 0.08 n.d 2.0 Oral lesions
n.d. 0.12 n.d. 2.0 Reduced bw gain
Chicken n.d. 0.01 n.d. 0.2 Oral lesions
0.05 0.1 1.0 2.0 Reduced bw gain
0.2 0.4 5.0 10.0 Reduced fertility
Laying hens n.d. 0.054 n.d 2.0 Oral lesions
0.33 0.60 5.0 10 Reduced bw gain
0.60 1.01 10 20 Reduced egg production
Ducks n.d. 0.022 n.d. 0.3 Oral lesions
Turkeys n.d. 0.012 n.d. 0.2 Oral lesions
0.047 0.29 0.86 4.0 Reduced bw gain
Dogs 0.031 n.d. 0.08 n.d. Emesis
0.016 0.031 0.04 0.08 Haematotoxicity
DAS: diacetoxyscirpenol; bw: body weight; NOAEL: no observed adverse effect level; LOAEL: lowest observed adverse effect
level; n.d.: not determined,
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formation by Fusarium species (this also holds true for Section 3.3.1.2). With few exceptions, LC/MS or
GC/MS was used as analytical technique to determine DAS. The publications contained data from 12
studies on DAS in food grains and from 13 studies on DAS in food products. Altogether 5562 analytical
data on occurrence of DAS were reported. Due to sometimes, incomplete and inconsistent reporting
details in the various papers, interpretation of the results was at times difﬁcult and conclusions should
therefore be made with caution. There is also an uncertainty for the classiﬁcation of grains as ‘food
grains’. It cannot be excluded that some of these grains were (also) used as ‘feed grains’.
The majority of the samples (n = 3,781; 68%) originated from the studies in which grains were
investigated. Only 183 samples (4.8%) were found positive for DAS. In ﬁve of the grain studies DAS
was not found at all. Highest concentrations were reported in samples of wheat (130 lg/kg) and
sorghum (91 lg/kg). Other types of grains (e.g. maize, barley and oats) were only occasionally found
contaminated with DAS, while concentrations were at lower levels.
In the studies in which food products were investigated, 1,781 samples were analysed, of which
122 samples (6.9%) were found positive for DAS. In ﬁve of the food product studies DAS was not
found at all. Highest concentrations were reported in samples of brewed coffee (402 lg/kg, expressed
as lg/kg roasted coffee), potato products (21 lg/kg and roasted soy beans (21 lg/kg). DAS was
infrequently detected at lower concentrations in corn germ oil, roasted coffee beans and oat products.
The literature data on occurrence of DAS in brewed coffee (Garcıa-Moraleja et al., 2015b) are
remarkable, since the mean DAS concentration reported in brewed coffee is a factor 30 times higher
than that in roasted coffee beans (all concentrations standardised to solid coffee and therefore
comparable), analysed by the same authors in another study. Because the DAS concentrations
reported for brewed coffee were inconsistent with the DAS concentrations reported for commercial
roasted coffee, the authors were contacted for explanation and further details. Since this did not yield
the required information, the literature data on DAS in brewed coffee were not accepted for inclusion
in the EFSA database for exposure assessment.
In summary, literature data about DAS in food grains and food products show that DAS has been
reported in the literature to occur at relatively low incidences and concentrations in grains and grain
products, while DAS has also been found to occur in coffee.
3.3.1.2. Feed
Relatively few studies (published since 2000) have analysed for the presence of DAS in feeds, and in
those that have been reported the frequency of detection was low. For example, in samples of maize
kernels (n = 21), maize silage (n = 18) and ‘other feed components (n = 15), DAS was only quantiﬁed in
one sample of each food type analysed (Schollenberger et al., 2005). It was also quantiﬁed in 1/21
samples of maize kernels, but not detected in whole plants (n = 9), or other maize-derived feeds
(n = 11) (Schollenberger et al., 2005). DAS was quantiﬁed in maize kernels (2/41 samples analysed)
and maize by-products (1/13 samples) by Schollenberger et al. (2006) and in all of the 17 samples of
feed oats examined by Gottschalk et al. (2009). Details of levels reported are given in Appendix D.
In complete feedingstuffs, DAS was quantiﬁed in 10 of 50 samples of complete feeds for poultry
(Labuda et al., 2005) with a mean concentration of 3.6 lg/kg. Dall’Asta et al. (2004) reported the
occurrence of DAS in maize-based feeds for fattening pigs. Of the seven samples analysed (LC/ESI–MS
(LOD = 30 lg/kg), ﬁve were < LOD, while levels in the remaining two samples were 376 and 847 lg/kg.
Since these values signiﬁcantly exceeded levels reported in cereal grains that would usually used in the
production of these compound feeds (see Table 15), the CONTAM Panel concluded that they were
unsuitable to use in the estimate of exposure.
However, in most of the published studies, DAS was not detected. For cereal grains, DAS was not
detected in Austrian maize (n = 23) or oats (n = 18) harvested in 2002 (Fuchs et al., 2002), in 446
samples of barley harvested in the UK (Edward, 2009), or in 115 sample of Finnish wheat, rye, barley
and oats (Eskola, 2002). DAS was also not quantiﬁed in samples of wheat (n = 41) or oats (n = 17),
(Schollenberger et al., 2006), nor in 46 samples of Italian wheat collected in 2009 and 2010 (Alkadri
et al., 2014).
For non-cereal feedingstuffs, DAS was not quantiﬁed in soybean meal (n = 13), rapeseed meal (n = 12),
ﬁeld peas (n = 25), lupines (n = 9) or other oilseed by-products (sunﬂower meal, linseed meal, palm kernel
expeller, n = 8) (Schollenberger et al., 2006).
For forages, DAS was looked for, but not detected, neither in maize silage and grass silages in the
Netherlands (Driehuis et al., 2008), nor in maize plants (n = 8), maize silage (n = 5) or grass hay (n = 28)
in Germany (Schollenberger et al., 2006).
Those studies in which DAS has been identiﬁed in feeds are summarised in Appendix D.
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3.3.2. Occurrence data submitted to EFSA
From 2000 onwards to December 2017, 20,061 analytical results of food and feed with analytical
data on DAS were available in the EFSA database.
During the data cleaning process, data providers were contacted to clarify a number of possible
inconsistencies which were identiﬁed during the data check. The following modiﬁcations were made to
the initial data set based on the feedback received:
• The product description of a number of records allowed a more accurate FoodEx classiﬁcation.
In these cases, the samples were reclassiﬁed to a more speciﬁc, detailed level.
• 56 samples reported as ‘suspect sampling’ were not taken into account in the current
assessment.
• Results of samples reported to be analysed by the ELISA method (n = 10) were not
considered sufﬁciently reliable to be included in the assessment.
• 1,152 analytical results were found to be duplicate submission and were disregarded.
• 1,409 analytical results were submitted with misreported parameter code and therefore they
were excluded from the assessment.
• One sample on unspeciﬁed feed terms was disregarded from the assessment as it was not
possible to identify which feedstuff was analysed.
The cleaned database contained 17,433 samples provided by national authorities from Finland,
Germany, Ireland, Luxembourg, the Netherlands, Slovenia and the United Kingdom (UK) for food (n
=15,485) and France, Germany, the Netherlands, Slovakia, Slovenia, Sweden and the UK for feed (n =
1,948).
3.3.3. Occurrence data used for the assessment
As an outcome of the literature search, additional occurrence data on DAS in food (i.e. 301 analytical
results) were obtained from the scientiﬁc literature (see Appendix C). Additional occurrence data on DAS
in feed (i.e. 150 analytical results) were obtained from the scientiﬁc literature (see Appendix D).
In summary, a total of 17,885 analytical results (i.e. 15,786 on food, 2,098 on feed) were available
for the exposure assessment. (Annex A, Table 1A-B, Annex A, Table 2A-B).
Occurrence levels used in the assessment from the available data set are presented in Tables 11
and 12. Note that the food categories represented by either very low number of samples (≤ 6
samples) or by all data left-censored on FoodEx Level 2, were considered not being suitable and were
not used in exposure calculation.
Table 11: Occurrence levels (lg/kg bw) of DAS in food categories considered in the exposure
assessment scenarios
Food category No samples LB mean UB mean LB P95 UB P95
Breakfast cereals 1,075 0.14 15.68 0.00 50.00
Fine bakery wares 504 0.05 9.45 0.00 10.00
Grain milling products 2,135 0.04 13.51 0.00 50.00
Grain for human consumption 7,101 0.14 11.43 0.00 50.00
Pasta (Raw) 292 0.001 22.75 0.00 50.00
Coffee beans, roasted 103 0.76 6.05 6.50 6.50
Oilseeds 476 0.05 35.96 0.00 50.00
Vegetable oil 136 0.09 7.18 0.00 10.00
Cereal-based food for infants and young children 265 1.06 17.76 20.00 50.00
Ready-to-eat meal for children, cereal-based 11 0.18 12.00 – –
Cereal-based dishes 50 12.02 56.82 – –
Snack food 128 2.34 14.05 8.00 50.00
DAS: diacetoxyscirpenol; bw: body weight; LB: lower bound; UB: upper bound; –: not determined (< 60 samples available, see
Section 2.8.2).
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Analytical methods
Considering all the available analytical results (i.e. the results submitted to EFSA by Member States
and the results extracted from the published literature), where classiﬁcation of the analytical method
used for determination of DAS in food was reported by the Member States, results were obtained by
LC–MS(/MS) (40%), GC–MS (31%) and HPLC-based methods (1%). For the remaining 29% of the
data, no information on analytical methods was reported.
For feed 74% of the data were analysed by LC–MS(/MS) and 26% by GC-MS.
3.3.3.1. Food occurrence data used for the assessment
Altogether, including the results submitted to EFSA by Member States and the results extracted
from the published literature 15,786 analytical results were available for food from 10 European
countries (Table 13). Detailed list of food categories and analytical results on FoodEx levels 2 and 3 is
shown in Annex A, Table 1A and 1B respectively. All analytical results shown in the table were
expressed on whole weight basis, thus no conversion had to be applied.
The origin of the samples was not always the European country who reported the data, i.e. the
data set also contained samples originating from North and South America, Africa, Asia and Australia.
The LODs/LOQs of the DAS data from the EFSA database and the scientiﬁc literature data varied
between laboratories and food matrices (i.e. LOD minimum–maximum 0.1–25 lg/kg, mean 10 l/kg;
LOQ minimum–maximum 0.1–50 lg/kg, mean 21 lg/kg). The lowest mean LOQs were reported for
the FoodEx level 2 categories of ‘Grains for human consumption’, ‘Grain milling products’ and ‘Breakfast
cereals’. A high percentage of results below LOD/LOQ in combination with high LODs/LOQs with
Table 12: Occurrence levels (lg/kg bw) of DAS in food categories considered in the exposure
assessment scenarios
Feed Group level 1 Feed category No samples LB mean UB mean LB P95 UB P95
Cereal grains, their
products and by-products
Maize_&_Corn 233 0.51 28.04 0.00 50.00
Cereal grains, their
products and by-products
Oats 380 0.92 5.93 4.44 13.91
Cereal grains, their
products and by-products
Rice, broken 194 0.49 49.77 0.00 50.00
Cereal grains, their
products and by-products
Wheat 591 0.01 6.14 0.00 10.00
Compound feed Complementary/
Complete feed
(Poultry, starter diets)
271 0.13 19.78 0.00 50.00
Forages and roughage, and
products derived thereof
Maize silage 35 1.83 42.07 – –
DAS: diacetoxyscirpenol; bw: body weight; LB: lower bound; UB: upper bound; –: not determined (< 60 samples available, see
Section 2.8.2).
Table 13: Number of food samples in the ﬁnal data set by countries
Sampling country No %
Finland 43 0.3
Germany 4,785 30
Ireland 129 0.8
Italy 14 0.1
Luxembourg 30 0.2
Netherlands 3,790 24
Poland 98 0.6
Slovenia 7 0.04
Spain 103 0.7
United Kingdom 6,787 43
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substantial differences between LB and UB scenarios were observed, increasing the uncertainty
associated with the dietary exposure estimations.
An evaluation of LOQs was performed for those DAS data for which the results were considered to
be suitable for the dietary exposure assessment, and in case of high LOQs data providers were
contacted, but as they were conﬁrmed by them no exclusion was made.
3.3.3.2. Feed occurrence data used for the assessment
Altogether, including the results submitted to EFSA by Member States and the results extracted
from the published literature 2,098 analytical results were available for feed from seven European
countries (Table 14). The detailed list of feed categories and analytical results on levels 2 and 3 is
shown in Annex A, Table 2A and 2B, respectively. Analytical results expressed on whole weight basis
were transformed to 88% dry matter (DM) basis, thus in the annex tables all the presented data is
expressed in 88% DM basis.
The LODs/LOQs of the DAS data from the EFSA database and the scientiﬁc literature data varied
between laboratories and feed matrices (i.e. LOD minimum–maximum 0.1–50 lg/kg, mean 10 l/kg;
LOQ minimum–maximum 0.1–100 lg/kg, mean 23 lg/kg). The lowest mean LOQs were reported for
the FoodEx level 2 categories of ‘Oats’, ‘Wheat’ and ‘Complementary/Complete feed. A high percentage
of analytical results below LOD/LOQ in combination with high LODs/LOQs resulted in substantial
differences between LB and UB exposure scenarios. This was considered as an uncertainty associated
with the dietary exposure estimations.
An evaluation of LOQs was performed for those DAS data for which the results were considered to
be suitable for the dietary exposure assessment, and no exclusion was made.
3.3.4. Food and Feed processing
3.3.4.1. Food processing
The extent to which cereals are processed depends on the cereal type and the ﬁnal feed/food
product. Processing reduces Fusarium toxin concentrations in products for human consumption but
may increase levels in food or feed by-products. Published studies on the effects of processing of
cereals and cereal products on the concentrations of DAS in food and feed are very scarce. As
common for trichothecenes, sorting of cereals by removing those extensively damaged or infected
kernels such as those with visible mould growth or shrivelled kernels, has the effect of lowering the
concentrations of most mycotoxins, including several trichothecenes, in products that are subsequently
produced (Ryu et al., 2008).
No speciﬁc studies could be identiﬁed on the fate of DAS during cleaning and sorting. However it is
assumed that, as for trichothecenes in general, mechanical cleaning of cereals (dehulling) may lead to
by-products (for the feed industry) in which DAS concentrates signiﬁcantly. This would be expected to
result in higher concentrations of DAS in these materials than in the cereals before cleaning.
Rolling and milling
Although no studies could be identiﬁed on the speciﬁc effects of rolling and milling on DAS in
grains, it would be expected that DAS behaves similarly as other trichothecenes. In general, milling
has the effect of reduction and redistribution of trichothecenes, probably also for DAS. Higher
concentrations of DAS in particular fractions such as the bran and shorts would be expected. During
dry milling, DAS is expected to concentrate in the fractions containing the outer parts of the grain
Table 14: Number of feed samples in the ﬁnal data set by countries
Sampling country No %
France 413 20
Germany 100 5
Netherlands 278 13
Slovakia 50 2.4
Slovenia 167 8
Sweden 228 11
United Kingdom 862 41
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rather than in those fractions containing the inner parts of the grain, as also is the case for DON
(Abbas et al., 1985; Lesnik et al., 2008). Therefore, the highest levels of DAS would be expected in
the germ, screenings, dust and bran while the ﬂour and grits would contain lower levels than those
found in the grain before dry milling (Hazel and Patel, 2004).
Cooking and baking
Only one study was identiﬁed on the effect of thermal food processing of DAS. Kanimura et al.
(1979) investigated the fate of DAS in bread and Japanese and Chinese noodles prepared from wheat
ﬂour under various conditions of manufacturing and cooking. When adding chloroform solutions
containing DAS, reductions of initial levels of DAS after heating were reported. Since initial and ﬁnal
concentrations of DAS were not given, these data were not used for assessing the role of cooking and
baking.
3.3.4.2. Feed processing
No information on impact of feed processing on DAS concentrations, speciﬁcally in feed materials,
has been identiﬁed. However, cereal grains intended for use as animal feed are usually subject to
some of the processes used for processing grains for human consumption (cleaning, sorting, drying,
rolling/grinding and/or extrusion) before being fed to livestock, and therefore the effects of these
processes reported above for food (Section 3.4.1) apply equally to cereal grains for animal feed.
For long-term storage of cereal grains, a maximum moisture content of approximately 12% is
generally recommended. In order to achieve this, air temperatures of up to 125–130°C may be used,
resulting in grain temperatures of up to 45°C. Like most trichothecenes, DAS is stable at these
temperatures (Schwake-Anduschus et al., 2010) and therefore drying is unlikely to affect DAS
concentrations in grains dried in this way.
Cereal by-products resulting from the processing of grain for human consumption are widely used
in livestock diets. The EC Catalogue of Feed Materials16 lists over 80 cereal by-products used as animal
feeds. In common with other mycotoxins, DAS is found predominantly on the outer layer of the grain.
Dry milling generally results in a redistribution of DAS into separate milling fractions, and an increase
of mycotoxins in particular fractions such as the bran and grits might be expected, although no data
speciﬁcally for animal feeds have been identiﬁed.
Compound feeds consist of mixtures of feed materials and additives formulated to meet the speciﬁc
nutritional requirements of the livestock to which they are fed. One of the ﬁnal stages in the
compound feed manufacturing process is the production of feed pellets, which results in an increase in
temperature, with temperature increasing up to 95°C (Thomas et al., 1997). Like most trichothecenes,
DAS is stable at these temperatures (Schwake-Anduschus et al., 2010) and therefore compound fed
manufacture is unlikely to affect concentrations in the ﬁnished product.
3.3.4.3. Summary
Published studies on the effects of food and feed processing on DAS were quite scarce and no ﬁrm
conclusions could be drawn. However, the CONTAM Panel assumed that these practices are expected
to result in a redistribution and/or reduction of DAS in the ﬁnal products, as is the case with other
trichothecenes.
3.4. Exposure assessment
3.4.1. Human exposure assessment
3.4.1.1. Mean and 95th percentile acute dietary exposure
The mean and 95th percentile of acute exposure estimates at the UB level are shown for the
different age groups of humans in Table 15 as minimum (Min) and maximum (Max) over from different
surveys and age groups. The numbers in brackets indicate the 95% conﬁdence intervals obtained from
the probabilistic approach (for more details, see Section 2.8.1), see also Annex A, Table 4.
16 Commission Regulation (EU) No 2017/2017 of 15 June 2017 amending Regulation (EU) No. 68/2013 on the Catalogue of
feed materials OJ L 159, p. 48–119.
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Infants (< 12 months)
The mean acute dietary exposure ranged from 22.6 to 181.1 ng/kg bw per day, and the 95th
percentile from 118.3 to 799.1 ng/kg bw per day.
Toddlers (≥ 12 months to< 36 months old)
The mean acute dietary exposure ranged from 50.4 to 186.0 ng/kg bw per day, and the 95th
percentile from 173.5 to 736.3 ng/kg bw per day.
Other children (≥ 36 months to < 10 years old)
The mean acute dietary exposure ranged from 34.8 to 175.1 ng/kg bw per day, and the 95th
percentile from 114.6 to 702.5 ng/kg bw per day.
Adolescents (≥ 10 years to < 18 years old)
The mean acute dietary exposure ranged from 24.6 to 106.2 ng/kg bw per day, and the 95th
percentile ranged from 89.0 to 354.4 ng/kg bw per day.
Adults (≥ 18 years to < 65 years)
The mean acute dietary exposure ranged from 21.7 to 85.4 ng/kg bw per day, and the 95th
percentile ranged from 62.5 to 283.1 ng/kg bw per day.
Acute dietary exposure in the two surveys of ‘Pregnant women’ from Portugal and Latvia,
respectively, were within the range of exposure estimates in the adult population with mean exposures
of 25.2 (23.3–29.7) and 53.0 (50.9–55.7) ng/kg bw per day and 95th percentile exposure of 78.7
(71.2–87.1) and 179.4 (170.7–187.4) ng/kg bw per day.
In the two surveys of ‘Lactating women’ from Estonia and Greece, respectively, the mean
exposures were 44.6 (42.6–46.7) and 102.5 (86.2–128.2) ng/kg bw per day while 95th percentile
exposures were 117.5 (106.6–132.6) and 346.8(322.5–371.2) ng/kg bw per day which are exceeding
the average exposure of the adult population.
Elderly and very elderly (≥ 65 years old)
The mean dietary exposure ranged from 17.1 to 83.2 ng/kg bw per day for the elderly and very
elderly, and the 95th percentiles ranged from 54.0 to 203.3 ng/kg bw per day.
3.4.1.2. Mean and 95th percentile chronic dietary exposure
The mean and 95th percentile of chronic exposure estimates at the UB to DAS obtained for
different age groups are shown in Table 16. Detailed mean and 95th percentile dietary exposure
estimates calculated for each dietary survey are presented in Annex A, Table 5.
Table 15: Summary of probabilistic acute dietary exposure assessment to DAS (UB) across
European dietary surveys by age group
Age group n
Mean UB exposure
(ng/kg bw per day) n
95th percentile dietary UB
exposure (ng/kg bw per day)(a)
Min Max Min Max
Infants 11 22.6 (16.6–29.4) 181.1 (165.0–196.1) 10 118.3 (90.9–185.2) 799.1 (673.1–931.6)
Toddlers 15 50.4 (46.8–56.8) 186.0 (163.6–221.5) 15 173.5 (167.1–180.3) 736.3 (705.7–771.3)
Other
children
21 34.8 (32.8–37.1) 175.1 (160.0–195.9) 21 114.6 (104.0–124.6) 702.5 (670.6–735.3)
Adolescents 21 24.6 (23.4–25.8) 106.2 (92.5–122.5) 21 89.0 (84.0–93.5) 354.4 (334.8–372.4)
Adults 23 21.7 (21.0–22.4) 85.4 (77.7–97.0) 23 62.5 (58.2–66.9) 283.1 (264.2–294.1)
Elderly 20 17.9 (17.2–18.6) 75.2 (72.3–78.6) 20 54.0 (48.6–60.7) 203.3 (182.3–224.8)
Very
elderly
17 17.1 (16.1–18.2) 83.2 (81.5–85.2) 15 62.5 (57.9–68.4) 182.6 (132.2–214.9)
bw: body weight; n: number of surveys; Min: minimum; Max: maximum.
The corresponding 95% conﬁdence intervals are presented in the brackets.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be
statistically robust (EFSA, 2011a). Those estimates were not included in this table.
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Infants (< 12 months)
The mean chronic dietary exposure ranged from 0.2 to 92.3 ng/kg bw per day (minimum LB and
maximum UB) and the 95th percentile dietary exposure from 0.5 to 315.9 ng/kg bw per day (minimum
LB to maximum UB).
Toddlers (≥ 12 months to < 36 months old)
The mean chronic dietary exposure ranged from 0.5 to 184.8 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 1.0 to 488.1 ng/kg bw per day (minimum
LB to maximum UB).
Other children (≥ 36 months to < 10 years old)
The mean chronic dietary exposure ranged from 0.4 to 174.3 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 1.0 to 490.5 ng/kg bw per day (minimum
LB to maximum UB).
Adolescents (≥ 10 years to < 18 years old)
The mean chronic dietary exposure ranged from 0.2 to 105.9 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 0.5 to 264.7 ng/kg bw per day (minimum
LB to maximum UB).
Adults (≥ 18 years to < 65 years)
The mean chronic dietary exposure to DAS ranged from 0.2 to 66.2 ng/kg bw per day (minimum
LB to maximum UB) and the 95th percentile dietary exposure estimate from 0.6 to 194.4 ng/kg bw per
day (minimum LB to maximum UB).
Chronic dietary exposure in the two surveys of ‘Pregnant women’ from Portugal and Latvia were
within the range of exposure estimates in the adult population.
Table 16: Summary statistics of the chronic dietary exposure to DAS (ng/kg bw per day) across
European countries
Age group N
Mean dietary exposure (ng/kg bw per day)
Minimum Median Maximum
LB UB LB UB LB UB
Infants 11 0.2 14.9 1.4 54.4 8.0 92.3
Toddlers 14 0.5 49.0 1.4 81.2 23.5 184.8
Other children 19 0.4 34.4 1.2 70.1 27.9 174.3
Adolescents 18 0.2 23.5 1.2 44.3 18.4 105.9
Adults 19 0.2 16.3 0.9 24.5 8.9 66.2
Elderly 18 0.2 12.6 0.8 19.8 5.9 46.2
Very elderly 15 0.2 12.2 0.7 23.3 4.5 39.5
Age class(a) N
95th percentile dietary exposure (ng/kg bw per day)
Minimum Median Maximum
LB UB LB UB LB UB
Infants 10 0.5 67.3 3.9 107.6 41.2 315.9
Toddlers 12 1.0 97.6 3.8 150.3 88.0 488.1
Other children 19 1.0 71.8 4.4 155.8 97.0 490.5
Adolescents 17 0.5 49.5 3.6 104.3 52.4 264.7
Adults 19 0.6 35.2 2.1 55.5 35.9 194.4
Elderly 18 0.4 29.1 1.4 45.7 28.8 156.9
Very elderly 10 0.4 30.9 1.1 51.2 21.8 110.8
bw: body weight; LB: lower bound; UB: upper bound; N: number of surveys.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be
statistically robust (EFSA, 2011a). Those estimates were not included in this table.
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In the two surveys of ‘Lactating women’ from Estonia and Greece, the mean exposure ranged from
0.4 to 97.0 (minimum LB to maximum UB) and the 95th percentile dietary exposure estimate from 0.9
to 228.5 ng/kg bw per day (minimum LB to maximum UB).
Elderly and very elderly (≥ 65 years old)
The mean dietary exposure to DAS ranged from 0.2 to 46.2 ng/kg bw per day (minimum LB to
maximum UB), the 95th percentiles dietary exposure estimate from ranged from 0.4 to 156.9 ng/kg
bw per day (minimum LB to maximum UB).
3.4.1.3. Contribution of different food groups to the exposure
Contribution of the different food groups across dietary surveys is summarised by age class in
Annex A, Table 6. These contributions were calculated on the basis of the LB exposure estimates. The
results are reported as a number of surveys for the following contribution ranges: 0–5, 5–10, 10–25,
25–50, 50–75, > 75%.
In all population groups, ‘Cereal-based dishes’ was the main contributor.
In the age class ‘Infants’ and ‘Toddlers’, additional important contributors were ‘Cereal-based food
for infants and young children’, and ‘Breakfast cereals’.
‘Snack food’ was contributing mostly in age classes ‘Toddlers’, ‘Other children’ and ‘Adolescents’.
In the adult population groups, ‘Coffee’ also occurs as an additional important contributing category.
3.4.2. Exposure assessment for farm and companion animals
Exposure estimates at the 95th percentile and mean concentrations for farm and companion
animals are reported below. These were calculated by using the occurrence data set for feed
(Section 3.3.3.2) and feed consumption as reported in Appendix E. For all species, the P95 and mean
exposures have been estimated based on the 95th percentile and the mean LB and UB concentrations,
respectively. According to EFSA (2010), caution is needed when calculating chronic exposure (95th
percentile) where data on less than 60 samples are available, since the results may not be statistically
robust. Therefore, in this Opinion, there are no acute exposure estimations where data on < 60
samples are available. Furthermore, EFSA (2010b) has indicated that estimates of chronic exposure
based on data for < 10 samples are unreliable, and therefore where data on less than 10 samples
have been provided these have not been used to estimate the mean LB and UB exposures.
Sufﬁcient data on levels of DAS in species-speciﬁc compound feeds have been reported for poultry
starters diet: there were sufﬁcient data (n = 118) with which to calculate mean and acute (P95)
exposures. For all other livestock and companion animals, exposures to DAS have been based on
concentrations in individual feed materials – mainly cereal grains – and their levels of inclusion in the
diets. Data were provided on levels of DAS in complementary feed for dairy cows (n = 15) and in
compound feeds for laying hens (n = 13); however, since all values were left censored they were not
used to estimate exposure, and estimates were made using levels of DAS in individual feedingstuffs
and their estimated intakes in diets for the individual animal species.
3.4.2.1. Ruminants and horses
Forages, either fresh or conserved, are essential ingredients in the diets of ruminants and horses,
and in some cases may be the sole ingredient. However, only data for maize silage (n = 35) have been
available for this Opinion and these, together with levels of DAS in non-forage feeds, have been used
to estimate exposure for dairy cows and beef cattle on maize silage-based rations. For other diets for
ruminants and horses, exposures have been made based on levels of DAS in cereal grains and
assumed inclusion rates in their diets (for details, see Appendix E). In the absence of data on forages
(other than maize silage) it is assumed that they make no contribution to exposure to DAS.
Estimates of exposures for ruminants and horses are given in Table 17.
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3.4.2.2. Pigs and Poultry
Estimates of 95th percentile and mean exposure by pigs and poultry to DAS were derived from
data on levels of DAS in cereals and assumed inclusion rates of cereal grains in their diets and are
given in Table 18. Details of assumed inclusion rates of cereals are given in Appendix E.
Table 17: Estimated 95th percentile (P95) and mean exposure to DAS by ruminants and horses,
derived from concentrations in individual feed materials and their relative proportions in
diets(a)
Animal species (diet)
Diet concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg
bw per day
Mean P95 Mean P95 Mean P95
Ruminants on maize-silage-based diets
Dairy Cows
(maize silage-based diet)(b)
LB 1.3 nd 36 nd 0.06 nd
UB 43 nd 1,193 nd 1.8 nd
Beef cattle
(maize silage-based diet)(b)
LB 1.5 nd 10 nd 0.03 nd
UB 35 nd 234 nd 0.78 nd
Ruminants and horses on other forage-based diets
Dairy cows
(grass-based diet)
LB nd nd 0.01 nd nd nd
UB 2.3 3.9 48 80 0.07 0.12
Beef cattle
(grass-based diet)
LB nd nd Nd nd nd nd
UB 0.51 0.68 4.87 6.55 0.01 0.02
Beef cattle
(cereal-based diet)
LB nd nd Nd nd nd nd
UB 4.3 5.8 43 57 0.11 0.14
Lactating sheep LB nd nd Nd nd nd nd
UB 2.8 4.6 7.8 13 0.10 0.16
Lactating goats LB 0.17 nd 0.59 nd 0.01 nd
UB 7.5 15 25 49 0.43 0.83
Horses LB 0.11 nd 0.16 nd nd nd
UB 3.9 15 5.8 23 0.15 0.58
bw: body weight; nd: not determined; LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
(b): Insufﬁcient samples of maize silage were available to reliably undertake 95th percentile exposure estimates.
Table 18: Estimates of 95th percentile (P95) and mean exposure to DAS for pigs and poultry
derived from assumed inclusion rates of cereal grains in their diets(a)
Animal species
Diet concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean P95 Mean P95 Mean P95
Estimates derived from LB and UB concentrations in species-speciﬁc compound
feeds
Poultry starters LB nd 0.02 0.03 0.31 nd 0.002
UB 0.06 0.32 0.84 4.3 0.005 0.024
Estimates derived from LB and UB concentrations in feed materials and their
relative proportions in diets
Pig starter LB nd nd nd nd nd nd
UB 18 32 18 32 0.92 1.6
Growing/fattening pigs LB nd nd 0.01 nd nd nd
UB 11 20 35 61 0.35 0.61
Pig ﬁnisher LB nd nd 0.01 nd nd nd
UB 11 20 35 61 0.35 0.61
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3.4.2.3. Farmed ﬁsh
In the absence of any data on concentrations of DAS in species-speciﬁc compound feeds for ﬁsh,
estimates of exposure were made by using example rations and concentrations in individual feed
materials (see Appendix E for details of rations used) and are reported in Table 19.
3.4.2.4. Farmed rabbits and mink
In the absence of any data on concentrations of DAS in species-speciﬁc compound feeds for ﬁsh,
estimates of exposure were made by using example rations and concentrations in individual feed
materials (see Appendix E for details of rations used) and are reported in Table 20.
Animal species
Diet concentration
lg/kg dry matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean P95 Mean P95 Mean P95
Lactating sow LB nd nd 0.02 nd nd nd
UB 14 25 86 151 0.43 0.75
Fattening chickens LB 0.22 nd 0.03 nd 0.01 nd
UB 24 43 2.9 5.2 1.44 2.6
Laying hens LB 0.21 nd 0.02 nd 0.01 nd
UB 27 48 3.2 5.8 1.61 2.9
Fattening turkeys LB nd nd nd nd nd nd
UB 14 24 5.7 9.8 0.48 0.81
Fattening ducks LB nd nd nd nd nd nd
UB 22 38 3.0 5.4 1.0 1.8
bw: body weight; nd: not determined; LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 20: Estimated 95th percentile (P95) and mean exposure to DAS for farmed rabbits and
farmed mink derived from concentrations in cereal grains and their relative proportions in
diets(a)
Animal species
Diet concentration
lg/kg dry feed matter
Exposure lg/day Exposure lg/kg bw per day
Mean P95 Mean P95 Mean P95
Farmed rabbits LB nd nd nd nd nd nd
UB 1.52 2.0 0.23 0.31 0.11 0.15
Farmed mink LB 0.04 nd nd nd nd nd
UB 2.39 4.2 0.18 0.32 0.09 0.15
bw: body weight; nd: not determined; LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 19: Estimated 95th percentile (P95) and mean exposure to DAS for farmed ﬁsh derived from
concentrations in cereal grains and their relative proportions in diets(a)
Animal species
Diet concentration
lg/kg dry feed matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean P95 Mean P95 Mean P95
Salmonids LB nd nd nd nd nd nd
UB 8.57 15.48 0.34 0.62 0.17 0.31
Carp LB 0.06 nd nd nd nd nd
UB 25 45 0.55 1.00 0.55 1.00
bw: body weight; nd: not determined; LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
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3.4.2.5. Dogs and cats
No data on levels of DAS in proprietary feeds for dogs and cats were available, and therefore
exposure was estimated using example rations (see Appendix E for details) and concentrations DAS in
cereal grains used. The estimated exposures are reported in Table 21.
Summary
Ideally, estimates of exposures should be made using levels of DAS in species-speciﬁc complete or
complementary feeds, but in this opinion, this was only possible for poultry starter diets. Based on
these data, the estimated LB and UB exposures, for both the mean and 95th percentile exposures,
were all < 1.0 lg/kg diet. For dairy cows, growing/fattening pigs and laying hens, data were also
provided, but all were left-censored and therefore considered unreliable to estimate exposure.
Therefore, exposures for all livestock (with the exception of young poultry) were made using the levels
of DAS in individual feeds and their inclusion rates in the diets.
With the exception of maize silage, there were only levels of DAS in forages. Consequently, the
highest estimated exposures for ruminants were for those fed on maize silage-based diets. For dairy
cows, the estimated mean exposures ranged from 1.3 (LB) to 43 (UB) lg/kg diet DM; while the P95
exposures were not determinable. Estimated exposures for beef cattle on maize silage-based diets
were marginally lower.
For most other livestock and farmed animals, the LB estimates for both the mean and P95
exposures were not determinable or < 1 lg/kg diet DM.
For pigs, the average for the UB mean and P95 estimates were 15 and 26 lg/kg diet DM,
respectively. For poultry, the highest UB exposures were estimated for laying hens (27 and 48 lg/kg
diet DM, for mean and P95 estimates, respectively), while for farmed rabbits and mink, the UB
(rounded) values were highest for mink (2.4 and 4.2 lg/kg diet DM, for mean and P95 exposures,
respectively).
For ﬁsh, due to the higher inclusion rates of cereals in their diets, UB estimates were highest for
carp (25 and 45 lg/kg diet DM, for mean and P95 estimates, respectively).
For companion animals, the UB mean and P95 and exposures were highest for cats (7.3 and 13 lg/
kg diet DM, respectively).
3.5. Risk characterisation
3.5.1. Human health risk characterisation
3.5.1.1. Acute human health risk from the dietary exposure to DAS
The CONTAM Panel characterised the human health risk associated with acute dietary exposure to
DAS by comparing the mean and 95th percentile acute dietary minimum and maximum exposure
estimates (summarised in Table 13) with the derived ARfD of 3,200 ng/kg bw.
The estimated mean acute dietary exposure to DAS in food ranged from 17.1 ng/kg bw (minimum,
calculated for the ‘very elderly’) to 186 ng/kg bw (maximum, calculated for the ‘toddlers’) across the
dietary surveys and age groups.
Table 21: Estimated 95th percentile (P95) and mean exposure to DAS by companion animals (dogs
and cats) derived from concentrations in cereal grains and their relative proportions in
diets(a)
Animal species
Diet concentration
lg/kg dry feed matter
Exposure lg/day
Exposure lg/kg bw
per day
Mean P95 Mean P95 Mean P95
Cats LB 0.03 nd nd nd nd nd
UB 7.3 13 0.44 0.78 0.11 0.20
Dogs LB 0.04 0.02 0.01 0.01 nd nd
UB 5.1 9.1 1.8 3.3 0.07 0.13
bw: body weight; nd: not determined; LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
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The estimated 95th percentile acute dietary exposure DAS in food ranged from 54 ng/kg bw
(minimum, calculated for the ‘elderly’) to 799 ng/kg bw (maximum, calculated for the ‘infants’) across
the dietary surveys and age groups.
Since even the largest 95th percentile acute dietary exposure estimates were below the ARfD of
3,200 ng/kg bw, the CONTAM Panel concluded that the current acute exposure to DAS in food raised
no health concern for humans.
3.5.1.2. Chronic human health risk from the dietary exposure to DAS
The CONTAM Panel characterised the human health risk associated with chronic dietary exposure to
DAS by comparing the mean and 95th percentile chronic dietary LB and UB exposure estimates across
the European dietary surveys and the age groups (summarised in Table 16) with the TDI of 650 ng/kg
bw per day.
The lowest LB to the highest UB chronic mean exposure across age groups and surveys ranged
from 0.2 ng/kg bw per day (‘Infants’) to 185 ng/kg bw per day (‘toddlers’). The lowest LB to the
highest UB chronic 95th percentile exposure ranged from 0.4 ng/kg bw per day (‘elderly’ and ‘very
elderly’) to 491 ng/kg bw per day (‘other children’).
Therefore, the CONTAM Panel concluded that there was no health concern associated with chronic
dietary exposure to DAS.
3.5.2. Animal health risk characterisation
3.5.2.1. Animal health risk characterisation
Because of the limited knowledge on the effects of DAS on farm and companion animals and on
the absence of a comprehensive database on feed consumption by livestock in the EU, it has not been
possible to properly assess the risk of DAS for animal health.
However the exposure estimates at the LB and UB concentrations for DAS in diets have been
estimated for the most relevant farm livestock and companion animal categories, based on expected
feed intakes and example diets. Those have been compared with the species speciﬁc overall LOAELs/
NOAELs for pigs, poultry and dogs (see Table 20). With this aim the estimates of dietary exposure to
DAS were expressed as concentration in diet (lg/kg DM), exposure per day and exposure per kg bw
per day, see Tables 16–19.
Pigs
For pigs, the CONTAM Panel characterised the health risk associated with dietary exposure to DAS
by comparing the estimated exposures at the UB mean and UB 95th percentile dietary exposure for
DAS with the identiﬁed LOAEL of 80 lg/kg bw per day for oral lesions in fattening pigs (see Tables 16
and 20).
The dietary exposure was highest for starter pigs at the estimated UB mean and 95th percentile
dietary exposures of 0.92 and 1.61 lg/kg bw per day, i.e. 1.2% and 2.0% of the LOAEL for these
pigs, respectively.
For growing/fattening and ﬁnisher pigs and lactating sows, the estimated UB mean and 95th
percentile dietary exposures ranged between 0.35 and 0.43 lg/kg bw per day and 0.61 and 0.75 lg/kg
bw per day, respectively, corresponding to 0.4–0.5% and 0.8–0.9 of the LOAEL (see Tables 10 and 22).
Therefore, the Panel concluded that the risk for adverse health effects from feed containing DAS is
low for pigs at the estimated exposure levels under current feeding practices. However, the CONTAM
Panel noted that the hazard characterisation was based on limited data on adverse effects and as such
the risk characterisation of pigs carries substantial uncertainty, in particular, for growing/fattening pigs
where the use of speciﬁc compound-feed could not be assessed.
Poultry
For poultry, the CONTAM Panel characterised the health risk associated with dietary exposure to
DAS by comparing the estimated exposures at the estimated UB mean and UB 95th percentile dietary
exposures with the identiﬁed LOAELs of 10, 54, 12 and 22 lg/kg bw per day determined for chicken,
laying hens, turkeys and ducks, respectively, (oral lesions being identiﬁed as the critical adverse health
effects, see Tables 18 and 22).
Among the poultry species, the highest estimated dietary exposure was for fattening chicken, for
which the exposure at the estimated UB mean and 95th percentile was 1.44 and 2.58 lg/kg bw per
day, corresponding to approximately 14 and 26% of the LOAEL.
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For laying hens, fattening turkeys and ducks, the dietary exposure at the estimated UB mean and
95th percentile ranged between 0.48 and 1.61 lg/kg bw per day and 0.81 and 2.90 lg/kg bw per day,
respectively, corresponding to 3.0–5.5% and 5.4–8.2% of the LOAEL.
From these results, the CONTAM Panel concluded that for fattening chicken the margins between
the LOAEL for oral lesions and the estimated UB dietary exposures to DAS were small and a possible
risk for adverse health effects may exist under current feeding practices. The risk for adverse health
effects was considered low for laying hens, fattening turkeys and ducks at the estimated exposure
levels under current feeding practices.
Dogs
For dogs, the CONTAM Panel characterised the health risk associated with dietary exposure to DAS
by comparing the NOAELs of 31 lg/kg bw and 16 lg/kg bw per day for the acute and chronic hazard,
respectively, with the estimated dietary exposures at the UB mean and 95th percentile.
The estimated dietary acute and chronic exposure of dogs at the UB were 0.07 and 0.13 lg/kg bw per
day, corresponding to 0.4 and 0.8% of the of the identiﬁed NOAELs, respectively (see Tables 21 and 22).
Based on this comparison, the CONTAM Panel concluded that the risk for adverse health effects
from feed containing DAS was for both acute and chronic exposure negligible for dogs at the
estimated exposure levels under current feeding practices.
Ruminants, horses, cats, farmed rabbits, ﬁshes and mink
For all other farm and companion animal species, the CONTAM Panel applied a conservative
approach and characterised the health risk associated with dietary exposure to DAS by comparing the
estimated exposures at the UB mean and 95th percentile dietary concentrations for DAS with the
lowest LOAEL. The LOAEL of 10 lg/kg bw per day for oral lesions in fattening chicken was identiﬁed
among all farm animals for which a RP was identiﬁed (see Tables 10 and 22).
The estimated mean UB exposures of all these other farm and companion animals together ranged
between 0.01 lg/kg bw per day (beef cattle with grass-based diet) and 1.8 lg/kg bw per day (dairy cows
fed with maize silage-based diet), see Tables 17–21. The few available UB 95th percentile exposure
estimates ranged between 0.02 lg/kg bw per day (beef cattle with grass-based diet) and 1.0 lg/kg bw
per day (carps). Because of scarcity of exposure data, the UB 95th percentile estimates could not be
calculated for all categories of ruminants, e.g. for dairy cows with maize silage-based diet.
The CONTAM Panel noted that the highest exposure estimates for ruminants, horses, cats, farmed
rabbits, ﬁshes and mink was 1.8 lg/kg bw per day corresponding to 18% of the LOAEL of 10 lg/kg
bw per day identiﬁed for oral lesions in chicken used in the absence of sufﬁcient data for the hazard
characterisation.
Therefore, it was concluded that overall adverse health effects from feed containing DAS are
unlikely for these farm and companion animals at the levels of exposure estimated for current feeding
practices, with the exception of dairy cows fed with maize silage-based diet where a possible risk may
exist. It is also noted that for these animal species conclusions would be affected by a high degree of
uncertainty.
Table 22: Comparison of reference points (NOAELs/LOAELs) for DAS as availbale for pigs, poultry
and dogs only with estimated exposure levels these animal species
Animal species
Reference point
(lg DAS/kg bw)
Estimated exposure
(lg DAS/kg bw per day)
Estimated exposure in %
of NOAEL or LOAEL
NOAEL LOAEL mean (UB) P95 (UB) Mean (UB) P95 (UB)
Pigs growing/fattening
starter
ﬁnisher
lactating sow
n.d. 80 0.35
0.92
0.35
0.43
0.61
1.61
0.61
0.75
0.4
1.2
0.4
0.5
0.8
2.0
0.8
0.9
Poultry Fattening
chicken
n.d. 10 1.44 2.58 14.4 25.8
Laying hens
Fattening turkeys
n.d.
n.d.
54
12
1.61
0.48
2.90
0.81
3.0
4.0
5.4
6.8
Fattening Ducks n.d. 22 1.02 1.80 5.5 8.2
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4. Uncertainty analysis
Evaluation of the inherent uncertainties in the assessment of exposure to DAS has been performed
following the guidance given in the Opinion of the Scientiﬁc Committee related to Uncertainties in Dietary
Exposure Assessment (EFSA, 2006). In addition, the report on ‘Characterizing and Communicating
Uncertainty in Exposure Assessment’ has been considered (WHO, 2008). According to the guidance
provided by EFSA (2006) the following sources of uncertainties have been considered: assessment
objectives, exposure scenario, exposure model and model input (parameters). In addition to the EFSA
opinion (2006), the CONTAM Panel also considered other uncertainties.
4.1. Assessment objectives
The objectives of the assessment were deﬁned in the terms of reference and no uncertainty was
associated in the objectives.
4.2. Exposure scenario and model
The analytical results of the samples collected between 2000 and 2016 on the occurrence of DAS in
food and feed reported to EFSA, identiﬁed as suitable for the evaluation (see Section 3.3), were very
limited. These data were augmented by the analytical results collected and extracted from the
publications reporting occurrence data in food and feed marketed in Europe and sampled since 2000.
Those data were combined with the data reported to EFSA to a ﬁnal data set when they were
considered suitable for evaluation, sufﬁciently detailed to extract quantitative information on the
concentrations in food or feed and compliant with standards established by EFSA. This included two
reports with plausible results where the analytical method was not completely speciﬁed. For the ﬁnal
data set, analytical results for food were available from 10 European countries and for feed from seven
European countries. However, the samples of food and feed did not always originate from the
European country which reported the data.
Both the data reported to EFSA as well as those extracted from the published literature showed a
high percentage of left censored results (98.6% of the results for human exposure and 93.9% of
those for farm and companion animals). From the results submitted to EFSA, only analytical results
obtained by non-targeted sampling were included in the evaluation. In the absence on information on
sampling non-targeted sampling was assumed also for the data from the published literature.
Therefore, the ﬁnal data set may not be fully representative at the European level, which adds
uncertainty for the exposure assessments for both humans and farm and companion animals. The use
of LB values tends to underestimate, while the use of UB values tends to overestimate dietary
exposure when using the substitution method to account for left censored data. The large portion of
LC data in the ﬁnal data sets for food and feed contributed substantially to the overall uncertainty of
the exposure assessment.
The lack of analytical methods formally validated through interlaboratory studies contributed to the
uncertainty of the currently available results on DAS. The lack of certiﬁed reference materials for DAS
(as calibrants and in particular matrix materials) is an additional limitation. Both issues contribute to
the overall uncertainty of occurrence data and are equally valid for the chemical analysis used in
toxicokinetic and toxicity studies. Available information on correction/non-correction for recovery was
not complete and contributes further to that uncertainty.
There were considerable differences in the number of analytical results across the food categories
with high prevalence of grains and grain-based foods and only few or no samples for other food
Animal species
Reference point
(lg DAS/kg bw)
Estimated exposure
(lg DAS/kg bw per day)
Estimated exposure in %
of NOAEL or LOAEL
NOAEL LOAEL mean (UB) P95 (UB) Mean (UB) P95 (UB)
Dogs 16 n.d. 0.07 0.13 0.4 0.8
Other farm and
companion animals
n.d. 10 0.01–1.8 n.d. 0.1–18 n.d.
bw: body weight; NOAEL: no observed adverse effect level; LOAEL: lowest observed adverse effect level; UB: upper bound;
n.d.: not determined.
Exposures have been calculated from dietary concentrations expressed on a fresh weight (88% dry matter) basis to make them
comparable with the data from which NOAELS/LOAELS have been derived.
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categories. No suitable data were available for several food categories (e.g. ‘bread and rolls’) where
the results were all left censored. For other food categories, the estimation of the highest reliable
percentile was not possible due to the small numbers of samples. This adds to the overall uncertainty
of the human exposure estimates.
The CONTAM Panel noted a large difference between the LB and UB values of the chronic dietary
exposure which introduces considerable uncertainty into exposure estimates for humans.
Regarding the exposure of farm and companion animals through feed consumption, only data on
the major cereal grains (wheat, barley, oats, and maize), and limited data for maize silage, were
available to assess exposure. As cereal by-products are widely used for animal feeding, the absence of
data on DAS concentrations in these products led to a likely underestimation of exposure. A large
variety of feed materials and forages are used to formulate diets for farm and companion animals in
Europe, and the lack of information on levels of DAS in these feeds added to the overall uncertainty of
the estimates of animal exposure. The Panel also noted that the database of DAS was for some
animals too scarce to estimate the high exposure at the 95th percentile, in particular for dairy cows
and beef cattle and growing/fattening pigs.
In addition, the Panel noted that for almost all animal species no LB values could be estimated, both
for the mean and high chronic dietary exposure, which introduces considerable uncertainty for animals.
4.3. Other uncertainties
At least in in vitro Fusarium culture the spectrum of DAS related type A trichothecenes of the
scirpentriol subgroup may change over time such that data from previous exposure to one
trichothecene may no more reﬂect human or animal exposure to that mycotoxin at present or in the
near future.
Data on toxicokinetics were missing for humans and were very limited for experimental animals. No
in vivo data were available for the quantiﬁcation of absorption after oral exposure in humans and data
on distribution, metabolism and excretion were scarce and no studies investigated repeated dosing.
For farm and companion animals, data on in vivo toxicokinetics were available only from one study in
heifers and one in chicken.
Therefore, the characterisation of the toxicokinetic of DAS in vivo was incomplete and the
uncertainty of the toxicokinetics of DAS is large.
No studies were available to assess the differences in toxicokinetics between oral and i.v.
administration of DAS, neither for humans nor for experimental animals. This adds to the uncertainty
of the risk assessment.
There is a lack of long-term oral toxicity studies and reproduction toxicity studies in experimental
animals. In addition, available in vitro and in vivo data on the mode of action of DAS are currently too
limited to conclude ﬁrmly on the toxicological evidence of several hypothetical mechanisms of action,
which hampered the use of this information for the identiﬁcation of critical effects for the dose–
response assessment of DAS.
There is a lack of genotoxicity data and the mechanism of induction of in vivo chromosomal
abnormalities is not fully understood.
In the absence of long-term toxicity data on the selected critical endpoint a relative large UFs of 10
was used to characterise chronic adverse health effects in humans. The use of this adjustment factor
might lead to an overestimation of the risk.
The CONTAM Panel noted that using data from clinical trials on DAS (anguidine) in cancer patients
who were pre-treated with cytostatic/cytotoxic drugs and had only limited life expectancy, might be
leading to an overestimation of the risk because of their greater sensitivity to adverse effects of DAS.
No data were available to identify NOAELs in farm animals, therefore LOAELs were considered
instead. This is adding additional uncertainties to the assessment.
There is also uncertainty around co-exposure and potential combined effects of DAS and other
trichothecenes; this could lead to underestimation of the risk.
Overall, the CONTAM Panel considered that the uncertainty of this current risk assessment for
humans and almost all farm and companion animals as large, in particular due to the lack of
toxicokinetic and toxicity data on DAS.
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4.4. Summary of uncertainties
In Table 23, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel concluded that the impact of the uncertainties in the human risk assessment of
DAS is large and that the risk is more likely to be over than underestimated.
The impact of the uncertainties in the risk assessment of farm and companion animals is large.
5. Conclusions
4,15-DAS is a type A trichothecene mycotoxin with low molecular weight, produced by several
Fusarium species. It has mainly been detected in cereal grains, cereal-based products and coffee but
presence in other foods and feeds cannot be excluded. A naturally occurring modiﬁed form of DAS has
been identiﬁed as DAS-glucoside.
LC–MS/MS is currently the most widely used and preferred technique for analysis of DAS in foods,
feed and biological samples, while HPLC-FLD, GC-FID or GC-ECD and GC–MS(/MS) have also been
applied. None of the applied methods for DAS have been formally validated in interlaboratory studies
and certiﬁed reference materials are not available. Calibrants are commercially available.
Occurrence
• In the open literature, DAS has mainly been reported in various grain cereals (wheat,
sorghum, maize, barley and oats) and cereal products, but also in potato products, soybeans
and coffee. The highest levels have been reported for wheat, sorghum and coffee.
• DAS co-occurs with many other mycotoxins in grains and grain based products, in particular
Fusarium toxins including type A and B trichothecenes, and zearalenone.
• For food and feed, a total of 15,786 and 2,098 analytical results, respectively, fulﬁlled the
quality criteria applied and have been used in the assessment. These include the data reported
to EFSA by Member States (97%) and literature data reported for Europe (3%).
• The proportion of left-censored data (results below the LOQ) were 98.6% in food and 93.9%
in feed.
Table 23: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of the human and animal dietary exposure to DAS
Sources of uncertainty Direction(a)
Extrapolation of the occurrence data to the whole of Europe +/
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/
Assuming non-targeted sampling for literature data used for exposure +
Uncertainty of the analytical measurements +/
No data for most grain based products and other foods and no data on other feed than grains 
High variability of the composition of feedstuffs used and feeding systems for farm animals in
Europe
+/
High percentage of left censored data resulting in large difference between LB and UB
exposure estimates
+/
Highest reliable percentile limited by the number of samples 
Lack of data on general toxicity and reproductive and developmental toxicity in experimental
and most farm and companion animals
+/
Limited data on the mode of action +/
Lack of data to asses genotoxicity and carcinogenicity 
Assumption of equivalent exposure and toxicity effects after i.v. and oral administration of the
same dose
+
Use of large adjustment factors for risk assessment (humans) +
Co-exposure and potential combined effects of DAS and other trichothecenes 
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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• The highest mean concentrations of DAS were recorded for food in the category of ‘Cereal-
based dishes’, for feed in the categories ‘maize grains and maize silage and ‘Rice, broken’.
Effects of processing
• No studies on the effect of cleaning, sorting and milling of grains could be identiﬁed, but these
practices are expected to result in a redistribution and/or reduction of DAS in the ﬁnal
products, as is the case with other trichothecenes.
Human exposure
• Acute exposure estimates at the upper bound ranged for the mean from a minimum of 17 ng/kg
bw to a maximum of 186 ng/kg bw across different surveys and population groups when
applying the probabilistic approach. When considering the 95th percentile the values were
ranging from 54 to 799 ng/kg bw. The highest values being recorded for ‘Infants’ and ‘toddlers’
• The estimates of mean chronic exposure to DAS across different dietary surveys and all age
groups ranged from 0.2 ng/kg bw per day (lowest minimum LB, observed in ‘infants’ and at
ages ≥ 18 years) to 185 ng/kg bw per day (highest maximum UB observed in ‘toddlers’) when
applying the deterministic approach. The highest values are generally recorded for young
people because of their high food consumption when expressed per kg bw.
• The estimates of 95th percentile chronic exposure ranged from 0.4 ng/kg bw per day (lowest
minimum LB, observed in ‘elderly’ and ‘very elderly’) to 491 ng/kg bw per day (highest
maximum UB observed in ‘other children’).
• The most important contributors to the chronic dietary exposure to DAS were ‘Grains and
grain-based products’, especially ‘cereal-based dishes’.
Farm and companion animal exposure
• Animal exposure to DAS is primarily from consuming cereal grains and cereal by-products.
• Due to the lack of data on compound feeds, exposures for all other livestock than poultry were
estimated using data for individual feed materials and their assumed inclusion rates in the diets.
• The highest estimated exposures were for ruminants (dairy cows and beef cattle) fed on maize
silage-based diets. For dairy cows on a maize silage-based diet, the estimated mean diet
concentration ranged from 1.3 (LB) to 43 (UB) lg/kg DM; corresponding to a maximum of 1.8
lg/kg bw per day. Estimated exposures for beef cattle on maize silage-based diets were
marginally lower. For horses the maximum estimated exposure was 0.58 lg/kg bw per day.
• Exposures for starter pigs, growing/fattening pigs, ﬁnisher pigs and lactating sows were
broadly similar, however not all mean and P95 LB values could be determined. The mean and
P95 UB estimates instead were ranging from 11-18 and 20-32 lg/kg DM, respectively
(corresponding to 0.35–0.92 and 0.61–1.6 lg/kg bw per day).
• For poultry, the highest diet levels were estimated for laying hens. The mean and P95
exposures ranged from non-determined (LB) to 27 (UB) or 48 (UB) lg/kg DM, respectively
(corresponding to 1.61 (mean) and 2.9 (P95) lg/kg bw per day).
• For farmed rabbits and mink, the mean and P95 LB estimates were < 1.0 lg/kg DM. The UB
values were highest for the mink (2.4 and 4.2 lg/kg DM, respectively, for the mean and P95
exposures that are corresponding to 0.09–0.15 lg/kg bw per day).
• Similarly, the estimated LB mean and P95 for ﬁsh (salmonids and carp) were < 1.0 lg/kg DM.
Due to the higher levels of cereals in carp diets, the UB estimates were highest for carp (25
and 45 lg/kg DM, for the mean and P95 estimates, respectively, corresponding to 0.55 and 1
lg/kg bw per day).
• For companion animals (cats and dogs), the mean and P95 LB estimates were < 1 lg/kg DM,
while the UB mean and P95 exposure estimates were higher for cats (7.3 and 13 lg/kg DM,
respectively; corresponding to a maximum of 0.20 lg/kg bw per day) than for dogs (5.1 and
9.1 lg/kg DM, respectively; corresponding to a maximum of 0.13 lg/kg bw per day).
Toxicokinetics and transfer
• No pharmacokinetic data in humans were available from clinical studies after i.v. administration
of DAS and no data on any oral administration were identiﬁed.
• After oral administration in rats and mice, the absorption of DAS has not been quantiﬁed but
the excretion ratio between urine and faeces indicated high absorption. DAS was rapidly
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distributed to most organs. Tissue concentrations decreased rapidly with no apparent
accumulation in any tissue and more than 90% of radiolabelled DAS was excreted within 24 h.
• In vitro, DAS is metabolised to a large number of metabolites. The main metabolic processes
are deacylations, hydroxylations, deepoxidations and glucuronide conjugations. Deepoxidation
reactions have primarily been found after incubation with GI content, rumen ﬂuid or faeces,
DAS was rapidly metabolised to a large number of metabolites also in vivo.
• Although in vivo studies on the toxicokinetics of DAS in farm animals were rare and not all
relevant parameters were determined, a rapid ADME was generally shown. The main systemic
metabolites were determined as 15-MAS and SCT. In pigs, a large portion of orally
administered DAS could be found in faeces, mainly as deepoxidised SCT.
• In chickens, DAS was rapidly absorbed from the GI tract, extensively metabolised and excreted
as 15-MAS and 7-OH-DAS in faeces and in urine
• No data were available for ruminants, horses, dogs and cats, and farmed rabbits, mink and ﬁsh.
• There was insufﬁcient evidence to conclude on the transfer of DAS from feed to food of animal
origin.
Toxicity of DAS in experimental animals
• The oral LD50 values in rodents ranged from 2 to 16 mg/kg bw. Haematological effects such as
anaemia, leucopenia and thrombocytopenia were observed. When administered i.v., the LD50
ranged from 1 to 12 mg/kg bw while the LD50 ranged from 0.8 to 23 mg DAS/kg bw after i.p.
administration.
• Repeated dose studies in rodents were scarce and not of sufﬁcient quality for hazard
identiﬁcation and characterisation.
• After single i.v. administration to dogs, DAS induced emesis, diarrhoea, haematological
changes and effects in bone marrow. Repeated dosing by i.v. in dogs and monkeys induced
emesis, diarrhoea, body weight loss, erythema, increased haematocrit, anaemia, leucocytosis
and/or leucopenia, neutrophilia, lymphopenia, elevated AST, ALT and BUN, and nucleated
erythrocytes. The NOAEL for emesis and haematological effects after i.v. administration was 31
and 16 lg/kg bw per day for dog, and 125 lg/kg bw per day for monkeys.
• Developmental and reproductive toxicity was reported after i.p. administration of DAS in
experimental animals, and adverse effects were seen in tissues with high proliferation rate. No
NOAEL could be identiﬁed, however the CONTAM identiﬁed:
 a LOAEL of 1 mg/kg bw in mice after a single injection of DAS, based on increases in
resorption, reduction in fetal body weight and observation of gross and skeletal
malformations.
 a LOAEL of 1.7 mg/kg bw in rats based on reduced testicular weight and sperm
production and an increased frequency of hypocellular seminiferous tubules.
• There was no evidence that DAS induces bacterial reverse mutation in vitro.
The only in vivo genotoxicity study in mice (i.p. exposure) reported chromosomal abnormalities in
somatic cells (bone marrow) and in germ cells (spermatocytes). Protein synthesis inhibition is likely to
be a mechanism underlying the observed in vivo chromosomal abnormalities. The Panel considered
that there are currently insufﬁcient data on the genotoxicity of DAS.
• No chronic toxicity or carcinogenicity studies were identiﬁed
• The limited available toxicological data for the main metabolites of DAS (4 or 15 MAS, SCT)
indicate that their toxicity is equal to or less than the toxicity of DAS in vitro and in vivo after
oral exposure.
Toxicity of DAS in humans
• The CONTAM Panel identiﬁed adverse health effects in humans exposed to DAS when it was
tested as a cytostatic anticancer drug (named anguidine) in phase I and phase II clinical trials
on cancer patients by i.v. administration.
• Based on the data of the phase I studies, the CONTAM Panel identiﬁed nausea and vomiting as
the most relevant acute adverse health effects of DAS when administered i.v. with a NOAEL at
1.2 mg DAS/m2 (equivalent to 32 lg DAS/kg)
• Haematotoxicity and myelosuppression were the most frequently observed and persistent
adverse effects observed in the phase I studies when DAS was given repeatedly (5-day
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regimen) in treatment cycles of 3–4 weeks. A NOAEL of 2.4 mg DAS/m2 (equivalent to 65 lg
DAS/kg bw per day) was identiﬁed from the same phase I studies.
• The reported adverse health effects at doses from 3 to 5 mg DAS/m2 (equivalent to 81-135 lg
DAS/kg bw per day) of the phase II clinical trials, performed at the proximity of the maximum
tolerable doses, supported these ﬁndings.
Mode of action of DAS
• DAS is binding to ribosomes, inducing a ‘ribotoxic stress response’ with activation of ribosome-
associated MAPKs and inhibition of protein synthesis.
• DAS also possesses cytotoxic properties, while no clear indications for ROS production are
available. Increase in gut satiety hormones (e.g. CCK) levels is considered the mechanism of
DAS (and trichothecenes) induced anorexia.
• In vitro assays indicated cytotoxic properties on haematopoietic progenitors which could be
due to stimulation of apoptosis or inhibition of protein synthesis.
Combined effects of DAS with other mycotoxins
• Data on combined effects of DAS and others mycotoxins in vivo were available mainly in
poultry and only one experiment was performed in pigs.
• Although limited, the effects observed for DAS in combination with T-2 toxin, AFB1, OTA and
fusaric acid were generally more marked than when DAS was administered alone. The
CONTAM Panel noted that because of the lack of dose–response data, it was difﬁcult to draw a
deﬁnitive conclusion concerning the nature of the combined effects and interaction with other
Fusarium toxins, including type A trichothecenes.
Adverse health effects and derivation of human health based guidance values
• Based on the conclusions on the genotoxicity and the MoA of DAS, the CONTAM Panel decided
to establish HBGV for both the acute and chronic exposure of DAS to humans.
• The Panel concluded that the database of the oral studies on rats and guinea pigs and the i.v.
studies in dogs and monkey was insufﬁcient for the identiﬁcation of a RP for the human hazard
characterisation. For both acute and chronic hazard characterisation, data from clinical studies
in patients treated by i.v. administration of DAS (anguidine) for cancer were used.
• The data from experimental and farm animals suggest almost complete absorption following
oral administration. The Panel therefore under a conservative approach considered an
equivalent bioavailability after oral exposure and i.v. dosing.
• The CONTAM Panel noted that following oral exposure DAS is subject to extensive pre-
systemic degradation in the GI tract and hepatic metabolisation. Based on limited information,
the Panel noted that DAS metabolites would have similar or lower toxicity than DAS and
consequently that oral exposure would not lead to higher systemic toxicity than i.v.
administration.
• The CONTAM Panel identiﬁed 32 lg DAS/kg bw as a RP for acute health effects, based on
nausea and emesis observed in clinical studies on cancer patients.
• The Panel applied the default UF of 10 accounting for interindividual toxicokinetic and
toxicodynamic variability and derived an ARfD of 3,200 ng DAS/kg bw.
• The haematotoxic and myelotoxic effects observed in clinical studies were identiﬁed as the
critical endpoint for human chronic hazard characterisation. The CONTAM Panel concluded that
these effects would not be expected in humans at a dose equal to or below 65 lg/kg bw per
day, and this was therefore selected as a RP for chronic effects.
• The CONTAM Panel considered the default UF of 10 as adequate to cover for interindividual
toxicokinetic and toxicodynamic variability. In addition the Panel applied an UF of 10 to account
for the limited duration and the intermittent dosing regimen of the human clinical studies used
for the chronic RP selection. Taking the overall UF into account the CONTAM Panel established
a TDI of 650 ng DAS/kg bw per day.
Adverse effects and identiﬁcation of reference points in farm and companion animals
• Among Tolerable Daily Intake ruminants studies indicated adverse health effects in heifers at
the only tested dose of 0.5 mg DAS/kg bw per day i.v., and in lambs at an oral dose
corresponding to 0.16 mg DAS/kg bw per day. The CONTAM Panel concluded that these data
were too scarce to identify a reference point for adverse health effects of DAS in ruminants.
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• Only few studies on adverse effects of DAS in pigs were available. Oral lesions in the GI tract
were observed following exposure to ≥ 2.0 mg DAS/kg feed, corresponding to 0.08 mg/kg bw
per day. Reduced body weight gain was seen at feed concentrations resulting in doses ≥ 0.12
mg/kg bw per day. No NOAEL could be identiﬁed from the available data.
• For poultry, oral lesions were observed at the lowest level of exposure in the following species:
chickens, laying hens, turkeys and ducks with LOAELs of 0.010, 0.054, 0.012 and 0.022
mg DAS/kg bw per day, respectively. At equal or higher doses, reduction of body weight gain,
decreased eggs production and decreased fertility were other adverse effects observed in
various studies in different poultry species.
• No data were available on the oral exposure of dogs. Emesis and haematotoxicity were
observed following i.v. administration. Assuming equivalent bioavailability and systemic toxicity
of DAS following i.v. and oral administration, the CONTAM Panel identiﬁed NOAELs of 0.031
and 0.016 mg/kg bw per day for acute and chronic toxicity, respectively.
• No toxicity data suitable for hazard characterisation of DAS were identiﬁed for ruminants,
farmed rabbits, farmed ﬁsh, farmed mink, horses and cats. In order to obtain an indication on
the risk of DAS in these species, the CONTAM Panel considered the LOAEL of 0.01 mg DAS/kg
bw per day identiﬁed for fattening chicken.
Human health risk characterisation
• All the estimated mean and 95th percentile acute and chronic exposure levels were below the
established ARfD and TDI, respectively, and therefore not of health concern.
• The impact of the uncertainties in the human risk assessment of DAS is large and the risk is
more likely to be over than underestimated.
Farm and companion animal health risk characterisation
• Because of the limited data on the effects of DAS on farm and companion animals only the
health risk to pigs, poultry and of dogs could be characterised.
• For pigs, the CONTAM Panel noted that the exposure levels in starter and growing/fattening
pigs were 1.2% and 2.0%, respectively, of the identiﬁed critical LOAEL of 80 lg/kg bw per
day. Although the hazard characterisation was based on limited data on adverse effects, the
Panel concluded that the risk for adverse health effects from feed containing DAS is low for
pigs at the estimated exposure levels under current feeding practices
• For poultry, the CONTAM Panel noted that the higher exposure estimates for fattening chicken
was up to 25% of the lowest LOAEL identiﬁed for oral lesions (10 lg/kg bw per day),
indicating a possible risk for adverse effects. The risk was considered low for laying hens,
fattening turkeys and ducks at the estimated exposure levels under current feeding practices.
• In the dog, the estimated exposure levels were lower than 1% of the identiﬁed NOAELs of 31
and 16 lg/kg bw per day for both acute and chronic effects, respectively, suggesting a low risk
for adverse health effects.
• The CONTAM Panel noted that the largest available exposure estimate for species where a RP
could not be identiﬁed (ruminants, horses, cats and farmed rabbits, ﬁshes and mink) were in
the majority of cases a small fraction of the LOAEL of 10 lg/kg bw per day for oral lesions in
poultry (maximum 18% in dairy cows). Therefore, the overall adverse health effects from feed
containing DAS would be unlikely for these farm and companion animals at the levels of
exposure estimated for current feeding practices, with the exception of dairy cows fed with
maize silage-based diet where a possible risk may exist. Conclusions for these animal species
are affected by a high degree of uncertainty.
6. Recommendations
• A well-designed 90-day oral toxicity study in rats using puriﬁed DAS performed according to
relevant OECD guidelines with special focus on the assessment of haematotoxicity,
myelotoxicity and reproductive performance is needed.
• Well-designed studies of the toxicokinetics of DAS after oral and i.v. exposure in experimental
animals are required.
• Studies on the in vivo genotoxicity of DAS are needed and more data are required on the
cellular and molecular MoA of DAS, in particular, for a better understanding of cytotoxicity, DNA
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and protein synthesis inhibition, stimulation of apoptosis and effects on haematopoietic
progenitors and bone marrow.
• Well-designed dietary studies on adverse effects (including the investigations for oral and GI
lesions) of DAS are needed in farm animals other than poultry.
• More occurrence data on DAS in food and feed obtained with state-of-the-art validated
analytical methods with adequate sensitivity, such as LC–MS/MS are needed to reduce the
uncertainty in the exposure assessment for humans and farm and companion animals.
• In consideration of the similar toxicity proﬁles and structural similarities of several
trichothecenes, together with their likely co-exposure via food and feed, it could be
appropriate to perform a cumulative risk assessment for this group of substances.
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ADME absorption, distribution, metabolism, excretion
AFB1 aﬂatoxin B1
AKA alimentary toxic aleukia
ALP alkaline phosphatase
ALT alanine aminotransferase
ARfD Acute reference dose
AST aspartate aminotransferase
BUN blood urea nitrogen
bw body weight
CAL calonectrin
CAS Chemical Abstract Service
CCK cholecystokinin
CDK cyclin-dependent kinase
CI conﬁdence interval
CNS central nervous system
CONTAM Panel EFSA Panel on Contaminants in the Food Chain
CRM Certiﬁed Reference Material
DAD diode array detection
DAS 4,15-diacetoxyscirpenol
DMBA dimethylbenzanthracene
DM dry matter
DMSO dimethyl sulfoxide
ECD electron capture detection
ERK1/2 extracellular signal-regulated kinase 1 and 2
FAO Food and Agriculture Organization of the United Nations
FEDIAF European Pet Food Industry Federation
FEEDAP Panel EFSA Panel on Additives and Products or Substances used in Animal Feed
FID ﬂame ionisation detection
FLD ﬂuorescence detection
GC gas chromatography
GGT gamma-glutamyltransferase
GI gastrointestinal
GIP glucose-dependent insulinotropic polypeptide
GLP-1 glucagon-like peptide-17–36 amide
HBGV health-based guidance value
HPLC high-performance liquid chromatography
i.p. intraperitoneal
i.v. intravenous
IC50 half maximal inhibitory concentration
IPCS International Programme on Chemical Safety (WHO)
JECFA Joint FAO/WHO Expert Committee on Food Additives
JNK c-Jun N-terminal kinase
LB lower bound
LC–MS liquid chromatography–mass spectrometry
LC-UV liquid chromatography-ultraviolet
LD50 lethal dose (median)
LDH lactate dehydrogenase
LOAEL lowest observed adverse effect level
LOD limit of detection
LOQ limit of quantiﬁcation
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mAb monoclonal antibodies
MAPK mitogen-activated protein kinase
MAS monoacetoxyscirpenol
Max maximum
Min minimum
ML maximum level
MoA mode of action
MTD maximum tolerated dose
NMR nuclear magnetic resonance
NOAEL no-observed-adverse-effect level
NRC National Research Council
OECD Organisation for Economic Co-operation and Development
OTA ochratoxin A
PMTDI provisional maximum tolerable daily intake
QuEChERS Quick, Easy, Cheap, Effective, Rugged, and Safe
ROS reactive oxygen species
RP Reference Point
SCE sister chromatid exchange
SCT scirpentriol
SMART somatic mutation and recombination test
SOP Standard Operating Procedure
TAS Triacetoxyscirpenol
TBC total body clearance
TDI tolerable daily intake
TLC thin-layer chromatography
TOF time-of-ﬂight
UB upper bound
UHPLC ultra-high-performance liquid chromatography
UPLC ultra-performance liquid chromatography
UV ultraviolet
WG Working group
WHO World Health Organization
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Appendix A – EFSA guidance documents applied in the assessment of DAS
in food and feed
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), i.e. hazard identiﬁcation and characterisation, exposure assessment
and risk characterisation. The following EFSA guidance documents were applied in the assessment of
DAS in food and feed:
• EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a
request from EFSA related to uncertainties in Dietary Exposure Assessment. EFSA Journal
2007;4(12):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: general
principles. EFSA Journal 2009;7(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2011. Overview of the procedures currently used at
EFSA for the assessment of dietary exposure to different chemical substances. EFSA
Journal 2011;9(12):2490, 33 pp. https://doi.org/10.2903/j.efsa.2011.2490
• EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal
Feed), 2012. Guidance for the preparation of dossiers for sensory additives. EFSA Journal
2012;10(1):2534, 26 pp. https://doi.org/10.2903/j.efsa.2012.2534
• EFSA Scientiﬁc Committee, 2011. Scientiﬁc opinion on genotoxicity testing strategies applicable
to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/10.
2903/j.efsa.2011.2379
• EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579, 33 pp. https://doi.org/10.2903/j.efsa.2012.2579
• EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10(5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck
D, Younes M, Bresson J-L, Grifﬁn J, Hougaard Benekou S, van Loveren H, Luttik R, Messean A,
Penninks A, Ru G, Stegeman JA, van der Werf W, Westendorf J, Woutersen RA, Barizzone F,
Bottex B, Lanzoni A, Georgiadis N and Alexander J, 2017. Guidance on the assessment of the
biological relevance of data in scientiﬁc assessments. EFSA Journal 2017;15(8):4970, 73 pp.
https://doi.org/10.2903/j.efsa.2017.4970
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck
D, Benfenati E, Chaudhry QM, Craig P, Frampton G, Greiner M, Hart A, Hogstrand C, Lambre C,
Luttik R, Makowski D, Siani A, Wahlstroem H, Aguilera J, Dorne J-L, Fernandez Dumont A,
Hempen M, Valtue~na Martınez S, Martino L, Smeraldi C, Terron A, Georgiadis N and Younes M,
2017. Scientiﬁc Opinion on the guidance on the use of the weight of evidence approach in
scientiﬁc assessments. EFSA Journal 2017;15(8):4971, 69 pp. https://doi.org/10.2903/j.efsa.
2017.4971
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger M, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Younes M,
Aquilina G, Crebelli R, G€urtler R, Hirsch-Ernst KI, Mosesso P, Nielsen E, van Benthem J, Carfı M,
Georgiadis N, Maurici D, Parra Morte J and Schlatter J, 2017. Scientiﬁc Opinion on the
clariﬁcation of some aspects related to genotoxicity assessment. EFSA Journal 2017;15
(12):5113, 25 pp. https://doi.org/10.2903/j.efsa.2017.5113
• EFSA Scientiﬁc Committee, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli
H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D,
Younes M, Craig P, Hart A, Von Goetz N, Koutsoumanis K, Mortensen A, Ossendorp B, Martino
L, Merten C, Mosbach-Schulz O and Hardy A, 2018. Guidance on Uncertainty Analysis in
Scientiﬁc Assessments. EFSA Journal 2018;16(1):5123, 39 pp. https://doi.org/10.2903/j.efsa.
2018.5123
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Appendix B – Literature search for supporting information and hazard
identiﬁcation and characterisation
The sources of literature were: ISI Web of Science, Embase and Pubmed
• Key word used was “diacetoxyscirpenol”
Search details:
1. Web of Science
“Topic” was selected for all key words for Web of Science
TOPIC: (diacetoxyscirpenol)
Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC.
Time span: All years.
2. Pubmed
A free-text search was performed using diacetoxyscirpenol as a key word:
“diacetoxyscirpenol”[Supplementary Concept] OR “diacetoxyscirpenol”[All Fields]
Database: PubMed
Time span: all years
3. Embase
Advanced search was performed, using the Embase mapping option: “Search as broadly as
possible”
‘diacetoxyscirpenol’/exp OR ‘diacetoxyscirpenol’
SourcesEmbase, Embase Classic, MEDLINE
Time span: all years
Conducted on 6 February 2017
In total, 2,281 references were found, after removing duplicates the amount was 796 references.
• Literature search for “Anguidine” performed on 12 October 2017
Three databases were used: ISI Web of Science, Embase and Pubmed
A literature search was performed using the diacetoxyscirpenol synonym: “anguidine”.
“Diacetoxyscirpenol” was excluded using the Boolean operator NOT.
1. Embase
Advanced search was performed selecting “Search as broadly as possible” option, and using the
following search string:
(anguidin* OR anguidin*/exp) NOT (‘diacetoxyscirpenol’/exp OR ‘diacetoxyscirpenol’)
Time span: All years
Results: 5
2. Pubmed
The following search string was used:
anguidin*[All Fields] NOT (“diacetoxyscirpenol”[Supplementary Concept] OR “diacetoxyscirpenol”[All
Fields])
Time span: All years
Results: 15
3. Web of Science
A basic search was performed selecting “all databases”, and using the following search string:
TOPIC: (anguidin*) NOT TOPIC: (diacetoxyscirpenol)
Time span: All years
Results: 78
All the references were uploaded in Endnote. The ﬁnal number of references after removal of
duplicates is 79.
• An update of the literature search on DAS was performed on 12 October 2017.
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Three databases were used: ISI Web of Science, Embase and Pubmed. As in the previous search
(February 2017), “DAS” was not used as a keyword since it’s the acronym of many other unrelated
words.
Search details:
1. Embase
Advanced search was performed selecting “Search as broadly as possible” option, and using the
following search string:
(‘diacetoxyscirpenol’/exp OR ‘diacetoxyscirpenol’)
Time span: from 2017
Results: 11
2. Pubmed
The following search string was used:
“diacetoxyscirpenol”[Supplementary Concept] OR “diacetoxyscirpenol”[All Fields]
Time span: from 2017
Results: 6
3. Web of Science
A basic search was performed selecting “all databases”, and using the following search string:
TOPIC: (diacetoxyscirpenol)
Time span: from 2017
Results: 7
All the references were uploaded in Endnote. The ﬁnal number of references after removal of
duplicates is 16.
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Appendix C – Occurrence of DAS in food identiﬁed from the open literature
Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Belgium + Germany Sorghum 2014 Random 8 + 2 1.2 2.5 70 44 < LOD 91 Ediage et al.
(2015)
Yes
Denmark Milk 2004 Random 42 0.03 0.05 0 < LOQ < LOQ < LOQ Sørensen and
Elbæk (2005)
No
Denmark Oats 2006 Random 11 30 n.r. 0 < LOD < LOD < LOD Rasmussen
et al. (2012)
No
Triticale 2007 5 n.r. 0 < LOD < LOD < LOD
Wheat 2007 6 n.r. 0 < LOD < LOD < LOD
Finland Wheat 2001–2002 Random 70 n.r. 25–50 0 < LOD < LOD < LOD SCOOP (2003) No
Barley 40 0 < LOD < LOD < LOD
Barley malt 50 0 < LOD < LOD < LOD
Oats 55 0 < LOD < LOD < LOD
Rye 25 0 < LOD < LOD < LOD
France Wheat 2001 Random 52 n.r. 20 100 n.r. n.r. n.r. SCOOP (2003) No
Maize Random 29 n.r. 20 100 n.r. n.r. n.r.
Barley Random 9 n.r. 20 100 n.r. n.r. n.r.
Soft wheat Random 31 n.r. 20 100 n.r. n.r. n.r.
Maize 2001 Targeted 25 30 n.r. 0 < LOD < LOD < LOD
Soft wheat 2000–2002 Targeted 225 30 60 0 < LOD < LOD < LOD
Durum wheat 81 30 60 0 < LOD < LOD < LOD
Malting barley 2001–2002 Random 194 30 n.r. 0 < LOD < LOD < LOD
Maize 2000–2001 Random 57 30 n.r. 0 < LOD < LOD < LOD
Soft wheat 306 30 n.r. 3 < LOD < LOD < LOD
Germany Barley 2009 Random 59 0.09 0.29 22 0.052 < LOD 0.52 Barthel et al.
(2012)
Yes
Germany Semolina 2000 Random 14 14 28 0 < LOD < LOD < LOD Schollenberger
et al. (2005)
No
Maize ﬂour 15 0 < LOD < LOD < LOD
Germany Oat ﬂakes 2005 Random 43 n.r. n.r. 86 0.08 < LOD 0.38 Gottschalk et al.
(2007)
No
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Germany Wheat ﬂour 2005/2006 Random 39 0.09 0.29 3 0.01 < LOD 0.25 Gottschalk et al.
(2009)
No
Whole wheat
ﬂour
11 0 < LOD < LOD < LOD
Wheat kernels 52 2 < LOD < LOD 0.25
Semolina 13 0 < LOD < LOD < LOD
Wheat bran 10 20 0.05 < LOD 0.25
Wheat contain.
infant food
5 0 < LOD < LOD < LOD
Rye ﬂour 15 0 < LOD < LOD < LOD
Whole rye ﬂour 9 0 < LOD < LOD < LOD
Rye kernels 37 0 < LOD < LOD < LOD
Oat ﬂakes 31 71 0.08 < LOD 0.38
Fine oat ﬂakes 23 65 0.04 < LOD 0.17
Oat kernels 19 47 0.04 < LOD 0.25
Oat bran 12 75 0.04 < LOD 0.12
Oat contain.
infant food
13 31 0.03 < LOD 0.25
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Germany Wheat-based
foods
2000–2001 Random 15 14 28 0 < LOD < LOD < LOD Schollenberger
et al. (2005)
No
Oat-based foods 21 0 < LOD < LOD < LOD
Maize-based
foods
20 0 < LOD < LOD < LOD
Pseudocereals 15 0 < LOD < LOD < LOD
Gluten-free food 23 0 < LOD < LOD < LOD
Potato products 21 5 n.r. < LOD 21
Red pepper 10 0 < LOD < LOD < LOD
Canned
tomatoes
5 0 < LOD < LOD < LOD
Legumes 23 0 < LOD < LOD < LOD
Onion powder 5 0 < LOD < LOD < LOD
Garlic powder 5 0 < LOD < LOD < LOD
Canned
asparagus
5 0 < LOD < LOD < LOD
Banana chips 6 0 < LOD < LOD < LOD
Tapioca 5 0 < LOD < LOD < LOD
Peanuts 5 0 < LOD < LOD < LOD
Sunﬂower seeds 5 0 < LOD < LOD < LOD
Pumpkin kernel 5 0 < LOD < LOD < LOD
Sesame seeds 5 0 < LOD < LOD < LOD
Hazelnut kernel 5 0 < LOD < LOD < LOD
Almond kernel 5 0 < LOD < LOD < LOD
Desiccated
coconut
5 0 < LOD < LOD < LOD
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Germany Soybeans n.r. Random 6 14 28 0 < LOD < LOD < LOD Schollenberger
et al. (2007)
No
Soybeans
roasted
5 20 n.r. < LOD 21
Soy ﬂour and
ﬂakes, not
defatted
10 0 < LOD < LOD < LOD
Soy ﬂakes
partially defatted
and products
(crisp)
5 0 < LOD < LOD < LOD
Texturised soy
protein
5 0 < LOD < LOD < LOD
Tofu 5 0 < LOD < LOD < LOD
Soy sauce 4 0 < LOD < LOD < LOD
Soy protein
isolates
5 0 < LOD < LOD < LOD
Germany Soybean oil 2004 Random 14 3 6 0 < LOD < LOD < LOD Schollenberger
et al. (2008)
No
Sunﬂower seed
oil
16 0 < LOD < LOD < LOD
Corn germ oil 17 6 < LOD < LOD < LOD Yes
Olive oil 10 0 < LOD < LOD < LOD No
Rapeseed oil 11 0 < LOD < LOD < LOD
Safﬂower oil 10 0 < LOD < LOD < LOD
Wheat germ oil 3 0 < LOD < LOD < LOD
Pumpkin oil 4 0 < LOD < LOD < LOD
Peanut oil 5 0 < LOD < LOD < LOD
Walnut oil 5 0 < LOD < LOD < LOD
Grape kernel oil 5 0 < LOD < LOD < LOD
Sesame seed oil 5 0 < LOD < LOD < LOD
Linseed oil 4 0 < LOD < LOD < LOD
Palm oil 1 0 < LOD < LOD < LOD
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Italy Durum wheat
grain
2009–2010 Random 46 2 5 0 < LOD < LOD < LOD Alkadri et al.
(2014)
No
Italy Wheat 2003–2004 Random 14 0.2 0.7 21 100 < LOD 130 Dall’Asta et al.
(2004)
Yes
Poland Maize 2010 Semi-
targeted
19 0.65 1.3 26 4.9 < LOD 5.9 Aniolowska et al.
(2014)
Yes
Poland Wheat 2014 Random 99 n.r. 1 0 < LOD < LOD < LOD Bryła et al.
(2014)
No
Barley 24 0 < LOD < LOD < LOD
Oats 4 0 < LOD < LOD < LOD
Triticale 20 0 < LOD < LOD < LOD
Poland Oats 2009–2011 Semi-
targeted -
conventional
and organic
58 n.r. n.r. 43 4.1 < LOD 20.8 Twaruzek et al.
(2013)
Yes
Poland Oat bran 2009–2011 Semi-
targeted -
conventional
and organic
11 1 3 0 n.r. < LOD < LOQ Twaruzek et al.
(2013)
No
Oat ﬂakes 21 5 4.8 Yes
Oat ﬂour 4 0 < LOQ No
Oat groats 1 0 < LOQ
Oat pasta 3 0 < LOQ
Spain Roasted coffee
beans
2013–2014 Random 103 3 5 12 6.5 < LOD 8.6 Garcıa-Moraleja
et al. (2015a)
Yes
Spain Brewed coffee 2013–2014 Random 169 1.38 5.99 7 196 < LOD 402 Garcıa-Moraleja
et al. (2015b)
No
Spain Oats n.r. Random 7 4 10 0 < LOD < LOD < LOD Juan et al.
(2013)
No
Spelt 3 0 < LOD < LOD < LOD
Wheat 57 0 < LOD < LOD < LOD
Barley 9 0 < LOD < LOD < LOD
Rye 11 0 < LOD < LOD < LOD
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
Spain Wheat semolina 2012 Random 49 2.5 5 0 < LOD < LOD < LOD Rodrıguez-
Carrasco et al.
(2013a,b)
No
Wheat couscous 14 0 < LOD < LOD < LOD
Wheat-based
small pastas
56 0 < LOD < LOD < LOD
Rice crackers 7 5 10 0 < LOD < LOD < LOD
Rice starch 6 0 < LOD < LOD < LOD
Rice dietetic
snacks
10 0 < LOD < LOD < LOD
Maize crackers 4 1.25 2.5 0 < LOD < LOD < LOD
Maize starch 3 0 < LOD < LOD < LOD
Maize dietetic
snacks
10 0 < LOD < LOD < LOD
Spain Breadsticks 2012 Random 61 0.6-5 1.25-10 0 < LOD < LOD < LOD Rodrıguez-
Carrasco et al.
(2014)
No
UK Rice 2000 Random 100 n.r. 10 0 < LOD < LOD < LOD SCOOP (2003) No
Cereal fractions 27 0 < LOD < LOD < LOD
Maize products 2000–2001 70 0 < LOD < LOD < LOD
Wheat products 95 0 < LOD < LOD < LOD
Wheat ﬂour 2000 29 0 < LOD < LOD < LOD
Flour 8 0 < LOD < LOD < LOD
Polenta 8 0 < LOD < LOD < LOD
Biscuits 54 0 < LOD < LOD < LOD
Bread 56 0 < LOD < LOD < LOD
‘Mixed’ 2000–2001 30 0 < LOD < LOD <LOQ
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Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
%
pos.
Mean(a)
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in
the exposure
assessment
UK Barley 2002 Random 111 10 n.r. 0 < LOD < LOD < LOD Edward (2009) No
Barley 2003 128 0 < LOD < LOD < LOD
Barley 2004 110 0 < LOD < LOD < LOD
Barley 2005 97 0 < LOD < LOD < LOD
Wheat 2001 283 0 < LOD < LOD < LOD Edward (2009) No
Wheat 2002 343 0 < LOD < LOD < LOD
Wheat 2003 328 0 < LOD < LOD < LOD
Wheat 2004 344 0 < LOD < LOD < LOD
Wheat 2005 326 0 < LOD < LOD < LOD
LOD: limit of detection; LOQ: limit of quantiﬁcation; n.r.: not reported.
(a): In most cases, mean of positives, but this is not always fully clear.
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Appendix D – Occurrence of DAS in feed identiﬁed from the open literature
Country Food type
Sampling
year
Sampling
strategy
No of
samples
LOD
lg/kg
LOQ
lg/kg
% pos.
Mean
lg/kg
Min.
lg/kg
Max.
lg/kg
Reference
Considered in the
exposure assessment
Slovak
Republic
Complete feedingstuff
(poultry)
2003–2004 Random 50 0.3 nr 20.0 3.6 nr nr Labuda
et al. (2005)
Yes
Germany Maize (corn) 2000–2001 Random 41 14 28 4.9 49 nr nr Schollenberger
et al. (2006)
Yes
Maize by-products 2000–2001 Random 13 14 28 7.7 21 nr nr No
Germany Maize silage 2000–2001 Random 18 14 28 6 nr nr 64 Schollenberger
et al. (2005)
Yes
Maize kernels 2000–2001 Random 24 14 28 4 nr nr 21 Yes
Germany Oat grains 2009 Random 17 0.33 0.89 100 1.19 < LOD 8.05 Gottschalk
et al. (2009)
Yes
Italy Complete feedingstuff
(fattening pigs)
2003–2004 Random 7 20 nr 29 612 < LOD nr Dall’Asta
et al. (2004)
No
LOD: limit of detection; LOQ: limit of quantiﬁcation; nr: not reported.
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Appendix E – Feed intakes and diet composition (livestock)
This Appendix gives details of the feed intakes, live weights and diet compositions for different
livestock, ﬁsh and companion animals used as the basis to estimate exposures to DAS. These are
based on published guidelines on nutrition and feeding (e.g. Carabano and Piquer, 1998; NRC 2000,
2007a,b; Ewing, 2002; Leeson and Summers, 2008; OECD, 2009; McDonald et al., 2011; EBLEX, 2008,
2012; EFSA, 2012) and information provided by European feed manufacturers. They are therefore
estimates of the Panel on Contaminants in the Food Chain (CONTAM Panel) but agree with common
practice. In Table E.6, the concentrations of DAS and its modiﬁed forms in feeds used to estimate
exposure are presented.
E.1. Feed intakes
E.1.1. Ruminants and horses
Dairy cows
The amounts of feed given to lactating dairy cows varies according to the amount and quality of
forages and other feeds available, the weight of the cow and its milk yield. In this Opinion, it is
assumed that non-forage (i.e. complementary) feeds are fed at the rate of 0.3 kg/kg of milk produced
(Nix, 2010). Exposure to DAS has been estimated for a 650-kg dairy cow, with a milk yield of 40 kg
per day. Assumptions on the amounts of forages and non-forage feed are given in Table E.1.
Beef cattle
There are a wide variety of beef production and husbandry systems in Europe. They may be
categorised broadly as forage-based or cereal-based systems, although combinations of these systems
are commonly found. In this opinion, three feeding systems are considered, in which the forages are
grass or maize silage with, in each case, appropriate supplementation with non-forage feed materials.
A third system, commonly known as ‘cereal beef’, is also considered. For exposure estimates, live
weights of 300 or 400 kg, and feed intakes of between 6.6 and 10 kg dry matter per day have been
assumed, depending on the feeding regime, based on guidelines published by EBLEX (2008, 2012),
and details are given in Table E.1.
Sheep and goats
Many breeds and systems of management have been developed for sheep and goats to suit the
land, climate and husbandry conditions in the EU. As for other ruminants, forages may be the only
feeds used after weaning (NRC, 2007a). Common exceptions to this are pregnant and lactating
animals, whose feed is usually supplemented with non-forage feeds or manufactured compound
(complementary) feeds (AFRC, 1993; NRC, 2007a). In this Opinion, exposure estimates have been
made for lactating sheep and goats. The CONTAM Panel has used a daily dry matter intake of 2.8 kg
for an 80-kg lactating sheep feeding twin lambs to estimate the exposures. For lactating goats, the
CONTAM Panel has used a daily dry matter intake of 3.3 kg for a 60-kg goat for milking (4 kg milk/
day); for fattening goats, a body weight of 40 kg and feed intake of 1.5 kg DM/day has been
assumed, of which 60% is forage (Table E.1).
Horses
Horses are non-ruminant herbivores. They generally consume 2–3.5% of their body weight in feed
(dry matter) each day, of which a minimum of 50% should be as forage (pasture grass or hay) (NRC,
2007b). Assumed intakes are given in Table E.1.
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E.1.2. Non-ruminant animals
Pigs
Although there is a considerable range of pig production systems in Europe, exposure estimates
have been made for piglets (pig starter), ﬁnishing pigs and lactating sows (using feed intakes
proposed by EFSA FEEDAP Panel (2012). Details are given in Table E.2.
Poultry
The CONTAM Panel applied the live weights and feed intakes reported for fattening chickens
(broilers), laying hens and turkeys proposed by EFSA (2009) and for ducks by Leeson and Summers
(2008) (Table E.2).
Farmed ﬁsh (salmonids and carp)
Commercially reared species include Atlantic salmon, rainbow trout, sea bass, sea bream, cod,
halibut, tuna, eel and turbot. In this Scientiﬁc Opinion, exposures to DAS and their modiﬁed forms
have been made for farmed salmon and carp. Details of the body weights and feed intakes used are
given in Table E.2.
Table E.1: Live weights, growth rate/productivity, dry matter intake for cattle, sheep, goats and
horses, and the proportions of the diet as non-forage
Animal species
Live weight
(kg)
Growth rate or
productivity
Dry matter
intake
(kg/day)
% of diet as
non-forage
feed
Reference
Dairy cows, lactating(a) 650 40 kg milk/day 20.7 40 OECD (2009)
Fattening cattle: beef(b) 400 1 kg/day 9.6 15 AFRC (1993)
Fattening cattle: maize
silage-based ration
300 1.4 kg/day 6.6 25 Browne et al. (2004)
Fattening cattle: cereal
straw-based diet
300 0.9 kg/day 8.0 68 EBLEX (2008)
Fattening cattle: cereal
beef
400 1.4 kg/day 10.0 85 EBLEX (2012)
Sheep: lactating 80 Feeding twin lambs 2.8 50 OECD (2009)
Goats: milking 60 6 kg milk/day 3.4 65 NRC (2007a)
Goats: fattening 40 0.3 kg/day 1.5 40 NRC (2007a)
Horses 450 Moderate activity 9.0 50 NRC (2007b)
(a): Months 2–3 of lactation.
(b): Housed castrate cattle, medium maturing breed.
Table E.2: Live weights and feed intake for pigs, poultry, ducks and ﬁsh
Animal species
Live weight
(kg)
Feed intake (kg dry
matter/day)
Reference
Pigs: starter 20 1.0 EFSA (2012)
Pigs: ﬁnishing 100 3.0 EFSA (2012)
Pigs: lactating sows 200 6.0 EFSA (2012)
Poultry: broiler starters 0.7 0.075 Leeson and Summers (2008)
Poultry: broilers(a) 2 0.12 EFSA (2012)
Poultry: laying hens 2 0.12 EFSA (2012)
Turkeys: fattening turkeys 12 0.40 EFSA (2012)
Ducks: fattening ducks 3 0.14 Leeson and Summers (2008)
Salmonids 2 0.04 EFSA (2012)
Carp 1 0.02 Schultz et al. (2012)
(a): Fattening chickens.
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Rabbits
Feed intakes of 65–80 g/kg bw per day have been reported (Carabano and Piquer, 1998). For the
exposure estimates, the CONTAM Panel have assumed a live weight of 2 kg, and a daily feed intake of
75 g/kg bw (derived from Carabano and Piquer, 1998).
Farmed mink
For estimating exposure, the CONTAM Panel have assumed a live weight of 2.07 kg for a male mink
at pelting, and with a feed intake of 227 g fresh weight per day (75 g dry matter) (NRC, 1982).
Companion animals: dogs and cats
The amount of food consumed is largely a function of the mature weight of the animal, level of
activity, physiological status (e.g. pregnancy or lactation) and the energy content of the diet. In this
Scientiﬁc Opinion, the CONTAM Panel assumed body weights (kg) and feed intakes (g dry matter/day)
for dogs and cats of 25/360 and 4/60, respectively (derived from NRC, 2006).
E.2. Diet compositions and inclusion of diet ingredients to the
exposure calculations
Many livestock in the European countries are fed proprietary commercial compound feeds. Where
sufﬁcient data have been provided on species-speciﬁc compound feeds, estimates of exposure have
been made using these data together with estimated intakes given in Tables E.1 and E.2. Where data
on proprietary compound feeds were not available, or were available but in insufﬁcient numbers,
estimates of exposure have been made using dietary inclusion rates of feed materials given in this
section. Levels of DAS species-speciﬁc compound/complementary feeds or feed materials used to
estimate exposure are given in Table E.6.
E.2.1. Cattle, sheep, goats and horses
For most ruminants and horses, forages (either fresh or conserved as silage or hay) are essential
ingredients in their diet, but they are normally supplemented with non-forage feeds such as cereals,
cereal by-products, oilseed meals and by-products of human food production. Although these non-
forages may be fed as commercially manufactured compound feeds, no data levels of DAS in these
feeds were available and therefore example diets and levels of DAS and DAS in individual feeds have
been used to estimate exposure.17
With the exception of maize silage, no data on levels of DAS are available. Therefore, two
approaches to estimating exposure by ruminants and horses have been taken. The ﬁrst assumes that
the main forages are fresh grass and/or grass silage, and that these make no contribution to
exposure. Inclusion rates of feeds, for which levels of DAS are available, are given in Table E.3.
Exposures have also been estimated for diets in which maize silage is the main forage. AFSSA (2009)
have provided example intakes of dairy cows fed maize silage supplemented with maize grain and
soybean meal, while example diets of beef cattle on maize silage are taken from EBLEX (2008, 2012),
and these are given in Table E.4.
Table E.3: Assumed inclusion rates (%) of feeds, for which information on levels of DAS are
available, in the diets of ruminants and horses
Non-forage feed
materials
Dairy
cows
Beef
cattle
Lactating
sheep
Lactating
goats
Fattening
goats
Horses
Wheat (%) 15 ni 14 ni ni ni
Barley (%) 20 40 18 25 20 ni
Oats (%) ni ni ni 35 40 40
Soybean meal (%) 5 ni 5 10 10 ni
% of non-forage feeds in
the diet
40 15 50 75 40 50
ni: not included in the diet formulations.
17 Although data were reported on levels of DAS in compound feeds for dairy cows (n = 15), the data were all left censored and
therefore considered unreliable for estimating exposure.
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E.2.2. Pigs and poultry
Data for species-speciﬁc compound feeds for poultry starter diets and fattening pigs were provided
(see Table E.6) and these were used to estimate exposure to DAS. For other categories of pigs and
poultry, inclusion rates of individual feeds (Table E.6) together with levels of DAS in these feeds
(Table E.6) were used to estimate exposure to DAS.18
E.2.3. Rabbits
Rabbits are usually fed a pelleted diet (in the form of complete feedingstuffs) consisting of dried
forages, cereals and vegetable proteins supplemented with minerals, vitamins and trace elements.
Lebas and Renouf (2009) reviewed diet formulations used in experimental studies: in 58 diets, cereals
and cereal by-products (mostly wheat bran) accounted for up to 40% of all ingredients. In these
studies, maize was a major cereal grain and was included in more than one-third of all diets. In
northern Europe, however, maize may be replaced by barley and wheat. In this opinion, the feed
ingredients used in a typical French commercial rabbit compound, as provided by T. Gidenne,
(personal communication, 2011) have been used, details of which are given in Table E.5.
E.2.4. Farmed ﬁsh (salmonids and carp)
Traditionally, the principal raw materials used for the manufacture of ﬁsh feeds in Europe have
been ﬁshmeal and ﬁsh oils, and although alternative sources of oil and protein (e.g. soybean meals
and vegetable oils) are increasingly being used ﬁsh-derived feeds still remain the major ingredients.
For many ﬁsh species, digestion of complex carbohydrates and the metabolic utilisation of the
absorbed glucose is low, reﬂecting the scarcity of carbohydrates in the aquatic environment (Guillaume
et al., 2001). Instead, ﬁsh obtain much of their energy from protein in the diet. Where carbohydrates
are used, they generally require some form of pretreatment (e.g. cooking, ﬂaking or toasting).
Berntssen et al. (2010) provided details of the composition of a diet for growing salmonids, and the
CONTAM Panel used this feed formulation to estimate the exposures (Table E.5).
In contrast, studies with the common carp (Cyprinus carpio) have demonstrated greater intestinal
amylase activity than in carnivorous ﬁsh, which accounts for the better utilisation of carbohydrates by
these ﬁsh. The optimum level of carbohydrates appears to be 30–40% (Food and Agriculture
Organization of the United Nations (FAO), Aquaculture Feed and Fertiliser Resources Information
System19), which allows for higher levels of cereals than in diets for salmonids. The CONTAM
Panel used the ingredients of commercial compound feeds for carp reported by Schultz et al. (2012) to
estimate exposure to DAS.
E.2.5. Farmed mink
Mink are carnivorous animals and are fed high protein diets consisting mainly of meat and meat by-
products. Commercially manufactured mink feed consists largely of ﬁsh and land animal by-products,
Table E.4: Assumed diet compositions and feed intake of lactating dairy cows and fattening beef
cattle fed diets based on maize silage, and beef cattle on cereal-based diets(a)
Animal species Forage
Maize
grain
Soybean
meal
Barley
grain
Reference
Lactating dairy cows: maize silage-based
diet
15.0 9.5 2.8 ni AFSSA (2009)
Fattening beef cattle: maize silage-based
diet
4.9 ni ni ni EBLEX (2012)
Fattening beef cattle: intensive cereal-
based diet(b)
1.5 ni ni 5.5 EBLEX (2008)
ni: not included in the diet formulations.
(a): Diets are also supplemented with rapeseed meal, but no data available on levels of DAS in this feed.
(b): Grass silage assumed as the forage.
18 Although data were reported on levels of DAS in compound feeds for laying hens (n = 13), the data were all left censored and
therefore considered unreliable for estimating exposure.
19 http://www.fao.org/fishery/affris/affris-home/en/
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with lesser amounts of cereals and cereal by-products, and supplemented with mineral/vitamin
premixtures. Mink are fed diets high in protein, although their nutritional requirements vary according
to the animal’s physiological stage (e.g. gestating, lactating and growing) and climatic conditions,
particularly temperature. The proportions of cereal grains, their products and by-products used in
estimating the exposure are given in Table E.6.20
E.2.6. Companion animals (dogs and cats)
Most small companion animals derive their nutritional needs from processed food, and in 2010 EU
annual sales of pet food products was ~ 8.3 million tonnes.21 Although a wide range of ingredients is
used in commercial diets, most dog and cat diets contain at least some animal protein. Other
ingredients include cereals (predominantly wheat, rice or maize), cereal by-products, vegetable
proteins and by-products of human food production. The ingredients will vary depending both on the
availability of feed materials and the nutrient requirements of the animals.
The European Pet Food Industry Federation (FEDIAF) has provided information on typical inclusion
levels of cereals, cereal by-products and other feed materials in dry cat and dog food. In the absence
of sufﬁcient data on species-speciﬁc manufactured complete feedingstuffs, the CONTAM Panel has
used example diets based on information provided by FEDIAF22 (details given in Table E.5).
Table E.5: Assumed diet composition (%) for farmed ﬁsh (salmonids and carp), farmed rabbits,
farmed mink and companion animals (cats and dogs)
Feed materials
Farmed ﬁsh
Farmed rabbits Farmed mink
Companion
animals
Salmonids Carp Cats Dogs
Wheat (%) 15 24 ni 6 10 10
Barley (%) ni ni ni 1 ni ni
Maize (%) ni 10 18 6 5 6
Oats (%) ni ni ni ni 1 0.5
Soybean meal (%) 12 32 ni ni 8 4
ni: not included in the diet formulations.
Table E.6: Levels of DAS and the sum of its hidden forms (lg/kg DM) in species-speciﬁc
compound/complementary feeds and feed materials used to estimate exposure by
farmed livestock and companion animals
Feed type
N
P95 Mean
LB UB LB UB
Compound/complementary feeds
Pig: growing/fattening 29 48 79 695 695
Poultry: starter diets 118 0.3 11 4.1 57
Feed materials
Wheat 588 0.0 6.7 0.0 11
Barley 336 0.0 8.5 0.0 11
Oats 282 0.7 4.7 3.7 11
Maize (corn) 232 0.6 32 0.0 57
Soybean meal 10 0.0 62 0.0 113
Oat feed 98 2.2 3.3 8.8 8.8
Maize silage 35 2.1 48 0.0 148
N: Number of samples; DM: dry matter.
20 Diet formulation based on data provided by the Finnish Fur Breeders Association in 2015 and translated from Finnish to
English, www.profur.fi
21 Available online: www.Fediaf.org
22 The European Pet Food Industry Federation (FEDIAF), Personal communication by email, May 2016.
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Annex A – Supporting tables on food and feed occurrence and human
exposure
Annex A contains supporting tables on food and feed occurrence and human exposure and is
available as excel ﬁle under supporting information at: https://doi.org//10.2903/j.efsa.2018.5367
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